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ABSTRACT
CHARACTERIZATION OF MOUSE PROSTATE TUMOR-INFILTRATING
LEUKOCYTES
Daniel Alan Holterman
Eastern Virginia Medical School and Old Dominion University, 2003
Director: Dr. Richard P. Ciavarra

Prostate cancer is the most common form of non-cutaneous cancer among men in
the United States and the second most common cause of cancer-related death among men
with approximately 189,000 new cases diagnosed and 30,200 deaths of the disease in
2002. Prostate cancer can be a treatable disease but once it becomes metastatic there are
no acceptable therapies. For this reason, immunotherapy has been attempted but the
results have been disappointing.

The TRAMP model was used to evaluate specific

interactions between an intact murine immune system and a prostate tumor that expressed
a naturally processed weak tumor antigen. Vaccination trials for cancer patients have
detected tumor-specific immune cells in the peripheral lymphoid organs such as blood,
even with progressing disease. This observation prompted us to hypothesize that factors
within the tumor microenvironment disable the immune response.

The first studies

characterized the cellular infiltrate of TRAMP tumors. Then the expression of signal
transducing molecules of infiltrating T cells was analyzed in vivo and an in vitro co
culture assay system examined the role of common tumor-infiltrating myeloid subsets in
the alterations to T cells.

These studies demonstrated that TRAMP tumors were

unexpectedly rich in host myeloid cells and that expression of components of the
CD3/TCR complex was decreased on infiltrating T cells. Unexpectedly, these studies
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determined that as many as 30% of infiltrating T cells expressed the y/5 TCR complex, a
very rare T cell subset with an unknown role in tumor surveillance and rejection.
Additionally, tetramers specific for the tumor antigen WT-1 identified tumor specific T
cells and showed that these cells were more normal in their expression of signal
transducing molecules. Finally, using in vitro co-culture assays it was determined that
GR1 positive cells mediated the loss of signal transducing molecules and that H2 O2
generated by these cells mediated the loss of the TCR-£ chain in infiltrating T cells.
These results show for the first time, that some of the same mechanisms that suppress
immune function in chronic inflammation also suppress immune function of infiltrating T
cells.
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CHAPTER I
INTRODUCTION
Prostate cancer is the most common form of non-cutaneous cancer among men in
the United States and is second only to lung cancer as a cause of cancer-related death
among men. The American Cancer Society estimates that 189,000 new cases of prostate
cancer will be diagnosed and that approximately 30,200 men will die of the disease in
2002 .

A. THE EPIDEMIOLOGY OF PROSTATE CANCER
Prostate cancer incidence rates are higher for men with a family history of the
disease. In fact, evidence of familial clustering of prostate cancer has been evident since
1960 (1). Prostate cancer exhibited the fourth highest degree of familial clustering after
lip cancer, skin melanoma and ovarian cancer and has a higher clustering value then
either colon or breast carcinoma. Men with a father or brother with the disease were
twice as likely to develop prostate cancer as men with no family history of the disease
(2). Men with two or three first degree relatives with prostate cancer had a 5-fold and 11fold increased risk of developing the disease with a particularly increased risk if any of
these relatives were less then 55 years old at diagnosis. The extent to which this familial
clustering represents common genetic traits or common environmental factors remains
unclear and is the subject of extensive investigations.

The model for this dissertation is Cancer Research.
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The incidence of the disease differs between racial and national origin groups.
Annual incidence rates are higher among U.S. blacks then either whites or Asian
Americans. Internationally, the U.S. and Canada have the highest prostate cancer rates
and Asian men have the lowest rates. Current estimates of prostate cancer incidence are
137/100,000 per year for black-USA, 101/100,000 per year for white-USA and
65/100,000 per year for Canadian men. Conversely, only 9/100,000 per year for
Japanese, 8/100,000 per year for Hong Kong and 2/100,000 per year for Chinese men are
expected to develop prostate cancer this year (3).
The incidence of prostate cancer has increased since the introduction of the serum
prostate-specific antigen (PSA) screening test in 1986 and peaked by 1992.

The

incidence rate has been declining from 1993 through 1995. The most dramatic increase
of incidence was in early stage disease in younger men. This earlier detection of prostate
cancer by PSA screening has been linked to a 6.7% decline of age-adjusted mortality rate
by 1995. This represents a decrease of 1.8 deaths per 100,000 men per year. In spite of
this decline in age-adjusted mortality prostate cancer continues to have a significant
impact on personal and societal health. Clearly more research is needed into the causes,
progression and effective therapy of this disease.

A 1. Prostate cancer impact upon newly diagnosed patients
The clinician must consider the impact of the diagnosis of prostate cancer on the
patient when deciding the proper management of the disease. In fact, a majority of men
with early stage disease will never progress, have minimal symptoms and will die of
other causes without therapy. Other men will progress rapidly, leading to metastasis
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severe morbidity and ultimately death from this disease. To balance these outcomes the
clinician will generally determine the stage of the disease at diagnosis. Prostate cancer
stage can be either localized (invasive disease confined entirely to the prostate gland),
regional (extension o f the neoplasm beyond the prostate capsule into regional lymph
nodes or surrounding tissues/organs) or distant (spread of the neoplasm to parts of the
body remote from the primary prostate cancer). In addition to staging, a pathologist will
determine the degree o f differentiation of the malignant prostate cancer cells.

For

prostate cancer the Gleason score is used to assign grade with 2-4 indicating well
differentiated tumors, 5-7 indicating moderately differentiated tumors and 8-10 indicating
poorly or undifferentiated tumor cells.

This staging and grading system of newly

diagnosed prostate cancer patients helps the clinician to determine the best treatment
options for these patients.
One ongoing area of scientific investigation is the generation of a prognostic
index to identify prostate cancer patients likely to progress and die despite conventional
therapy. For example, investigators used a prognostic index for newly diagnosed prostate
cancer patients that combined standard staging and Gleason scores with the percentage of
Gleason 4 and 5 scored tumor cells, tumor volumes, serum PSA levels, source of tumor
origin and tumor cell DNA content. Using this index, Pisansky and colleagues were able
to preoperatively predict the outcome of 48 men undergoing radical prostatectomy with
84% sensitivity, 82% specificity, 94% positive predictive value and 83% diagnostic value
(4). Most importantly, this prognostic index accurately identified a cohort of patients at
high risk of tumor recurrence of local disease following radiation therapy. It is these

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

4

patients, and those with confirmed metastatic prostate cancer, for whom novel therapeutic
interventions are needed.

A 2. Progression of prostate cancer from benign hyperplasia to lethal metastatic
disease
Prostate cancer is similar to the majority of solid tumors in that the disease
follows a series of cellular steps as the cancer cells progress from normal tissue to the
advanced, metastatic lethal form of the disease (5). The first step of prostate cancer
progression is escape of the tumor cells from the prostate gland into local surrounding
tissue or regional lymph nodes. This process is termed invasion and is common to all
solid tumor progression. The next step of prostate cancer progression is the development
of androgen-resistant tumor cells able to grow despite androgen ablation therapy. These
cells are termed hormone independent and have a similar component in progressing
breast cancer. Benign hyperplasia is androgen responsive, localized prostate carcinoma
is usually androgen responsive but invasive prostate cancer can be either hormone
responsive or non-responsive. The third step of prostate cancer progression is the ability
of the cancer cells to escape the local environment and survive in the patient circulation
long enough to seed distant sites. This process is called metastasis and is common to all
solid tumor progression.
While the process of cancer progression may be similar with most solid tumors it
is the rate o f metastasis and the target organs that varies between cancer types and even
individual patients with similar disease. For example, prostate cancer is generally a slow
growing disease and advanced metastatic disease is presently incurable with most men
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succumbing to this disease over a period of months or years.

The most common

metastatic sites are lymph nodes (74%), bone (69%), lung (39%), liver (40%) and adrenal
gland (11%) (5).

A 3. Need for innovative therapies for advanced prostate cancer
Currently, treatments for localized prostate cancer include hormone ablation
therapy, surgery, radiotherapy and chemotherapy. However, as much as one third of men
initially diagnosed with localized disease and treated with conventional therapies
eventually develop metastasis. Available treatments for metastatic prostate cancer are not
curative.

Hormone ablation therapy may control androgen-sensitive tumor cells but

hormone-refractory tumor cells often continue growing limiting the usefulness of this
therapy. Ongoing research is looking for new therapeutic interventions aimed at the
elimination of metastatic prostate cancer. The process has been slow and difficult and
metastatic prostate cancer remains largely incurable. These disappointments have led
investigators to examine innovative approaches to prostate cancer therapy and
immunotherapy remains one o f the most active and promising of these novel therapies.
The rationale for using the host immune system to fight prostate cancer is based
on cases o f spontaneous remissions of various cancers (6) and reports of tumorinfiltrating lymphocytes, the majority of which are T cells (7).

However, the very

existence of cancer in hosts with intact immune systems demonstrate the inefficiency of
this natural defense against tumors and the ability of neoplastic cells to evade immune
surveillance and rejection.

The major objective of immunotherapeutic approaches to
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prostate cancer therapy is to augment the efficiency and effectiveness of the natural
immune response against malignant tissues.

B. IMMUNE EVASION STRATEGIES EMPLOYED BY SOLID TUMORS
A variety o f mechanisms have been proposed to account for defective anti-tumor
immune response including the secretion of suppressive factors into the TME. These
factors include TGF-p (8), IL-10 (9), nitric oxide (10), tumor-derived gangliosides (11),
prostaglandin E2 (12) and reactive oxygen species (13). Additionally, the lack of co
stimulatory molecules on tumor cells has been linked to T cell tolerance (14).

The

presence of suppressive CD4+ T cells have been shown to inhibit anti-tumor CD8 cells
and furthermore, elimination of these suppressive cells can induce regression of advanced
lymphoma in animal models (15).
Another well documented evasion strategy of tumors is the loss of antigen
presentation by tumor cells either through down-regulation of antigenic proteins or loss
of MHC molecules required for presentation of antigens to the immune system (16).
Finally, both direct tumor-induced T cell signaling defects and indirect tumor-induced T
cell signaling molecule defects have been detected in T cells isolated from tumors (17,
18). The indirect alterations o f tumor-infiltrating T cells can be mediated by host cells
infiltrating the progressing TME.
The evasion strategies are not mutually exclusive and there is considerable
overlap between these mechanisms. The complicating factors of tumor heterogeneity,
complex interactions between the innate and acquired arms of the immune system and the
plasticity of the developing TME all conspire to allow for cancer growth in

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

7
immunocompetent hosts. Therefore, multiple evasion strategies may be employed by
tumors simultaneously with the resultant outgrowth of successful clones leading to cancer
progression and ultimately the death of the host.

B 1. Evidence That T cells Within Solid Tumors are Dysfunctional
It is well known that T cells infiltrating tumors (TILs) in humans and animals
have impaired function. Previous studies indicated that these T cells express decreased
IL-2 receptors and failed to proliferate in the presence of IL-2 (19).

These tumor-

infiltrating cells failed to proliferate in response to the mitogens PHA, Con A and
phorbolester TP A compared to autologous peripheral blood lymphocytes (PBLs) that had
normal proliferation. Freshly isolated TILs are not capable of tumor cell lysis in ex vivo
studies (20). This dysfunction correlates with the loss of signaling molecules in these
cells, most notably the cytoplasmic TCR-C, chain (21). Most importantly, the loss o f both
CD3s and TCR-£ molecules in TILs correlate with the stage of the patient’s disease and
is less pronounced further from the tumor site (22).
One o f the most vexing paradoxes of tumor immunology is the continued growth
of tumors in patients or animals that exhibit tumor-specific peripheral immune responses
following experimental tumor vaccination. In these studies, a vigorous immune response
can be detected in the blood of some patients, yet the survival of these patients is no
better then those without detectable anti-tumor response (23).

Using the newly

developed tetramer technology (fluorochrome labeled MHC-I/tumor peptide complexes)
and flow cytometry, tumor-specific CD8 lymphocytes can be detected in the peripheral
blood and draining lymph nodes (dLNs) of melanoma patients (24). Additionally, these
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CD8 positive tumor-specific cells within metastatic dLNs were antigen experienced;
demonstrated CCR77CD45RO+/CD45RA‘ phenotype and secreted IFN-y in ELISPOT
assays.

Animal studies using adoptive transfer protocols have also demonstrated that

tumor-specific CD8 cells proliferate in dLNs of tumor-hearing mice (25). However, in
spite o f a robust peripheral anti-tumor response, tumors in most patients continue to
progress leading ultimately to death (23).

Obviously, the growing tumor is able to

develop immune evasion strategies that prevent the eradication of the tumor by the host’s
immune system. One intriguing observation in tumor vaccination studies was that mice
immunized against tumors before implantation of tumor cells, demonstrated increased
survival when compared to mice immunized post transplantation. This study indicated
that the immune system was able kill single tumor cells but not after the development of
the TME. In conclusion, tumor-specific T cells that are able to function in the periphery
either do not enter the tumor or become non-functional once exposed to the TME. The
mechanism of this TME-induced dysfunction remains unknown at this time.

C.

ALTERATIONS

COMPONENTS

OF

OF
THE

EXPRESSION
CD3/TCR

OF

SIGNAL-TRANSDUCING

COMPLEX

CORRELATE

WITH

IMPAIRED FUNCTION OF TUMOR-INFILTRATING T CELLS
The T cell antigen receptor is a multi-component complex consisting o f the
clonotypic antigen recognition structure, TCR-a/p heterodimer (TCR-8/y in a small
subset of T cells) and a group of invariant peptides designated CD3e, CD3y, CD35 and
CD3^ or CD3r| chains.

CD3s and the zeta chains are invariant signaling molecules

proposed to transduce activation signals to intracellular signaling pathways following
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antigen engagement by the TCR. Two main signal transduction pathways have been
identified in T cells, namely, phospholipase C (PLC) and protein tyrosine kinase (PTK).
Recent evidence indicates that other components of the complex can contribute to signal
transduction and T cell activation. For example, CD3y, CD35, CD3s and CD3^ become
phosphorylated after TCR stimulation and CD3y-deficient T cells do not secrete IL-2 but
exhibit normal calcium flux, CD69 up-regulation and proliferation (26, 27). Similarly,
Klausner and Samuelson demonstrated that the gamma chain is required for assembly of
the complete complex although T cell activation is normal with activation motif deficient
y chains (28). These studies indicate that all components of the CD3 complex contribute
to or modify T cell signaling, antigen-driven activation and T cell survivability in the
tumor-bearing host.
Studies in tumor-bearing animals and cancer patients indicate that peripheral
blood T cells and tumor associated T cells show improper assembly of the TCR/CD3
complex as well as loss of T cell signal-transducing CD3s molecules (21,29). Typically,
tumor-infiltrating T cells show loss of CD3£, with preservation of CD3s although loss of
the epsilon chain has been reported in late disease (21, 22). This abnormal expression
and assembly o f the TCR/CD3 signaling complex in T cells associated with solid tumors
accounts for at least some of the tumor-associated T cell dysfunction.

In addition,

decreased expression of the co-receptor molecules CD4 and CD8 and up-regulation of the
inhibitory molecule CTLA-4 may also inhibit immune-mediated tumor regression.
Indeed, in a murine model, antibody-mediated blockade of CTLA-4 eliminated residual
metastatic prostate cancer after surgical excision of the primary tumors (30).
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It is unclear why solid tumors such as prostate cancer induce a preferential loss of
CD3s on T cells (31).

Furthermore, little is currently known about CD3e‘ T cells

although a recent study reported that blocking CD3s-mediated signals inhibited NFAT
activation and IL-2 production (32). Additional studies are required to define precisely
the tumor-induced changes in the CD3/TCR complex and determine the extent to which
these alterations impact anti-tumor immunity and ultimately tumor regression or
progression in patients.
Finally, while fresh TILs lack anti-tumor function, several investigators have
cultured these cells with IL-2 and demonstrated reappearance of anti-tumor function even
demonstrating a partial clinical response when these cultured TILs are re-infused into
patients (33). All of the evidence listed above support the notion that tumors establish an
immunosuppressive environment for infiltrating T cells.

Although a multitude of

different mechanisms could account for this, recent and interesting studies of cancer
patients support the notion that tumors may actively target the TCR/CD3 signaling
complex (34).

D. ROLE OF GAMMA/DELTA T CELLS IN THE ANTI-CANCER IMMUNE
RESPONSE
The vast majority of T cells express the TCR-ot/p complex but a minor T cell
population expresses the TCR-y/8 complex. Less is known about gamma/delta T cells
than alpha/beta T cells and their role in cancer defense is even less clear. Gamma/delta

cells have been described as primitive T cells sharing components of NK and T cells.
These cells have been proposed to contribute regulatory functions to the immune
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response.

Gamma/delta T cells can recognize common pathogen antigens and may

represent a link between the innate and acquired immune systems (35). The antigen
recognition complex of gamma/delta cells is able to recognize antigens in an MHC
restricted and unrestricted fashion indicating a duality of antigen recognition by these
cells (36).
For example, researchers have shown that y8 T cells are able to recognize proteins
directly and in association with MHC molecules, can recognize nonproteinacious
phospholigands, surface stress signals and even phosphorylated metabolites of aberrant
metabolic pathways in cancer cells (35, 37, 38 and 39). Gamma/delta T cells appear to
provide innate immunity against cancer, specifically against cutaneous malignancies (40).
The very localization of gamma/delta T cells in the epithelia suggests that these cells may
play a role in regulation of cutaneous malignancies. Additionally, gamma/delta T cells
also play a role in protection against renal cell carcinoma but the mechanism of this
protection is not understood (41).
Because gamma/delta T cells appear to recognize unique tumor associated
antigens that are hidden from alpha/beta T cells they have been proposed to represent a
nonredundant system of immunosurveilance against cancer (42). Finally, these cells have
been proposed to constitute targets for novel immunotherapies against human cancer and
their exploitation may increase the effectiveness of current cancer immunotherapies (43).
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E.

IDENTIFICATION OF TUMOR-INFILTRATRATING T CELLS AND

TUMOR-SPECIFIC TUMOR-INFILTRATING T CELLS
The selection of molecular markers to identify T cells within tumors is a
controversial topic. Previously, investigators have used the expression of CD3e chain to
identify T cells.

Fluorochrome conjugated anti-CD3s antibodies are commercially

available and flow cytometry is the most common method used. While this molecule is
only expressed on T cells and not on other cells, previous studies indicated that a
significant portion of tumor-infiltrating T cells loose their expression of this molecule
(22). Therefore, investigators who have used and continue to use the expression of this
marker to identify T cells run the risk of missing a population of T cells and limiting their
analysis to merely a sub-population of cells.

Specifically, using the expression of a

molecule whose expression is altered by exposure to the TME may dramatically
underestimate the total numbers of tumor-infiltrating T cells and underestimate the true
alterations o f all T cells.
The CD3/TCR complex is not the only T cell specific complex that researchers
can use to identify T cells. Other molecules expressed on T cells include CD5 and Thy-1.
These molecules have the disadvantage of not being solely expressed on T cells, but also
on rare non-T cells as well. While the CD3 complex serves the investigator well for
peripheral T cells, from blood, LNs or spleen, T cells within tumors may lose
components o f this complex.

Furthermore, components of the complex can be

internalized after antigen engagement of activated T cells further complicating the task of
identifying T cells.
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E 1. Use of WTl(130-138)H-2Db tetramers to detect TRAMP specific CD8 cells
With the development of MHC-I tetramers (fluorochrome labeled complexes of
viral/tumor specific peptide/MHC-I molecules), investigators are now able to identify
tumor-specific CD8 cells (44). Tetramers are fluorochrome-labeled research reagents
capable of binding to T cells that express a complimentary TCR complex.

These

compounds consist of 4 MHC class I molecules with an antigenic peptide localized
within the folds o f the MHC molecule. This complex is labeled with a fluorochrome in
order to identify T cells with TCRs that can recognize the naturally occurring
MHC/peptide complex in vivo. See below for an illustration of a tetramer reagent.

Illustration 1. The structure of tetramer reagent. The fluorochrome selected is at the
discretion of the investigator depending on the experimental design and the gating
strategies employed.

For the first time, the number of CTLs capable of binding specific viral/tumor
peptides could be quantified using flow cytometry. Using tetramers, for example, the
percentage of immunodominant EBV peptide specific CTLs in the blood of
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mononucleosis patients was as high as 5% of CD8 positive T lymphocytes (45).
Similarly, tumor specific CTLs in the blood or draining LNs of melanoma patients have
been detected using tetramers, albeit at lower frequencies (<1% and <4% of CD8 positive
T cells in the blood and tumor involved lymph nodes respectively) (24).
The WT1 gene was originally identified in sporadic and hereditary cases of
Wilms’ tumor. Recently it has been shown to be over expressed in many human cancers
including most leukemias, some myelodysplastic syndromes, melanomas and lung,
thyroid, breast, testicular and ovarian carcinomas (46, 47, 48). Thus, WT1 is a common
tumor-specific antigen with clinical relevance beyond TRAMP tumors since human
tumors also overexpress this protein. During embryogenesis, the WT1 gene is involved
in the regulation of cellular growth and differentiation and has been shown to interact
with a variety of target genes (49). It has been proposed that aberrant expression of the
WT1 gene product results in uncontrolled proliferation with aberrant differentiation and
eventual tumor formation (50).
Transgenic adenocarcinoma of mouse prostate (TRAMP) cells express high levels
of mRNA for Wilms’ tumor gene transcription factor (WT1) but only low levels of the
WT1 protein are expressed in normal adult tissues such as hematopoietic precursors,
kidney and gonadal cells (51). The TRAMP-C1 model is a transplantable prostate cancer
cell line developed from a spontaneous prostate tumor in transgenic mice. The transgene
in these mice is the oncogenic SV-40 T antigen (SV-40 Tag) under the control of the rat
probasin promoter. In this system the gene is only expressed in the epithelial cells of the
mouse prostate (52).
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E 2.

Advantage of tetramers versus Limiting Dilution Assays (LDA) to detect

tumor-specific CD8 T cells
The development of tetramers to detect CTLs capable of recognizing specific
peptide/MHC-I complexes has revolutionized the fields of viral and tumor immunology
(34).

Previously, viral or tumor specific CTLs were considered an extremely rare

population of PBLs in virally infected or tumor-bearing individuals, however, limiting
dilution assays (LDA) were used to detect these specific CTLs (53). This assay requires
the proliferation of CTLs cultured with virus-infected (or tumor) cells as antigen
presenting cells. LDAs provide an under-estimation of CTLs within the sample because
the majority of functional CTLs are not able to proliferate or proliferate only to a limited
extent. Only a subset of CTLs that are destined to be memory CTLs are detected in this
assay. Additionally, no information about the specific peptide recognized by each CTL is
obtained with this assay.
Gaiger and colleagues have recently demonstrated that C57B1/6 mice “naturally”
process the 130-138 peptide of WT1 and present it complexed with H-2Db MHC
molecules (46).

Surprisingly, these investigators demonstrated that TRAMP-C2 cells

grew at the same rate in WT1 vaccinated mice compared with control animals. This
unexpected observation supports the hypothesis that tumor-specific CTLs are rendered
non-fimctional in the tumor microenvironment. It is also not unlike the results of studies
o f tumor vaccines in cancer patients where the presence of peripheral immunity did not
translate into significant cures (23)
This unimpeded tumor growth in mice vaccinated against a known tumor antigen
is similar to vaccine trials in humans where tumor specific CTLs can be detected in the
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blood o f patients even with progressing disease (33). There are two possible explanations
for these results; 1) the tumor may evade T cell lysis by down regulating MHC
expression, effectively hiding tumor antigens from responsive T cells or 2) functional T
cells may be rendered nonfunctional once they enter the tumor microenvironment. One
mechanism o f inducing T cell dysfunction is through the loss of T cell signaling
molecules (22).

F. LOCAL VERSUS GLOBAL T CELL DYSFUNCTION ASSOCIATED WITH
CANCER
The bulk of the scientific evidence indicates that T cell dysfunction is more
pronounced and occurs at an earlier stage in T cells isolated from within solid tumors
compared with T cells from the periphery. In fact, systemic immune dysfunction tends to
be subtle and to occur only in the late stages of advanced cancer patients when it is
detected at all (54). It has been proposed that the systemic immune defects seen in latestage cancer may represent a “spreading” of the same mechanisms that were initially only
operating within the tumor (55).

Evidence which supports this hypothesis include the

observation that both CD 8+ TILs and PBLs from late stage cancer patients can regain
their function when cultured with IL-2 (21). Additionally, surgical removal of tumors
from patients or animal models have been shown to restore T cell function and signaling
molecule expression of peripheral T cells (56). Collectively, these observations indicate
the presence o f tumor-associated factors that repress the function of TILs locally and
peripheral T cells eventually. Examples of such factors could include soluble factors
produced by tumor associated cells, the migration of T cells through the TME and out
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into the periphery or other host cells activated within the tumor but migrating into the
bloodstream to mediate the immune-dampening condition. In fact, the best evidence of a
gradient o f immune suppression out from tumor is demonstrated by Kiessling and
colleagues who show TCR-zeta levels in T cells from non-cancerous colorectal tissue
from colon cancer patients is lower then PBLs but higher than TILs (22). Therefore,
while TME-mediated T cell dysfunction may be concentrated in the tumor, with time this
dysfunction can be detected in the periphery o f animals or patients with solid tumors.

F 1.

Tumor-induced immune suppression shares characteristics with tumor

suppression associated with chronic inflammatory diseases.
Recently, investigators have identified immune dysfunction in T cells isolated
from chronic inflammatory sites that is similar to the dysfunction noted in TILs and PBLs
of cancer patients.

This chronic inflammation can be associated with autoimmune

conditions such as rheumatoid arthritis (RA) or chronic infections such as leprosy,
tuberculosis or HIV infections. Each of these diseases share several characteristics with
cancer including, chronically activated (but ineffective) immune cells, exposure of large
amount of antigens to the immune system and the activation of the innate immune
system, including macrophages and neutrophils. In animal models, some transplantable
tumors induce immune dysfunction similar to the dysfunction seen in human cancer
patients while others do not. The tumors that are associated with dysfunction are all slow
growing tumors requiring more then thirty days to suppress immune function (57).
Chemically induced tumors in animals have disadvantages however, and lack of
synchrony and tumor heterogeneity can complicate studies in these models.
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Functionally, T cells from peripheral blood or synovial fluid of RA patients
showed poor proliferative responses to the mitogens phytohemagglutinin (PHA) and
pokeweed antigen (PWM) and to cross-linking of the CD3 complex (58). Additionally,
these cells demonstrated decreased IL-2 production upon stimulation (59). A decrease in
the cellular levels and phosphorylation of the CD3C, molecule were seen in these cells
implicating defective T cells signaling as the underlying mechanism of T cell dysfunction
in RA (60, 61). There is evidence that the hypo-responsiveness of T cells associated with
RA is mediated by an altered redox state of the T cells, specifically decreased levels of
the redox-regulating molecule glutathione (GSH) (62). Additionally, the dysfunction of
T cells from RA patients was corrected when the GSH levels were elevated by N-acetylL-cysteine.
Alterations o f T cell signaling molecules, especially components of the CD3/TCR
complex may be the common features linking immune dysfunction associated with
chronic inflammation and cancer. For example, in advanced mycobacterial diseases like
leprosy or TB, decreased CD3£„ the tyrosine kinase p56 lck and the nuclear transcription
factor NF-kB have been described in isolated T cells (63). CD3£, levels are decreased in
T cells from the peripheral blood of HIV infected individuals, but as with TILs from
cancer patients, CD3^ normalizes following culture with IL-2 (64).

F 2. Tumor associated T cell dysfunction may be mediated by feedback mechanisms
similar to those noted in chronic viral infections
T cells isolated from within solid tumors have been described as being ignorant of
tumor antigens expressed by tumor cells and mechanisms that explain this ignorance
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include clonal anergy or clonal exhaustion.

However, the nature of T cell clonal

exhaustion associated with cancer is not well understood but it has been speculated that
overwhelming levels of antigen may drive T cells into antigen induced cell death (AICD)
(Reviewed in 65).

Two signals are required for T cell activation, one is antigenic

recognition through the TCR and the second is signaling through co-receptors. Examples
of this second signal include the B7/CD28 molecule interactions when T cells are
stimulated by antigen presenting cells (APC) (66).
There is evidence that CD4 positive T cells play a role in anergized CD8 cells.
Zajac and colleagues demonstrated that T cells with high affinity TCRs for viral antigens
expressed at high levels in viral infections first became dysfunctional and then
disappeared from the host, perhaps because of AICD. Conversely, T cells with lower
affinity receptors to less common viral antigens became anergized but remained in the
periphery o f the host for long periods of time (67). Studies such as this suggest that the
strength of the antigenic signal through the CD3/TCR complex can determine whether a
T cell becomes activated to become an effector cell with cytolytic function, dies by AICD
or is anergized within the host.
T cell cytokine production, cytolytic activity and proliferation upon activation all
require different thresholds of antigenic peptide binding (68). CD4 or CD8 expression by
T cells can modulate the activation thresholds of T cells. In fact, Eisen and colleagues
demonstrated that lack of CD4 or CD8 co-receptors in T cells increased the amount of
antigen required to activate T cells by 10 to 100 fold (69). Studies indicate that CD4 and
CD8 interact with the MHC molecules of the APC or target cell and stabilize the
TCR/MHC-peptide binding resulting in increased affinity of the TCR for its peptide.
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Chronic activation of the innate immune system has been detected in both late
stage cancer and chronic inflammation (70, 61). Intriguingly, both types of disease share
similar cell types, specifically activated macrophages and granulocytes. Each of these
cell types have been demonstrated to alter the function and expression of signaltransduction molecules of T cells (71). Activated granulocytes also secrete H 2 O2 and
nitric oxide (NO); both of which can suppress T cell function (70). Therefore, the TME
and chronic inflammation expose infiltrating T cells to reactive oxygen metabolites and
oxidative stress leading to loss of signal-transducing molecules, T cell dysfunction and
immune system evasion (13).

F 3. The TME is composed of the total tumor associated cells and secreted factors
from these cells
Solid tumors have been described as pathologic “organoids” composed of
heterogeneous cancer cells, host derived stromal cells and inflammatory cells all
interacting within a dynamic extra-cellular matrix. Researchers have studied the complex
interactions among these cell types during the pathological process of tumorigenesis with
particular emphasis in angiogenesis, tumor-cell invasion, metastasis and support of
cancer cells because of host-derived factors (Reviewed in 72).

In fact, the dynamic

interaction between tumor cells and host immune and stromal cells typically determines
the clinical behavior o f the tumor.
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G. TWO CONFLICTING PARADIGMS OF TUMOR IMMUNOLOGY
Contemporary tumor immunologists can be divided into two camps based on the
underlying paradigms of cancer that they follow. The majority of investigators follow a
paradigm that describes cancer as a parasite growing within a host. In this model there is
a clear distinction made between the tumor (considered foreign) and the host (considered
self). A less common paradigm describes cancer as an abnormal growth of transformed
cells, other non-malignant cells and abnormal connective tissue.

In this model no

distinction is made between host and tumor cells within the tumor mass and non
transformed cells often play as great a role in disease progression as the malignant cells.
In the parasitology model of cancer, the tumor damages the host by its
unrestrained growth. The host attempts to fight the cancer by sending in lymphocytes,
antibodies, NK cells and myeloid cells such as macrophages and neutrophils to kill the
tumor. A battle is envisioned where the tumor is attacked by the host immune system
and simultaneously the cancer attacks the immune system.

This view of tumor

immunology has also been tempered by the “immune surveillance theory of cancer
development”. In this theory, transformed cells occasionally develop within the host and
are efficiently eliminated by the immune system. With the immune surveillance theory
of cancer development, only malignant cells that successfully avoid immune-mediated
rejection are able to grow to clinically detectable tumors. Cancer is considered a failure
of the immune system and therapies that use this paradigm work toward augmenting the
normal immune response against cancer to fight the disease. Typical of such therapies
are cytokine therapies or vaccine studies in cancer patients.
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In the parasitology-based paradigm, cells of the immune system and malignant
cells are on opposite sides of a battle using weapons such as secreted factors and
compounds to attack the other. The rest of the tumor mass is considered inert, or at least
less important, and has little effect on the outcome of the battle and the progression of the
disease.
In the organistic paradigm of cancer, the tumor is described as a disease of both
malignant cells and tumor stromal cells. It is the interaction between these cell types that
determines the progression of the disease in this model. No motives or agendas are
attributed to the cells that comprise tumors but rather their actions and functions are
considered simply the result of secreted factors within tumors.

For example, it is

assumed that lymphocytes are present within tumors because of cytokines or chemokines
secreted by cells within tumors, which attract these cells.
This model describes cancer as a disease where malignant cells usurp the normal
cellular components allowing these cells to support the continued growth of the
malignant cells rather then to eliminate them. In this view it is crucial that tumor tissue
consists of malignant cells, fibroblasts, lymphoid cells, blood vessels and extracellular
matrix components. It is the relationship between these components that is crucial in this
model. The immune cells generally found within tumors include T and B lymphocytes,
NK cells, macrophages and granulocytes. Importantly, this paradigm states that these
cells are not necessarily there to fight the cancer cells any more then the same cells are
present in the gut or the placenta to fight those tissues.
Because this second paradigm takes a neutral position regarding tumor-associated
cells no ulterior motives are attributed to them. For example, the process of angiogenesis
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is required for tumor growth (73). The tumor endothelium does not understand that by
constructing new vessels it helps the tumor grow. It is simply responding to secreted
factors in its predetermined fashion. Similarly, tumor associated lymphocytes are not
aware that they are supposed to attack the tumor cells. Instead they are simply present
because of chemotactic factors within the tumor mass. Both the malignant and nonmalignant cells within tumors can produce these factors. Therefore, the parasitic theory
of cancer assumes that a breakdown of the normal immune response allows a tumor to
develop while the organistic theory contends that a tumor develops because the malignant
cells are able to usurp the normal function of infiltrating cells allowing these cells to
support the cancer cells rather then destroy them.

G 1. Differing paradigms lead to differing interpretation of experimental data.
Obviously, the different paradigms can lead to alternative interpretations of
experimental data. For example, in the parasitology based paradigm, tumor infiltratingdysfunctional T cells are considered cells which are unable to complete their mission,
most likely because of successful immune evasion strategies employed by the malignant
cells. It is assumed that these killer cells were sent to the tumor with the purpose of
eliminating cancer cells. In the organistic paradigm, any tumor-specific T cells are drawn
into the tumor because of chemotactic factors and will function according to
predetermined immune regulatory mechanisms.

While the parasitology paradigm

concentrates on direct tumor-immune cell interactions, the organistic paradigm considers
all components of the tumor mass as contributing to the disease process.
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fundamental differences between the two overriding paradigms of contemporary tumor
immunology may at first glance appear to be incompatible.
However, as researchers investigate the intricacies of tumorigenesis, tumorimmunology and normal and diseased immune systems, a new view of tumor
immunology is beginning to emerge that incorporates components of both paradigms.
One theory called immune-based evolution of cancer development has recently been
proposed which does appear to combine aspects of both paradigms (reviewed in 74).
This theory incorporates the broad concepts of tumor heterogeneity and immune
surveillance into a view that tumor progression occurs within the context of an immune
response against the tumor. Cancer develops during a multi-step process of mutations
and selection leading to the unregulated growth of transformed cells.

The immune

system shapes the evolving tumor since only successful malignant cells that can evade
the immune response survive and pass on the survival characteristics.
Cancer cells have unstable genomes with a higher mutation rate then normal cells.
Because of these mutations each cancer cell can have a different genetic profile from its
sister cells leading to a heterogeneous population of cancer cells within a tumor mass.
The evolutionary theory of tumor progression proposes selective pressures with only the
most fit (able to survive and proliferate) having an advantage and outgrowing their
neighboring cancer cells. One selective pressure is the ability of the immune system to
control the replication of cancer cells. Cells able to avoid immune-mediated killing have
an advantage over sensitive cells. In fact this is the basis of the contemporary concept of
immune evasion strategies of cancer cells.
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Newer theories of tumor progression incorporate these concepts but also consider
all components of the tumor mass when evaluating the interaction of the immune system
with cancer. With this integrated concept of tumor immunology, the immune response
can be dampened by direct interactions between cancer cells and immune cells through
secreted factors like TGF-p or IL-10 or by interaction with other tumor components such
as stromal cells or infiltrating myeloid cells. Perhaps successful cancer cells are able to
engineer a TME that allows for tumor growth unimpeded by the growth constraining
factors like hypoxia or the immune system.
Solid tumors are composed of a heterogeneous combination of cancer cells, host
derived stromal cells (including fibroblasts and blood vessels) and host immune cells. A
progressing tumor contains an environment that can be cytotoxic to both cancer cells and
host cells. Some of the cytotoxicity is mediated by factors secreted by the cancer cells
with direct suppression o f T cells such as TGF-(3 and IL-10. Increasingly, investigators
are discovering complex interactions between cancer cells and the immune system.
Many different tumor types can be infiltrated by large numbers of host derived immune
cells.

Some of these cancers are actually defined by a large inflammatory infiltrate.

Examples of these types o f tumors include; Hodgkin’s disease, some lung cancers,
melanomas, squamous cell carcinomas, oral carcinoma and inflammatory breast cancer
(75). Much o f the infiltrating immune cells are of the myeloid lineage. For example as
many as 40% o f cervical tumors have high numbers of infiltrating granulocytes.
Furthermore, many solid tumors have been demonstrated to contain large numbers of
macrophages (76).
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H. ROLE OF MYELOID LINEAGE INFILTRATING CELLS IN TUMOR
PROGRESSION
H 1. Macrophages and tumor progression
Several investigators have demonstrated that tumor associated macrophages
(TAMs) can have cytotoxic activity against cancer cells (77). This contact dependent
tumor cytotoxicity is most likely mediated by reactive oxygen and nitrogen metabolites
including superoxide radicals, hydrogen peroxide and nitric oxide (78, 79).

In fact,

recent studies have linked macrophage mediated killing with tumor progression with the
observation of a negative correlation between infiltrating macrophages and tumor size in
human tumors inoculated into nude mice (80).
Unfortunately, there is still much that is unknown about the function of TAMs in
vivo. Most in vitro studies analyzing macrophage and cancer interactions use artificially
high numbers o f macrophages. Additionally, the progressing tumor does not represent
normal tissue but rather diseased tissue.

Therefore, conclusions drawn about the

cytotoxic capacity o f macrophages without considering all components of the progressing
TME could lead to erroneous conclusions.
While normal macrophages can be cytolytic for cancer cells, recent studies also
indicate that TAMs can actually enhance cancer cell proliferation.

Products of

macrophages that promote ovarian cancer cell proliferation include IL-6, II-1 and TNF
(81). Additionally, TAMs are able to regulate and modify the deposition of extracellular
matrix components (ECM) (72). This TAM-mediated modification of the tumor ECM
may support the survival, proliferation and metastasis of cancer cells within tumors.
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There is even evidence that some tumor cells secrete factors that attract
macrophages and other leukocytes of myeloid lineage.

Monocyte Chemoattractant

Proteins (MCP-1-2-3) and TNF are secreted by both murine and human tumors, each of
which attracts macrophages to tumors.

Specifically, human ovarian carcinomas have

been shown to produce macrophage colony stimulating factor (m-CSF) and TNF, both of
which attract monocytes to tumors (81). Interestingly, recent studies have demonstrated
that TAMs produce cytokines that can stimulate cancer growth by paracrine loop
mechanisms (82). This study was among the first example of cancer cells engineering
their TME to support continued survival and proliferation through the recruitment of
myeloid lineage cells.
In tumors that contain large numbers of infiltrating immune cells, these cells are
activated and secreting pro-inflammatory cytokines and other immune-modulating factors
(70). The rare lymphoid cells seen in these tumors can also be activated resulting in a
TME that is typical of inflammatory tissue.

Therefore, the dysfunction of tumor-

infiltrating T cells may actually represent a normal immune regulatory pathway, present
in inflammatory tissue but subverted by the cancer cells in order to induce tumormediated immune evasion.
One theory that considers the complex interactions between tumor and host cells
holds that stromal cells such as tumor-infiltrating macrophages can be “enslaved” by the
cancer cells, retained within the tumor to carry out specific functions or to synthesize
critical substances that tumors cannot. These substances include growth factors required
by the cancer cells and critical functions include angiogenesis, breakdown of the ECM
and suppression of the local immune response (72). An interesting study demonstrated
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the importance of tumor stromal cells by showing that single cell suspensions of mouse
fibrosarcoma cells were rejected when injected into mice while the same number of cells
transplanted as a tumor fragment grew progressively (83).

H 2. Granuloctes and tumor progression
Other leukocytes of myeloid lineage that are commonly associated with solid
tumors are cells of the granulocytic lineage, for example polymorphonuclear cells
(PMNs) and mast cells.

PMNs have been shown to contribute to the process of

tumorigenesis because they secrete proteases, angiogenic factors and chemokines
(reviewed in 84).

Intriguingly, neutrophil infiltration of animal tumors has been

correlated with increased tumor growth rates in some studies (85) and with decreased
tumorigenicity in others (86). The tumoricidal function of granulocytes within tumors
appears to be mediated by secreted factors including reactive oxygen species, proteases,
membrane perforating compounds or immune modulating compounds like TNF-cx and
other mediators o f cell killing (IL-lp and IFNs). The reactive oxygen species generated
by granulocytes appears to kill tumors using two mechanisms: they act synergistically
with granulocyte-derived proteases and they inactivate plasma membrane bound anti
proteases of tumor cells.

PMNs can also kill tumors by antibody-dependent cell-

mediated cytotoxicity (ADCC). In fact, recent studies using bi-specific antibodies (aEGF-R/a-Fc receptor) have demonstrated that granulocytes are the most active effector
cells in these studies (87).
However, the tumor-promoting role of granulocytes has also been described. One
pro-tumor mechanism attributed to neutrophils is the intra-tumor secretion of matrix
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metalloproteinase-9 (MMP-9), a protein linked to carcinogenesis and metastasis of cancer
cells (88). While PMNs are the most abundant circulating blood leukocytes and they
provide a first line of defense against infections, their presence within tumors can be a
double-edged sword (89). The tumoricidal attributes of the myeloid cells infiltrating
tumors may be offset by dampening of the specific acquired anti-tumor immune
response.

H 3. Immature granulocytes are able to mediate T cell dysfunction within tumors
T cell dysfunction associated with cancer has recently been attributed to the
presence of high levels o f GR-1+, immature myeloid lineage cells in tumor-bearing mice
and human cancer patients (90). Specifically, Almand and colleagues demonstrated that
tumor-associated, immature myeloid cells can inhibit antigen-specific CD8+ T cell
responses and that direct cell-cell contact is required to inhibit CD8 function.

The

authors of separate studies speculate that myeloid cell production of nitric oxide (NO)
may mediate these alterations to T cells because the NO synthetase competitive inhibitor
LMMA (N°-monomethyl-L-arginine) significantly decreased the suppression of T cell
function (91). Conversely, macrophages, another commonly infiltrating myeloid cell,
secreted hydrogen peroxide that has also been shown to suppress T cell function (13).

H 4 . Tumor progression is related to loss of tumoricidal characteristics of myeloid
cells
Many tumors are infiltrated with high numbers of myeloid cells. For example,
macrophages may represent common tumor-infiltrating cells; as many as every second or
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third cell using immunohistochemistry analysis (76). The percentage of macrophages
within tumors is regulated by intrinsic factors of the tumor.

For example, ovarian

carcinomas can secrete macrophage chemoattractant factors such as M-CSF and TNF
(81).

When activated, macrophages can be tumoricidal-using mechanisms such as

secretion of TNF-oc, which is directly cytotoxic and Interferon-y which has
immunoregulatory properties and is indirectly cytotoxic to tumor cells.

The very

presence of macrophages within growing tumors implies a loss of tumoricidal function of
these cells.

Finally, Mantovani and colleagues have shown that tumor infiltrating

macrophages appear to express decreased class II molecules and secrete high amount of
IL-6 and little IL-1 both of which is proposed to inhibit their anti-tumor function (92).
Neutrophils are a second myeloid cell detected within tumors and they can kill
tumors by direct tumor cell killing by secretion of reactive oxygen species, proteases and
membrane-perforating agents (84). Circulating neutrophils and monocytes in lung cancer
patients demonstrate decreased superoxide generating capacity implying that their anti
tumor function is decreased in these patients (93). Several experimental studies attempt
to exploit neutrophils’ innate anti-tumor properties (94).
Very little is known about the function of tumor-associated myeloid cells. The
few studies that have studied myeloid lineage cells within tumors have extrapolated the
results of normal cell function and simply applied these functions to cancer. However,
tumor-infiltrating myeloid cells may not function normally in this environment.

For

example, granulocytes from cancer patients are immature and express decreased levels of
MHC class-II molecules (91). Additionally, there is evidence that the highly complex
cytokine/chemokine milieu of the TME can alter the function of myeloid cells.
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example, tumors are rich in cytokines, growth factors, chemotactic molecules and
proteases, each of which can alter myeloid lineage cell function. Molecules such as IL4,
IL-6, IL-10, MDF, TGF-pi, PGE2 and M-CSF are present in the TME and can suppress
macrophage function.

Clearly, cells of the innate immune system, which have the

potential to kill tumor cells, can be modified to support tumor growth and suppress CTL
function. The mechanisms by which these myeloid cells are altered by the TME and how
they suppress T cell function, is currently being actively investigated.

I. TRAMP-C1P3 ORTHOTOPIC PROSTATE CANCER MODEL
Progress toward understanding the biology of prostate cancer and the
development of new therapies has been slowed by the lack of adequate animal models for
this uniquely human disease. Although spontaneously occurring prostate cancer has been
observed in canine and rodents, these animals are not proper models to evaluate
molecular mechanisms o f prostate cancer development and progression. With the goal of
developing adequate animal models that mimic human prostate cancer, Greenberg and
colleagues developed a transgenic mouse model where 100% of male mice develop
prostate cancer, by 24 weeks of age, without any chemical or hormonal treatment (95).
These mice express a transgene containing the minimal -426/+28bp regulatory element
of the rat probasin promoter upstream of the simian virus 40 (SV-40) T antigen protein.
These investigators have demonstrated that this probasin promoter was sufficient to target
expression of a linked gene to prostatic epithelium (96). The SV-40 early region tumor
antigens are able to induce transformation in vivo. Specifically, the SV-40 large tumor T
antigen (SV-40 Tag) has been shown to act as an oncoprotein through interaction with the
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tumor suppressors retinoblastoma protein (97) and p53 (98).

The expression of the

oncoprotein was restricted to the prostates leading to the development of prostate cancer
in these mice.
Three cell lines have been established from spontaneous prostate tumors in
TRAMP mice.

These lines have been designated TRAMP-C1, TRAMP-C2 and

TRAMP-C3. TRAMP-C1 and TRAMP-C2 are tumorigenic while TRAMP-C3 is not
(52). Like human prostate cancer, male TRAMP mice undergo a sequence of histologic
steps beginning at puberty with mild hyperplasia, followed by severe hyperplasia, then
neoplastic transformation and finally metastasis (99).

While the metastasis of the

prostate cancer cells can occur anytime after transformation there appears to be a
stoichiometric relationship to tumor burden and time from tumor development. These
investigators demonstrated that distant metastasis can be detected in these transgenic
mice at 12 weeks of age. At this time point the primary tumors are still small but as the
tumors grow the likelihood of metastasis increases with 100% of mice showing large
primary tumors and distant metastasis by 28 weeks of age (99).
Before the development of transgenic mouse models like TRAMP, most
investigators used one of three human prostate cancer cell lines (PC-3, DU-145 and
LNCaP)

injected into

immunodeficient mice.

One obvious weakness

of the

immunodeficient mouse models is that the interaction of the competent immune system
with prostate cancer cannot be evaluated. Alternatively, some investigators have used the
mouse prostate reconstitution model: urogenital cells from p53 null mice injected into the
prostates of syngeneic mice. This model has been shown generate prostate tumors with
the ability to metastasize to the lungs, liver, LNs and bone in these mice (100).
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1 1. Orthotopic TRAMP-C1P3 model to evaluate tumor-immune system interaction
We have developed and characterized a novel orthotopic treatment model for
mouse prostate cancer using the transgenic adenocarcinoma of mouse prostate (TRAMP)
cell line termed TRAMP-C1P3.

This cell line was generated by three intra-prostate

passages o f TRAMP-C1 cells. Prostate tumor cells were isolated, expanded in culture
and re-injected into a separate syngeneic mouse. With sequential passage of these cells
the resultant tumors appeared earlier and were more metastatic compared to the parental
line.

The orthotopic TRAMP-C1P3 model represents a clinically relevant system to

evaluate tumor-host interactions during an immunotherapeutic intervention.

Several

features o f this model make it an ideal system to study the human disease progression and
immune system/tumor interactions.

First, as is common in human prostate cancer,

TRAMP-C1P3 cells down-regulate MHC class I antigens in vivo.
This phenomenon represents a challenge for therapies designed to augment MHC
class I-restricted tumor rejection. Second, TRAMP-C1P3 cells express a well defined
tumor antigen (WT1) as a potential target for the immune system. WT1 is a weak tumor
antigen and provides an opportunity to assess the efficacy of novel therapies to augment
the anti-tumor immune response to this naturally processed tumor antigen. Third,
TRAMP-C1P3 cells predictably metastasize to the draining lymph nodes (dLNs) in a
high number o f tumor-bearing mice. Because of the high incidence of metastases, the
efficacy of a specific therapy to prevent metastatic spread or eliminate metastatic disease
once established can be addressed in this model.
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I 2.

Prostate cancer chemoprevention and immunotherapy studies using the

TRAMP model
Because male TRAMP mice reliably develop prostate cancer, this model has been
used

in

chemoprevention

and

immunotherapy

studies.

For

example,

a-

Difluoromethylomithine was shown to decrease the size of prostate tumors and the
incidence o f metastasis in TRAMP mice (101).

Additionally, green tea polyphenol

delayed tumor incidence, decreased tumor burden and almost completely inhibited distant
site metastasis (102).

Immunotherapy using Flt3-Ligand (flt3-L) induced a transient

regression o f ectopic TRAMP tumors (103). Flt3-L therapy stimulates the bone marrow
of mice to produce large numbers of immature myeloid cells by binding to a surface
tyrosine kinase receptor (flt-3) which stands for fyms-like tyrosine kinase-3 (104).
Binding o f this receptor by its ligand activates the tyrosine kinase and stimulates
proliferation of myeloid precursors. Myeloid cells that are increased in the blood and
spleens of flt3-L treated mice include increased DCs, macrophages and granulocytes.
Each of these myeloid lineage cell types has the potential to be tumoricidal and inhibit
TRAMP tumor growth. These studies indicate that the progression of TRAMP tumors
can be halted or reversed by therapeutic intervention.
Therefore, several important topics must be addressed before truly effective
immunotherapies can be developed for long term control of cancer in patients with
established tumors. In this dissertation I quantified tumor specific CD8 lymphocytes and
characterize these cells for expression of signaling molecule, co-receptors, activation and
inhibitory molecules from spleens, dLNs and prostate tumors of tumor bearing mice. The
extent to which tumor-specific CD8 cells are protected or selectively suppressed within
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the TME and the components of the TME that mediate these changes must be determined
before novel immunotherapies can be developed to treat established cancer.
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CHAPTER II
SPECIFIC OBJECTIVES
The purpose of this study was to identify the component(s) of the TRAMP-C1P3
TME that alter the expression of signaling molecules, of tumor-infiltrating T cells.
Additionally, the mechanism(s) by which the TRAMP TME alters tumor-infiltrating T
cells was evaluated.

With the information generated by these studies, a greater

understanding of cancer-mediated T cell dysfunction may allow for the development of
novel therapeutic interventions to circumvent the immunosuppression associated with
cancer.
The specific objectives of this project were:
1) Characterization of the cellular composition and chemokine/cytokine milieu
of the TRAMP TME.
These studies were designed to evaluate the major cellular components of the
TRAMP TME.

To characterize host-infiltrating leukocytes, prostate tumors were

subjected to enzymatic digestion, ficoll-hypaque gradient separation and flow cytometric
analysis using lineage-specific antibodies.

2) Characterization of TRAMP TME-induced alterations of T cells.
Changes in T cells mediated by the TRAMP TME with respect to protein
expression were analyzed. Protein expression studies included surface and cytoplasmic
analysis of CD3/TCR complex components, co-receptors of the CD3/TCR complex and
molecules with known function for T cells including activation and inhibition (CTLA-4)
associated molecules using flow cytometry.

The extent to which the TME-mediated

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

37

alterations o f T cell signaling molecules could be reversed by removal of the cells from
the TME was also evaluated.

3)

Determine which and by what mechanism(s) TRAMP tumor-infiltrating host

immune cells alter infiltrating T cells.
An in vitro co-culture assay was developed that recreated the complex
interactions between T cells and specific components of the TRAMP TME. This assay
was used to evaluate what cell types contribute to the observed perturbations of the
CD3/TCR complex and to examine the role of H 2 O2 as a potential effector molecule
responsible for the disruption of the CD3/TCR complex.
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CHAPTER III
MATERIALS AND METHODS.
A. CELLS USED IN THESE STUDIES
A l . TRAMP-C1P3 cells
TRAMP-C1P3 cells are prostate tumor cells derived from three intra-prostatic
passages of TRAMP-C1 cells into C57B1/6 mice. Greenberg and colleagues developed
TRAMP-C1 cells by tissue culture isolation of tumor cells from a spontaneous prostate
tumor in transgenic mice (95).

The TRAMP acronym stands for transgenic

adenocarcinoma of mouse prostate and this transgenic model consists of mice with the
SV 40 T-antigen (SV40 Tag) downstream of a rat probasin promoter.

This gene

arrangement only allows for the expression of the oncogenic SV40 Tag gene in prostate
epithelial cells. In this model ~100% of male mice develop prostate cancer by 3 months
of age. The TRAMP-C1 line is a transplantable tumorigenic cell line and most studies
using this line have employed an ectopic model where 5 million cells are injected
intradermally and the resulting tumor growth is evaluated in immunotherapy studies
(103).
In order to generate a more metastatic variant of the TRAMP-C1 cell line 5
hundred thousand TRAMP-C1 cells were injected directly into a prostate gland of the
syngeneic C57B1/6 mouse. When prostate tumors were detected by palpation, the tumor
was excised and the tumor cells were expanded in vitro. After expansion the process was
repeated twice more and the resultant tumor cells cultured from the third passage were
expanded, cryopreserved and used in these orthotopic tumor treatment studies. O f note is
the observation that the TRAMP-C1P3 cells grew faster in the prostate glands of mice
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and were more likely to metastasis to dLNs indicating that TRAMP-C1P3 cells were
accustomed to growth in mouse prostates and developed a more metastatic phenotype
(manuscript in preparation).
All TRAMP derived cell lines were cultured and/or expanded in TRAMP media.
This media consisted o f RPMI media (Gibco BRL) supplemented with 25 pg/ml
penicillin and 25ug/ml streptomycin (Gibco BRL), 2mM L-glutamine (Gibco BRL), 10'

o

M Dihydrotestosterone (), lOpg/ml Insulin (Sigma), 5% FBS (Hyclone), 5% Nu-serum
IV Culture Supplement (BD Biosciences).

A 2. Generation of Orthotopic TRAMP-C1P3 tumors
In order to generate orthotopic prostate tumors 6-8 week old male mice were
anesthetized using methyoxyflurane in an airtight chamber.

Animal procedures were

performed under EVMS #99-001 animal use protocol and IACUC regulations. When
completely unconscious, the mice were transferred to a surgical platform with a nasal
hood over their nose with anesthetic flowing to keep them unconscious. The abdomen of
each mouse was shaved and washed with Betadine antiseptic and swabbed dry with
sterile gauze. A 2 to 3 cm mid-line incision was made using a forceps and surgical grade
scissors. The bladder and seminal vesicles were lifted out of body cavity using sterile
cotton tipped applicators, and the prostate gland was identified.
TRAMP-C1P3 cells were resuspended in PBS at 10 x 106 cells/ml. Then five
hundred thousand TRAMP-C1P3 cells in 50pl of fluid was injected into the prostate
gland. With proper injection, a bleb forms in the prostate.
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A cotton-tipped applicator was used to lightly dab any leakage of cancer cells
from the prostate surface. Then the prostate, seminal vesicles and bladder were replaced
into mouse abdomen and the incision was closed using sterile surgical staples and stapler.
Following surgery the mice were removed from the anesthetic cone and allowed
to recover in clean cage on paper towels with surveillance. After complete recovery of
the mice from anesthesia, the incisions and the mice were checked every day for the next
5 days, then every other day for general health and tumor development.
After about 21 days the mice were palpated daily in order to detect the
development of prostate masses, engorged seminal vesicles or distended bladder. Mice
were sacrificed at specific intervals or when moribund because of tumor progression
(usually urinary blockage).

A 3. Tumor excision
Mice with palpable prostate tumors were sacrificed using a CO2 chamber and
their abdomen was swabbed down with 70% ETOH using sterile gauze. Sterile scissors
and forceps were used to make a mid-line incision to the right side of previous surgical
incision. Then the bladder and seminal vesicles were lifted from body cavity to search
for any prostate masses.
Once a prostate mass was identified, the seminal vesicles and bladder were
removed and the mass excised from underneath using sterile scissors.

The overall

dimensions o f the excised tumors were estimated and recorded using a metric ruler. The
extracted tumor mass was transferred to a sterile tube containing media or PBS (Cellgro
Inc.) depending on the protocol.
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A 4. Enzymatic TRAMP-C1 tumor Digestion
The purpose of enzymatic digestion of tumors is to make a single cell suspension
of solid tumors so individual cells can be analyzed with regard to their protein
expression. The digested tumor cell suspension is assumed to be equivalent to the total
cell population o f the original TRAMP tumor.
In order to achieve this, the ex-planted prostate tumor was thinly sliced and
minced using two opposing scalpels or one scalpel and one forceps to hold tumor chunks
in a small volume of digestion buffer (see appendix I for buffer recipe). Basically, this
buffer contains collagenase (Barringer Mannheim), DNase I (Sigma) and hyaluronidase
(Sigma) in a saline solution. The tumors were minced until the resultant chunks were
~1mm cubes in order to optimize digestion efficiency of the enzymes. When sufficiently
minced, the tissue was transferred to a digestion beaker with a magnetic stir bar and an
additional volume of digestion buffer was added to submerge all tumor chunks (typically
-1 0 -2 0 mis).
The digestion flask was transferred to 37C incubator and placed on an inverted
petri dish on stir plate set at medium speed just enough to keep the tissue moving for 45
minutes. The stir plate as monitored closely throughout the process to assure mixing.
After digestion the supernatant was transferred to a sterile 50ml tube and allowed to settle
for 5 minutes before transferring the supernatant to a fresh tube. Then the cells were
washed once with RPMI (Cellgro, Inc.) with 10% FBS (Hyclone, Inc.) to stop the
digestion process. The tumor digests were examined under the light microscope with
trypan blue to determine viability and percentage of single lymphocytes.
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A 5. Ficoll-hypaque gradient separation of TILs (tumor-infiltrating leukocytes).
To separate leukocytes from tumor cells, 2.5ml aliquots of the tumor digests were
carefully pipeted over 2.5 mis of Isolymph (Gallard-Schlessinger, Inc., Germany) and
centrifuged at 1500 rpm (280xg) for 45 minutes at room temperature with no brake.
Tubes were carefully removed from centrifuge and the band of cells at the interface
between the Isolymph and tissue culture media were removed using a glass pipette
making certain that any cells in the pellet remained behind.
Once all the gradient cells were collected they were washed in PBS or complete
media in 15 mis centrifuge tubes to full volume.

Finally, the leukocytes were

resuspended in 2 mis and counted in a Coulter counter. Typically I recovered between 13 x 106/mm3 leukocytes from each tumor but this number varied depending on the size
and age of the tumor examined, any immunotherapy provided to the animal and also on
the efficiency o f the digestion procedure.

B. FLOW CYTOMETRIC STAINING
B 1. Protocol for staining of lymphocytes for flow cytometry.
Ideally one million cells per tube should be stained for each combination of
antibodies, but lower numbers of cells can be used and the amount of antibodies adjusted
accordingly. As few as 300,000 cells per tube can be used but fewer cells may not allow
enough events for analysis by the flow cytometer.
Cells are blocked with 5 pi of normal rat serum (Sigma) for 15 minutes at 4C.
Then, with the rat serum still present, the recommended amount of primary antibodies
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was added as determined by the number of cells in the tube (see appendix 3 for optimum
antibody concentrations). The mixture is incubated at 4 C, in the dark for 15-30 mins.
After antibody incubation, 2 mis of cold wash buffer (PBS with 1% normal goat
serum (Sigma) and 0.1% Na-azide (Sigma)) is added to the cells and the tube was
centrifuged at 1300 rpm for 5 minutes in order to pellet cells. The supernatant was
recanted and the pellet was re-suspended in the residual volume. If secondary antibodies
are required for the staining protocol these antibodies can be added at the appropriate
concentrations at this time, with additional 15-30 minutes incubation at 4 Cin the dark.
Unbound secondary antibodies were removed by repeating the wash step above.
The fluid was decanted and the cell pellet resuspended in 1% paraformaldehyde (Electron
Microscopy Sciences) in PBS as a fixative for storage. The cells can be stored at 4C in
the dark for several day/weeks and analyzed with the flow cytometer. Before analysis the
fixative should be washed off with 2 mis of wash buffer to reduce autofluorescence
caused by the fixative.

B 2. Permeabilization of cells to analyze intracellular protein expression
In order to detect intracellular antigens by flow cytometry, cells were
permeabilized using the detergent digitonin. Cells were washed once in PBS (Cellgro,
Inc.) containing 1% bovine serum albumin and 0.1% sodium azide.

Cells were

resuspended in 100 pi of 1% digitonin solution (Calbiochem) in PBS and incubated for 12 minutes at 4C. The selected antibody against the intracellular antigen was added using
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optimal concentrations as determined by the manufacturer or as determined by the
investigator.

B 3. Identification of lymphoid cells using gating strategies of the flow cytometer
In order to identify T cells for analysis, the list mode generated data was subjected
to multiple gating strategies so that only single T cells were analyzed. The first gate used
forward scatter versus side scatter to identify small relatively agranular cells distinct from
cellular debris. This gate is commonly called the lymphoid gate and is based on control
splenocytes to identify the placement of lymphoid cells. This first gate was important for
the analysis because cellular debris often binds antibodies non-specifically. This would
lead to the mistaken conclusion that the protein was expressed on these fragments when it
was not.
Additionally, large or granular events were also excluded from analysis to exclude
doublets and myeloid cells from the analysis. Analysis of doublets would result in the
erroneous conclusion that a single cell expressed protein profiles of both cells.

For

example, analysis o f a B cell/T cell complex would lead to the false conclusion that T
cells expressed B cell-restricted molecules. By only analyzing events within the single
cell lymphoid gate these problems were minimized.
Once the lymphoid cells were identified by laser light scatter properties,
lymphoid cells were subjected to a second gate. This gate was based on expression of
one of the T cell specific proteins as identified by fluorochrome positive cells.
Expression was considered positive if two criteria were met. First, the antibody binding
was higher then background staining of an irrelevant control antibody and second, T cell
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specific antibody binding was higher then the background binding of the anti-T cell
specific antibody to non-T cells.
These criteria were established using splenic lymphocytes and were confirmed
for each antibody used and for each analysis performed. As controls to confirm proper
dilution and binding of antibodies, cells not exposed to the TRAMP TME were included
in every staining procedure. These control cells were either normal C57B1/6 spleen cells
or spleen cells from tumor-bearing mice. If one antibody did not function as expected in
the control group, this antibody was removed from analysis.

Additionally, the non

functioning antibody data was not used to gate T cells and the expression of the
corresponding protein was not analyzed on gated T cells using antibodies that stained
properly in that study.

In the vast majority of staining procedures, all antibodies

performed as expected and were included in the analysis.
To confirm that enzymes used to digest prostate tumors to a single cell
suspension do not alter the percentage of T cells expressing individual molecules, normal
spleens were digested in the same manner as prostate tumors. These studies showed that
exposure of T cells to digestion enzymes did not decrease expression of signaltransducing molecules. Therefore, the enzymes do not mediate any alterations to T cells
within tumors.

B 4. Procedure to create Tetramers from monomers
To stain one million cells for tetramer staining, use 1.5 pi of the assembled
tetramers as described below. Tetramers should be made and used fresh, less then a week
old because these structures may be unstable and lose conformation and thus antigen
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binding with time. Like all antibodies, tetramers must be stored at 4C in the dark. It is
important to keep fluorochrome compounds in the dark as much as possible to decrease
quenching o f the fluorochrome.
In order to assemble tetramers from monomer subunits, Ultra-Avidin conjugated
to phycoerythrin fluorochrome (PE) (Leinco Tech.) was gradually added to the monomer
subunits until a 4:1 ratio is attained. Monomers were a gift from the tetramer-facility at
Emory University created by linking the WT1 (130-138) peptide to the MHC-I molecule
H2-Db.

These monomers recreate the folding pattern of the naturally occurring

peptide/MHC complex in C57B1/6 mice. Any T cell able to recognize and bind to this
fluorochrome-labeled molecule is also able to recognize this complex in the mouse
immune system. Tetramers are typically used for flow cytometry studies because the
presence of four ligands for T cell TCRs is more stable then single fluorochrome-labeled
molecules.
Monomers are provided from the tetramer facility at 1 mg/ml.

To create

tetramers, lOpl o f momomers were added to a 1.5 ml Eppendorf tube. Then, 35 pi of
PBS was added to the tube.

Next 1 pi of Ultraavidin-PE conjugate (1 mg/ml) and

incubated for 5 minutes at room temperature. Then, 2pi of Ultraavidin-PE was added
and incubated for another 5 minutes at room temperature. This step was repeated with
another 2pl o f Ultraavidin-PE. After a five minute incubation 5pi o f Ultraavidin-PE was
added and incubated, followed by a second addition of 5pi of Ultraavidin-PE and
incubation. Therefore, a total of 15pl of Ultraavidin was added to lOpl of monomer
complexes slowly over 25 minutes at room temperature. The final volume of tetramers is
60pl and 1.5pl of these tetramers is used to stain one million cells. The 60 pi is enough
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for 40 tests o f one million cells each. These tetramer complexes can be stored at 4C for
up to 3 months and the monomers can be stored at -20C in 25 pl/tube aliquotes for long
term storage.

B 5. Statistical Analysis
All statistical analysis in these studies was performed using the PRISM
statistical software package (Graphpad Software, Inc.).

This package was used to

perform One way ANOVA analysis to compare different groups of data generated in
these studies. This package gives the probability that statistically significant differences
exist between any of the groups of data.

If the P value is determined to indicate a

significant difference between any groups then the program performs a subsequent Multi
variant analysis of the operator’s choosing.

For these studies Tukey Multi-variant

analysis was chosen in order to compare individual groups. The software provided P
values for each comparison and any significant differences (P<0.05) were noted in the
text and/or in figures corresponding to the data.

C. PREPARATION OF SINGLE CELL SUSPENSION OF SPLEEN CELLS
Spleen(s) were aseptically removed from mice euthanized in a CO2 chamber.
Spatulas are used to mechanically tease apart spleens in 2 mis of RPMI media (Cellgro
Inc.) with 10% FBS (Hyclone), 10 mis of PBS (Cellgro Inc.) was added and the mixture
centrifuged at 1500 rpm (280xg) for 5 minutes. The supernatant fluid was decanted and 5
mis o f a hypotonic RBC lysing solution/spleen (see Appendix 4 for recipe) was added
and incubated at 37C for 2 minutes. Finally, 7 mis of RPMI-10% FBS media was added
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to the solution to stop cell lysing process and centrifuge at 280xg for 10 minutes. The
pelleted cells were resuspended in 2 mis of RPMI-10% and counted using either a
Coulter counter or a hemocytometer.

D. T CELL ENRICHMENT USING NYLON WOOL ADHERENCE
Dry, sterile nylon wool column was hydrated by adding 10 mis of RPMI-10%
FBS media, sealing both ends of column and incubating for 1 hour at 37C in a tissue
o

culture incubator. Following incubation as many as 10 cells in 2-5 mis of media was
added to the nylon wool column and incubated for 45 minutes to allow adherence of nonT cells to the nylon wool. After the incubation, the column was washed with 25 mis of
RPMI-10% FBS media, the non-adherent cells (T cell enriched population) was collected
in a 50 ml centrifuge tube counted in a Coulter counter and stored on ice until ready to
use.

E. IL-2 CULTURE OF EXTRACTED TUMOR-INFILTRATING CELLS
Tumor-infiltrating leukocytes were isolated from orthotopic TRAMP tumors by
digestion of the solid tumor with collagenase digestion buffer (see above) and the
resulting single cell suspension was separated by cell density using a ficoll-hypaque
gradient (Gallard-Schlessinger, Inc). Mononuclear cells were cultured in six well plates
in tissue culture media containing RPMI-1640 media (Cellgro, Inc.) supplemented with
10% fetal bovine serum (Hyclone, Inc.), 2mM L-glutamine (Gibco-BRL) and 25 u/ml
penicillin streptomycin (Gibco-BRL). To this media, 100 units/ml of recombinant human
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IL-2 (Immunex) was added and the TILs incubated for 20 hours at 37C in a CO2
incubator.

F. MILTENYI COLUMN PURIFICATION OF CELLS
Isolate single cells according to standard laboratory preparation method (Ficollhypaque if suspension contains debris). The cells were labeled with biotin-conjugated
antibodies according to the procedure above, with the exception that de-gassed MACS
buffer (PBS (Cellgro Inc.) with 2mM EDTA (International Biotechnologies, Inc.) and
0.5% BSA (USB Inc.)) was used in place of PBS with 1% normal goat serum and 0.1%.
n

The stained cell pellet was re-suspended in 80ul of MACS buffer per 10 total
n

stained cells and 20ul of Miltenyi Anti-Biotin Microbeads per 10 cells stained were
added. This solution was incubated at 4C for 15-30 minutes after which the cells were
o

washed with 2 mis of MACS buffer and carefully resuspend the in 500pl/10 total cells of
MACS buffer.
n

Using the MS (Miltenyi Biotec) magnetic column for up to 10 positively
selected cells and LS (Miltenyi Biotec) magnetic column for less then 108 positively
selected cells, the cells stained with the magnetic beads were applied to the Miltenyi
column while exposed to the magnetic field of the Miltenyi MiniMACS Magnetic cell
separator device.

The column was washed with three times the cell volume while

continuously exposed to magnetic field. Any cells that migrate through the column at
this step are considered flow through cells and are therefore negative for the stained
antibodies.
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The column was removed from the magnet and three mis of MACS buffer was
added and a plunger was forcefully depressed forcing the buffer to wash any cells
remaining in the column into a centrifuge tube. These are positively selected cells and
are therefore positive for the stained antibodies. The cells were washed in PBS buffer,
counted and kept on ice until further use.

F 1. Isolation and purification of GR1 positive cells
In order to purify GR1 positive cells for in vitro co-culture assays, mice were first
injected subcutaneously with 5 million B16-FL tumor cells and tumors were allowed to
grow in these mice for ~30 days. B16-FL cells are mouse melanoma cells that were
transfected with the trimerized form of the flt3-L gene so that they secrete this ligand into
the circulation of the mice. As the tumors grow the tumor burden increases and the level
of flt3-L in the blood increases. After 30 days the tumors are quite large and the spleens
of tumor-bearing mice become about five times normal size and are greatly enriched for
myeloid cells because of the flt3-L therapy. Many of these cells are GR1 positive cells so
these spleens served as a rich source of myeloid cells for the in vitro co-culture assays.
Single cell suspensions of splenic mononuclear cells were prepared from B16-FL
tumor-bearing mice, counted in a Coulter counter and stained for the expression of GR1
protein using the optimum concentration of antibody (clone Ly6G) used for flow
cytometry. Cells were stained with anti-mouse immunoglobulin bound magnetic beads
and the GR1 positive cells isolated using a Miltenyi magnetic (either LS or MS
depending on cell numbers) column according to the procedure above. Purity of these
cell populations generally exceeded 90%.
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F 2. Isolation and purification of Macrophages
To purify splenic macrophages for use in in vitro co-culture assays, anti
macrophage F4/80 antibody was used to stain cells using the optimum concentration
determined for flow cytometry.

Stained cells were applied to a Miltenyi magnetic

column and the purified macrophages (F4/80+) cells were counted and used in in vitro co
culture assays. Purity of these populations generally exceeded 90%.

G. IN VITRO CO-CULTURE ASSAY
The in vitro co-culture assay developed in this laboratory used up to three types of
cells which occur within TRAMP tumors to investigate tumor/host cell interactions.
Three cell types studied were: 1) nylon wool-enriched T cells from normal mouse
spleens, 2) GR1+ cells isolated using Miltenyi magnetic bead columns from flt3-L treated
mouse spleens and 3) TRAMP-C1P3 cells.

Since TRAMP cells required the most

complex tissue culture media supplements, the assay was performed in TRAMP media
(see above). Purified cell types were added to individual wells using various ratios in a
final volume of lOmls of TRAMP media. Plates were incubated for 48 hours at 37C with
agitation at 24 hours to disperse the cell suspensions. Following incubation cells were
collected from each well and aliquoted into separate tubes for staining and phenotyping
by flow cytometry. The volume of media used in these assays (lOmls) was selected in
order to mimic the high cell density of tumors growing in vivo and the lower surface area
exposed to the CO 2 during incubation mimics the hypoxia common for poorly
vascularized tumors.
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The wells were incubated for 48 hours at 37°C to allow the cells to interact and
respond to each other to mimic similar TME interactions. This length of time for co
culture of the cells was selected based on published procedures showing that co-cultured
T cells and tumor cells in increasing ratios altered the expression of signaling molecules
(21). The cell ratios chosen for these studies were based on ratios similar to those noted
within flt3-L treated TRAMP tumors. Myeloid cells comprise the most common cell
types within flt3-L treated tumors, followed by TRAMP tumor cells and T cells. For
these studies, as many as five times more GR1 positive cells were co-cultured with the T
cells because this is approximately the ratio seen in flt3-L treated tumors. Additionally,
the number of TRAMP-C1P3 cells was about half as many as the T cells because
previous studies indicated that this number of TRAMP cells co-cultured with T cells was
insufficient to alter the signaling molecules of T cells. For these studies, five tubes of
cells were stained and analyzed in order to evaluate the expression of nine markers and
negative controls. Since 106 cells were needed for staining in each tube, 5 million T cells
were added to each assay well and the numbers of other cells were based on the number
of T cells.

H. CATALASE ASSAY
To determine the extent to which H 2 O 2 is responsible for changes to T cells in
the in vitro co-culture assays, increasing amounts of catalase (Sigma) were added to co
culture wells. The procedures for these assays were similar to the standard co-culture
assays with the exception that catalase was added to specific wells at the initiation of the
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assay and remained in the wells for the entire 48 hour incubation period. Cultured cells
were stained and phenotyped by flow cytometry as described above.
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CHAPTER IV
RESULTS
A. INTRODUCTION
The studies described below began with the objective to characterize TRAMP
tumor-infiltrating T cells.

I hypothesized that, factors within the TRAMP tumor

microenvironment (TME) fundamentally altered infiltrating T cells, perhaps as a
mechanism o f immune evasion by the tumors. However, the TME is very complex,
composed o f TRAMP cells, infiltrating myeloid cells and the factors secreted by each of
these cells. The studies described below incorporate three main areas of investigation.
The first defines the cellular composition of TRAMP TME. The second section uses an
in vitro culture system to identify the cells and molecular mechanisms responsible for the
disruption o f the TCR/CD3 complex.
Therefore, the first series of experiments sought to identify the most common
leukocytes infiltrating ectopic TRAMP-C1 tumors.

Specifically, the percentage of

infiltrating T cells, B cells, natural killer cells, macrophages/monocytes, dendritic cells
(DCs) and granulocytes were determined using flow cytometry with lineage specific
antibodies.

The expression of the maturation molecule MHC class II and the co

stimulatory molecule B7.1 was determined for tumor-infiltrating DCs in order to
determine their ability to stimulate tumor-specific T cells in these mice.
Because many of the T cell specific molecules are lost on tumor-infiltrating T
cells, studies were performed to identify the best preserved T cell specific molecules on
tumor-infiltrating T cells. TILs were isolated and removed from the TME to determine if
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the loss o f signaling molecules was permanent or transient. Finally, the expression of
signaling molecules of the CD3 complex as well as the activation molecule CD95 (fas)
and the inhibitory molecule CTLA-4 was determined on tumor-infiltrating T cells and
compared with WT1-specific tetramer binding tumor-specific T cells.

A 1. Prostate cancer models were used for phenotyping studies.
In order to obtain prostate tumors to characterize the cellular composition of the
host cell infiltrate, six orthotopic tumor studies and two ectopic studies were initiated in
the laboratory. Ectopic tumors were generated with the injection of 5 million TRAMPC l cells subcutaneously.

Because ectopic tumors from the TRAMP-C1 line do not

metastasize from the injection site, tumors can grow to ~ 10% of body mass (limit
allowed by IACUC) without causing morbidity to the mice. Additionally, the tumors do
not inhibit any critical function of the mouse. The orthotopic tumors induce profound
morbidity by blocking the ureter of the host causing kidney failure and death. Therefore,
ectopic tumor-bearing mice can live much longer then orthotopic-tumor bearing mice.
For example, no tumor can be palpated in the skin of mice until about 30 days
post-injection. The tumor is only the size of a seed at this point.

Conversely, mice

injected into the prostate glands with half a million TRAMP-C1P3 cells have very large
prostate tumors at 30-40 days, have urologic complications and expire 35 to 42 days post
injection. Mice with ectopic tumors suffered no obvious ill effects from large tumors. In
fact, mice were routinely followed for 60-90 days post injection and only sacrificed for
humane reasons when the total tumors constituted greater then 10 percent of body mass.
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The differences in the growth of TRAMP-C1 and TRAMP-C1P3 are likely
mediated both by the differences in the site of injection and innate differences in the cell
lines. For example, the TRAMP-C1P3 variant o f the TRAMP-Cl line was created in our
laboratory by three sequential passages of the parental line through syngeneic mouse
prostates. When half a million parental cells were first injected in host prostates, no
tumors were detected for 60 days and no metastases were noted. A tumor was excised
and tumor fragments were expanded in culture. This line was designated TRAMP-C1P1.
Then, half a million of these cells were injected into another syngeneic mouse.

A

palpable prostate mass was detected within 45 days. The tumor from this injection was
also explanted and expanded in vitro and designated TRAMP-C1P2.
No metastases were noted with these cells but the tumors grew faster than with the
parental line. Finally, TRAMP-C1P2 cells were injected into a new syngeneic prostate.
With these cells, a prostate tumor was palpable by approximately 40 days, draining
lymph nodes were enlarged, and tumor cells could be grown from these enlarged lymph
nodes. This tumor was explanted and became the source of the tumor cells that were
designated TRAMP-C1P3. These cells were expanded in vitro and frozen for long term
storage. Only early passages of these cells (<p5) were used in the orthotopic studies.
The TRAMP-C1P3 cells were selected by their ability to grow within mouse prostates.
Therefore, any cells of the parental line that had a growth advantage were selected and
expanded within the tumors.

In this way the increasing growth rates and higher

metastatic rate in the later tumors can be explained by the in vivo selection of tumor cells
with enhanced survival factors within syngeneic mouse prostates.
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A 2. C haracterization of B cells, T cells and NK cells within TRAMP tumors.
To determine the type of infiltrating cells in ectopic and orthotopic TRAMP
tumors and whether flt3-L therapy alters the type of infiltrating cells phenotyping studies
were performed. In these studies, mice bearing ectopic TRAMP-C1 tumors were treated
for 30 days with either subcutaneous injections of 30 pg/day flt3-L or carrier buffer only.
Ectopic TRAMP-C1 tumors were excised, digested into single cell suspensions, and
stained and phenotyped using a flow cytometer. Five tumors from both flt3-L and carrier
treated mice were combined for these studies.
Fig. 1A shows that relatively few infiltrating cells stained with the anti-B cell
antibody CD45R/B220 isoform. Only about 5% of tumor-infiltrating cells within the
lymphoid FSC vs. SSC gate from flt3-L treated tumors were B220 positive and less then
1% o f these cells were positive in carrier treated tumors. This antibody binds a 220 kDa
isoform of a transmembrane glycoprotein of the tyrosine phosphatase family (105).
Unfortunately, while this antibody was previously thought to be B cell specific, recent
evidence indicates that other cells express this protein including rare subsets of T cells,
NK cells, T cells and even DCs and monocytes or macrophages.

I minimized this

problem by restricting the cells within TRAMP tumors that were analyzed for expression
of B220 to low side scatter and small cells. This gating strategy prevented the analysis of
all the myeloid cells, such as DCs and monocytes. Because only very rare subsets of T
cells and NK cells also express the B220 antigen, the number of cells within the
lymphoid gate reflects an accurate estimation of the number of tumor-infiltrating B cells
in flt3-L and carrier treated tumors.
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TRAMP infiltrating cells binding the pan-NK antibody DX5 identified a rare
population of cells of less then 1 x 105 lymphoid cells/tumor (data not shown). In fact,
DX5 positive cells were often undetectable in TRAMP tumors. Tumor-infiltrating T
cells, both CD4 positive or CD8 positive cells isolated from the Ficoll interface also
comprised a minor population of mononuclear cells at the Ficoll interface. For example,
after 8 days of therapy (-37 post implantation) less than 5 x 105 cells/tumor expressed
any lymphoid markers (B cell, T cell or CD4 and CD8 T cell subsets). Eight days later,
the number of infiltrating lymphoid cells increased in the flt3-L treated tumors but
decreased in the carrier treated tumors. There were about 1 x 106 CD4 cells, 2 x 106 CD8
cells and -2 x 106 B220 positive cells/tumor in the flt3-L treated tumors but lymphoid
cells were undetectable in carrier treated tumors.

This lymphoid infiltrate was

undetectable in both carrier and flt3-L treated tumors after 20 days of treatment. After 70
days later, only flt3-L treated mice were still alive. The tumor infiltrate at that time was
low than tumors after 8 days of therapy with only 5 x 105 of the cells expressing CD3, 7 x
105 of the cells expressing CD4 and CD8 and less than 5 x 105 of the cells/tumor
expressing B220.

A 3. Analysis of myeloid lineage cells infiltrating TRAMP tumors
Fig. IB shows the percentage of tumor infiltrating cells in the same studies that
expressed myeloid lineage markers. These studies demonstrate that the majority o f the
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Fig. 1. Phenotyping of TRAMP-C1 tumor-infiltrating immune cells.
Single color flow cytometry analysis was performed in order to determine the
percentage of TRAMP-C1-infiltrating cells from ectopic tumors treated with either flt3L or carrier that expressed the indicated molecules. Tumors were excised at the
indicated times post therapy and a single cell suspension was made by enzymatic
digestion according to procedures in the Materials and Methods section. Cells were
stained using the optimal concentrations of antibodies for flow cytometry according to
manufacturer’s recommendations and the total number of cell type was determined
based on the percentage of positive cells for each antibody used. Tumors were either
from Flt3-L treated or carrier treated animals. Three to five tumors were pooled from
each group for these studies.
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large numbers o f mononuclear cells isolated from ectopic TRAMP-C1 tumors were
myeloid lineage cells. Additionally, this figure shows that flt3-L therapy increases the
number o f myeloid but not lymphoid infiltrating cells with a peak infiltrate noted after 16
days o f therapy. My expectation was that mouse TRAMP cells would make up the vast
majority o f the mononuclear cells. Instead as many as 6 x 10 isolated cells/tumor from
ectopic TRAMP tumors expressed the myeloid lineage restricted marker C D llc after 16
days o f flt3-L therapy.

The number of C D llc positive cells in flt3-L treated mice

reached a peak after 16 days of therapy and declined after that to levels of about 2.5 x
106/tumor after 20 days of treatment. This antibody specifically binds the mouse alphax
integrin chain (105). This chain consists of a 150 kDa transmembrane glycoprotein that is
a non-covalent binding partner with CD 18. Together this pair forms the integrin receptor
called CR4.

C D llc has been detected on dendritic cells, natural killer cells,

granulocytes, monocytes and macrophages. Additionally, flow cytometric back-gating
procedures confirmed that the C D llc positive cells were larger and more granular then
lymphoid cells further confirming the myeloid lineage of the majority of the cells within
TRAMP tumors (data not shown).

A second surprising result of these phenotyping

studies was that many o f TILs also bound an antibody specific for mouse Ly-6G antibody
(Grl). This antibody specifically binds a 21-25 kDa GPI-linked membrane protein is
expressed on the mouse granulocytes some monocytes and macrophages (105).
Specifically, about 1.5 x 106/tumor of infiltrating mononuclear cells expressed GR1 after
8 days o f treatment with flt3-L which increased to almost 60 x 106/tumor after 16 days of
treatment and then declined to less then lx 106 cells/tumor after 20 days of therapy.
Carrier treated tumors showed relatively few C D llc or GR1 positive cells at any time
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during therapy. As with the C D llc binding cells, the Ly-6G positive cells were also
larger and more granular then lymphoid cells (data not shown).
Finally, many of the cells within the TIL fraction were positive for binding of a
cocktail o f antibodies specific for subsets of mouse macrophages (mac). This cocktail
included the rat antibodies against Moma-1(Serotec), SK-39 (gift from M. Julita,
Montana State University) and Ser-4 (gift from P. Croker). A fluorochrome-conjugated
goat anti-rat antibody served as a second antibody to detect positive cells by flow
cytometry.

As with the other myeloid lineage cells isolated from ectopic TRAMP

tumors, these cells were larger and more granular then lymphocytes from these tumors
(data not shown) and showed a similar peak of about 40% after 16 days of therapy and a
decline after 20 days of therapy.
In summation, these single color flow cytometry phenotyping studies of ectopic
TRAMP-Cl tumors treated with either flt3-L or carrier showed that myeloid cells
represented the predominant host infiltrating cell type in TRAMP-Cl tumors.
Additionally, the percentage of infiltrating myeloid cells was dramatically increased in
mice receiving flt3-L therapy.

B.

IMMUNOTHERAPIES TO IMPROVE SURVIVAL OF MICE WITH

PROSTATE CANCER
Two immunotherapy studies were performed. In the first experiment, eighteen 810 week old C57B1/6 mice were injected orthotopically with 5 x 105 TRAMP-ClP3 cells
and immunotherapy was initiated 7 days later and continued for 28 days. Treatment
consisted of control vehicle, CD40 Ligand (CD40L) and/or Flt3-Ligand (flt3-L) or both
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CD40L and flt3-L treatments. There were 4 mice in the control and CD40L groups and 5
mice in the flt3-L and combination group. All mice were examined daily during the
treatment period to assess the development of prostate cancer. When the mice became
moribund because o f urologic complications associated with prostate cancer progression
they were sacrificed, the tumors were explanted and digested to a single mononuclear cell
suspension and the resultant single cell suspension was stained for flow cytometric
analysis.
In a second immunotherapy study, eighteen 8-10 week old mice were injected with
5 x 105 TRAMP-C1P3 cells into the prostate gland and immunotherapy was also begun
seven days later. The mice were randomly divided into two groups, the first 8 mice
received 30pg flt3-L/mouse/day and the remaining ten mice received only the carrier
without the drag. 25pg/mouse/day of CD40L was given to mice for the last 7 days of
therapy (day21-28). The therapy was given for 28 consecutive days and the mice were
monitored for the development of prostate tumors. Twenty-one days after injection of the
tumor cells, 5 carrier treated mice and 3 flt3-L treated mice were sacrificed and examined
for the presence o f any prostate tumors.

None were noted and the remaining mice

received an additional week of therapy. At the end of therapy, prostate tumors could be
detected by palpation in all mice receiving carrier treatment but only 3 of the remaining 5
mice receiving flt3-L therapy. At the end of therapy a mouse from each group with
detectable prostate tumor was selected for phenotypic analysis of the infiltrating
mononuclear cells by three-color flow cytometry.
The pooled survival data of tumor-bearing mice receiving immunotherapies from
the two studies outlined above is shown in Fig. 2. These studies showed that mice that
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Fig. 2. Flt3-L therapy improves the survival of mice with TRAMP-C1P3 prostate tumors.
The survival data shown above represents pooled data from two immunotherapy studies
with 18 mice in each study. Mice were injected intra-prostatically with TRAMP-C1P3
cells according to procedures in the Materials and Methods section. Mice received Flt3L, CD40L, both flt3-L and CD40L or no treatment for their prostate cancer. Mice
received therapy from day 7 through day 35 post-implantation. Mice were sacrificed for
humane reasons as they became moribund because of urologic complications of prostate
cancer.
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received flt3-L or combination therapy survived significantly longer then mice that
received CD40L or carrier treatment. The mean survival (50% expired) for carrier mice
and CD40L treated mice was 28 days and -40 days, respectively, while flt3-L and
combination treatment resulted in a significant delay of tumor growth and a mean
survival of -7 0 days.

Additionally, 25% of orthotopic TRAMP tumor bearing mice

became long term survivors; surviving as long as 200 days before eventually succumbing
to prostate cancer.
To determine whether the prostate TME alters the CD3/TCR signaling complex,
tumor-infiltrating T cells were compared with T cells from normal C57B1/6 spleens,
splenic T cells from TRAMP tumor-bearing mice and T cells from periaortic lymph
nodes of tumor-bearing mice. The periaortic lymph nodes are the draining lymph nodes
(dLNs) o f prostate tumors. Cells from each group were stained with fluorochrome labeled
antibodies specific for T cell signaling or activation proteins.
In order to identify intracellular proteins such as the zeta chain of the CD3/TCR
complex, a permeablization procedure was employed as described in the Materials and
Methods section. Permeabilization of cells with digitonin altered the forward and side
scatter properties of lymphoid cells so the lymphoid gates were adjusted using the nonTME exposed lymphoid control cells.

Using this procedure, both surface and

intracellular protein expression was assessed on individual T cells.
Orthotopic tumor-bearing mice for these studies were all sacrificed from 28-42
days post injection of TRAMP cells. Because mice receiving flt3-L did not develop
prostate tumors for at least three weeks after therapy ended, these late developing tumors
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were not subjected to flow cytometric analysis. Only carrier and CD40L treated mice
developed tumors during this period and these tumors were excised and analyzed by flow
cytometry. However, spleen cells from the treated mice were analyzed at the end of
therapy (day 28 post-injection) in order to determine the extent to which therapy altered
TCR-<!j expression within splenic and tumor-infiltrating T cells. Additionally, T cells
from carrier treated mice were examined on day 32 and 42 of carrier treated mice as
prostate tumors progressed and the mice became ill.
The single color-phenotyping and immunotherapy studies from ectopic tumors
indicated that TRAMP tumors from mice treated with flt3-L showed an increased
infiltration o f host myeloid cells and also that this therapy resulted in increased survival
in mice with prostate tumors receiving flt3-L therapy. There were increased numbers of
cells in the lymphoid gate that expressed CD4 or CD8 about 3 x 106/tumor for each
marker while only 1 x 105 cells/tumor expressed CD3s. This result indicated that T cells
within the TRAMP TME lose expression of the CD3e molecule.

Therefore, studies

utilizing the orthotopic tumor model were initiated to evaluate the components of the
CD3 complex in TRAMP tumor-infiltrating T cells.

C. CHARACTERIZATION OF TME-INDUCED CHANGES OF THE CD3/TCR
SIGNALING COMPLEX
During preliminary phenotyping studies of tumor infiltrating T cells, I was
surprised by the observation that expression of components of the CD3/TCR complex
was not consistent in these cells. I stained tumor-infiltrating T cells with fluorochrome
conjugated antibodies against the CD3e and TCR-P molecules. Normal T cells expressed
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both molecules as expected and demonstrated normal co-expression. However, I noted
that when tumor-infiltrating CD3s positive cells were gated, only a subset of these “T
cells” also expressed the TCR-p molecule (data not shown).

Staining and digestion

controls were analyzed in order to rule out the possibility that alterations of observed
expression o f surface molecules were caused by the digestion buffer or spatial hindrance
between the molecules and the antibodies. Normal splenic T cells digested with the
enzymatic digestion buffer in the same manner as the tumor demonstrated expression of
both components of the CD3/TCR complex. This surprising result, that tumor-infiltrating
CD3s positive cells could be TCR-P negative, led me to investigate tumor-mediated
alterations o f the critical T cell signaling complex, CD3/TCR. Therefore, a series of
experiments was performed to examine the expression of signaling and activation
molecules on T cells isolated from normal and TRAMP tumor-bearing C57B1/6 (B6)
mice.

These tumor-bearing mice were either control (carrier treatment only), flt3-L

treated, CD40L treated or received both flt3-L and CD40L immunotherapy.
The hypothesis for these studies was that T cells exposed to the TRAMP TME
expressed decreased levels of signal transducing molecules relative to cells from the
spleen of the same tumor-bearing animals.

To analyze the TRAMP TME-mediated

alterations o f T cells, tumor-infiltrating T cells were compared with T cells from normal
C57B1/6 spleens, splenic T cells from TRAMP tumor-bearing mice and T cells from
periaortic lymph nodes of orthotopic TRAMP tumor-bearing mice.

Cells from each

group were stained with fluorochrome labeled antibodies specific for T cell signaling or
activation proteins of T cells according to the procedures outlined in the Materials and
Methods chapter.
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C 1. Expression of TCR-p molecule on TRAMP-infiltrating T cells
A total of three orthotopic prostate cancer studies and two ectopic tumor
phenotyping studies were performed in order to determine the extent to which factor(s) or
cell(s) within the TRAMP TME alters the expression of the TCR-P molecule on T cells.
The studies were pooled to minimize any variations observed between groups.

All

orthotopic tumors were analyzed after 28-42 days post implantation, when animals had
palpable tumors. Ectopic tumors were from late-stage mice (>50 days post implantation).
Three questions were addressed with these studies and the results are summarized in Fig.
3. The first question addressed the extent to which the TRAMP tumor burden alters
expression of the TCR-p molecule on T cells from the spleens of mice. Splenic T cells
were chosen because previous studies by other investigators indicated alterations of
signaling molecules in peripheral T cells in advanced stage cancer patients (21). I wanted
to determine the extent to which TRAMP tumors mediated similar alteration of TCR-P
expression in our models. Panel A shows a comparison of TCR-P expression on splenic
T cells, as defined by either CD3s or Thy-1 expression, isolated from normal mice,
control ectopic tumor-bearing mice or orthotopic tumor-bearing mice given carrier or
CD40-L or a combination of flt3-L and CD40-L. Additionally, T cells isolated from the
dLNs o f tumor-bearing mice were analyzed for the percentage of T cells expressing the
TCR-p molecule.
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Fig. 3. Prostate tumor microenvironment mediated alteration of T cell expression of the
TCR-P molecule. Panels A-C represent pooled data from 2-5 experiments.
A, Percentage o fT cells expressing the TCR-P molecule from the indicated peripheral
lymphoid organs. Single cells suspensions were made o f the lymphoid organs by
physical teasing apart of the organs and contaminating RBCs were lysed with hypotonic
lysing buffer. Normal spleens analyzed T cells from the spleens of age and sex matched
C57B1/6 mice, Ectop. Spl. (ectopic spleens) analyzed T cells from spleens o f C57B1/6
mice with ectopic TRAMP tumors, Ortho. Spl. (orthotopic spleens) analyzed T cells from
the spleens of C57B1/6 mice with orthotopic TRAMP tumors with no immunotherapy.
CD40L spleen analyzed T cells from the spleens o f C57B1/6 mice with orthopic TRAMP
CD40L treated tumors for one week beginning 21 days after implantation o f cancer cells.
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Fig. 3 (continued) FL spleen (Flt3-L treated spleens) T cells from the spleens of C57B1/6
mice with orthotopic TRAMP tumors receiving 30ug of f!t3-L daily for 21 days
beginning 7 days post-implantation of TRAMP cells. Combination Spleen T cells from
C57B1/6 mice with orthotopic TRAMP tumors receiving both CD40L and flt3-L
immunotherapy. Fresh dLNs freshly isolated T cells from the periaortic LNs of C57B1/6
mice with orthotopic TRAMP tumors receiving no immunotherapy. T cells were
immunostained using PE-conjugated anti-TCR-P antibody and FITC-conjugated antiThyl antibody was used to identify T cells. The stained cell suspension was double gated
using forward vs. side scatter to identify lymphoid cells and expression of FITC-Thyl to
identify T cells. The expression of TCR-P molecule was determined with isotype
matched negative controls from normal C57B1/6 spleens. * Identifies the T cell source to
which treated T cells were statistically compared, n.s. no statistically significant
difference between the indicated column and the control column. B, Percentage of
tumor-infiltrating T cells expressing the TCR-p molecule compared with T cells isolated
from peripheral lymphoid organs. Ectop. TILs (T cells isolated from ectopic TRAMP
tumors) freshly isolated ectopic tumor-infiltrating T cells from C57B1/6 mice receiving
no immunotherapy. Ortho. TILs (T cells isolated from orthotopic TRAMP tumors)
freshly isolated T cells from C57B1/6 mice with orthotopic TRAMP tumors receiving no
immunotherapy. CD40L TILs (T cells isolated from Orthotopic TRAMP tumors from
CD40L treated mice) T cells freshly isolated from orthotopic TRAMP tumors of mice
receiving CD40L immunotherapy seven days post implantation of TRAMP cells. *
Identifies the T cell population to which the tumor-infiltrating T cells were compared.
The P values of the comparisons between the orthotopic splenic T cells and tumorinfiltrating T cells are indicated above each column. C Percentage of tumor-infiltrating T
cells expressing TCR-P molecules after 20 hour incubation of isolated cells in tissue
culture media containing 100 units/ml of IL-2. Cult. Ectop. TILs (Cultured T cells from
Ectopic TRAMP tumors) T cells isolated from ectopic TRAMP tumors following 18-22
hour in vitro culture with 100 units/ml of IL-2. Cult. Ortho. TILs (Cultured T cells from
orthotopic TRAMP tumors) T cells isolated from orthotopic TRAMP tumors following
20 hour in vitro culture with 100 units/ml IL-2. *Identifies the population of T cells to
which the other population was compared and the indicated P values defined the
probability of statistically significant differences between the indicated groups and the
comparison group. D Flow Cytometry Histograms shows typical flow cytometry
histograms from selected tubes of a single representative experiment. The numbers in
each quadrant represent the percentage of Thyl gated lymphoid cells that were identified
in each quadrant.

The pooled data demonstrate that the percentage of TCR-P positive T cells was
-80% in all spleens or dLNs analyzed with no significant differences detected between
groups (Fig. 3A). Statistical analysis indicated no difference in the percentage of T cells
from the spleens or dLN of any group of mice described above. Therefore, late stage
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orthotopic or ectopic TRAMP tumors do not alter the expression of TCR-p molecule
expression on T cells from the periphery o f C57B1/6 mice.
We next decided to determine the extent to which T cells isolated from within latestage orthotopic TRAMP tumors displayed altered expression of the TCR-P molecule.
Fig. 3B is a comparison of T cells from the periphery of tumor-bearing mice with T cells
isolated directly from late-stage TRAMP tumors. In this analysis, splenic and dLN T
cells were compared with T cells isolated from carrier or CD40L treated tumorinfiltrating T cells.

The pooled data from these experiments indicated that -80% of

splenic T cells express the TCR-P molecule but only -35% of TRAMP-infiltrating T cells
expressed TCR-p.

Statistical analysis indicated a significant decrease in TCR-P

expression on T cells from TRAMP tumors, regardless of the immunotherapy given to
the mice. The P values were highly significant with values less then 0.001.
Finally, there is controversy in the scientific literature regarding the ability of T
cells exposed to TME to recover once removed from the deleterious effects of the
TRAMP microenvironment. In order to address this question, T cells isolated from latestage prostate tumors were cultured for -2 0 hours in tissue culture media supplemented
with 100 units/ml of IL-2 as described in the Materials and Methods section. Then the
cells were stained with the same panel of antibodies as the freshly isolated tumorinfiltrating cells and analyzed by flow cytometry.

The results of this study are

summarized in Fig. 3C. The data indicate that only -35% of T cells immediately after
isolation from TRAMP tumors expressed TCR-P molecules but with culture the
percentage of T cells expressing TCR-P increased to normal levels of -70%. Statistical
analysis indicated that there was a significant decrease in the percentage of T cells
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expressing TCR-P molecule in the freshly isolated T cells, but the percentage of TCR-p
positive cells returns to normal levels after culture.

The differences were highly

significant with P values less then 0.001 when comparing the percentage of TCR-P
positive T cells before culture with the percentage of TCR-P positive T cells after culture.
Panel D shows the flow cytometric histograms from a typical phenotyping study which
were pooled and used for the statistical analysis.

C 2. Expression of TCRy/8 chains on tumor-infiltrating T cells
Not all T cells express TCR-P molecules as part of their normal CD3 complex. A
small percentage of T cells express a TCR complex composed of TCRy and TCR8
molecules as their TCR complexes. In phenotyping studies performed in this laboratory
approximately 3.5 percent of splenic T cells from C57B1/6 mice expressed the y/5 TCR
complex (data not shown) and approximately 10% of T cells from spleens and dLN of
carrier treated mice expressed TCR-y5 (Fig. 4). Surprisingly, -30% of T cells isolated
from carrier treated TRAMP-C1P3 tumors bound fluorochrome-conjugated antibodies
against TCR-y8 molecules (Fig 4A & B). Thus there was a dramatic and statistically
significant (P< 0.05) increase in gamma/delta T cells within prostate tumors.

These

results indicated that tumor-bearing mice had an increased percentage of gamma/delta T
cells in their peripheral lymphoid organs such as dLNs and spleens as compared to
normal spleens and that the percentage of gamma/delta T cells within the TRAMP tumors
was significantly increased above these levels.
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Fig. 4. Prostate tumor microenvironment mediated alteration of T cell expression of the
TCR-y/8 complex. Panel A represents pooled data from 2 experiments. A, Percentage of
T cells expressing the TCR-y/5 complex from orthotopic TRAMP tumor-bearing C57B1/6
mice. Single cells suspensions were prepared according to Fig. 3 legend with the
following exceptions. Tumor-spl (Tumor-bearing spleens) T cells freshly isolated from
the spleens o f C57B1/6 mice with orthotopic TRAMP tumors receiving no
immunotherapy. dLNs (draining lymph nodes) freshly isolated T cells from periaortic
LNs o f orthotopic TRAMP tumor-bearing mice. Carrier TILs (Carrier treated tumorinfiltrating lymphoid cells) freshly isolated tumor-infiltrating lymphocytes from C57B1/6
mice with Orthotopic TRAMP tumors receiving no immunotherapy. Cultured TILs
(Cultured tumor-infiltrating lymphoid cells) isolated orthotopic TRAMP tumorinfiltrating T cells following 18-22 hour cultured with 100 units/ml IL-2. B, Flow
Cytometry Histograms shows flow cytometry histograms from selected tubes of a single
representative experiment. T cells were identified using a double gated strategy, gating
lymphoid cells first using forward versus side laser light scatter and then identification of
T cells using expression of Thyl molecules. The histograms shown are of Thyl positive
T cells. The numbers in each quadrant represent the percentage of Thyl+ gated
lymphoid cells that were identified in each quadrant.
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When these phenotyping studies were performed to analyze the y/5 T cells within
prostate TRAMP tumors, I noted that even this subset of T cells lost expression o f the
CD3e chain of the CD3/TCR complex (Fig. 4B-3). However, unlike the a/p T cells the
y/8 TCR complex appeared stable within the TRAMP TME and in fact, culture for 20
hours in media containing IL-2 did not increase the percentage of 5/y TCR positive cells.
However, these cells paralleled the a/p T cells in that they also re-expressed the CD3s
chain after removal from the TRAMP TME (Fig. 4B).

C 3. Expression of CD3s on tumor-infiltrating T cells
The percentage of T cells that expressed the CD3e molecule was determined
using the same orthotopic phenotyping studies. The expression of TCR-P, Thy-1 or CD5
molecules was used to identify T cells. Three questions were addressed. First was to
what extent do late-stage TRAMP tumor burden alters the expression of CD3s on T cells
from the spleens or dLNs o f mice? Late-stage is defined as greater than 35 days post
implantation for orthotopic tumors and greater than 50 days post implantation for ectopic
tumors. Fig. 5A, shows a comparison between the percentage of T cells that expressed
the CD3e molecule from spleens of normal C57B1/6 mice and orthotopic tumor-bearing
carrier treated mice. T cells from the spleens of tumor-bearing mice receiving CD40L,
flt3-L or combination treated mice were included in the analysis along with T cells
isolated from dLNs of carrier treated mice. Statistical analysis indicated that there was no
statistical difference in the percentage of splenic T cells that expressed the CD3s
molecule between any of the groups of mice (Fig. 5A).
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T cells isolated from within late-stage orthotopic TRAMP tumors displayed
reduced expression of the CD3s molecule; where as, there was no loss of CD3s
expression in T cells from the spleens or dLNs of tumor bearing mice (Fig. 5B). There
was a statically significant loss of CD3s on T cells isolated from TRAMP tumors.
While the percentage of T cells expressing CD3s from spleens was -85%, the
average percentage of CD3s positive T cells from tumors was <30% (compare Fig 5A
&B). Statistical analysis indicated a significant decrease in the percentage of T cells
expressing CD3e (P>0.001). This decrease of CD3s positive T cells was evident in TILs
isolated from both carrier and CD40L treated mice.

C 4. Expression of the TCR-£ molecule in tum or-infiltrating T cells
To analyze TME-mediated alterations of TCR-£, chain expression of prostate
tumor-infiltrating T cells, three individual experiments were performed. The results were
pooled for statistical analysis and to minimize variation of expression between different
studies. Phenotyping studies o f T cells from day 28 through day 42 post-implantation of
orthotopic tumors were evaluated for the expression of the TCR-(^ molecule. The same
orthotopic tumor studies used to analyze the expression of CD3e and TCR-p were used to
analyze the expression of TCR-<^ molecules.
Fig. 6A compared the percentage of T cells from the spleens and dLNs from
TRAMP tumor-bearing mice.

Mice with prostate tumors were treated with

immunotherapies to determine the extent to which therapy could inhibit the progression
of prostate cancer. The percentage o f TCR-£, positive T cells from the spleens of normal
C57B1/6 mice and tumor-bearing mice receiving CD40L or carrier treatment ranged from
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Fig. 5. Prostate tumor microenvironment mediated alteration o fT cell expression of the
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following modifications. T cells were immunostained using FITC-conjugated anti-Thyl,
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Identifies the T cell source to which treated T cells were statistically compared, n.s. no
statistically significant difference between the indicated column and the control column.
B, Percentage o f tumor-infiltrating T cells expressing the CD3e molecule compared with
T cells isolated from peripheral lymphoid organs. C, Percentage o f tumor-infiltrating T
cells expressing CD3e molecules after 18-22 hour incubation o f isolated cells in tissue
culture media containing 100 units/ml of IL-2. identifies the population o f T cells to
which the other population are compared and the indicated P values determines the
probability o f differences between the indicated groups and the comparison group. D,
Typical Flow Cytometry Histograms shows typical flow cytometry histograms from
selected tubes o f a single representative experiment. The numbers in quadrants represent
the percentage o f Thyl gated lymphoid cells that were identified in each quadrant.
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80-90%. The percentage of TCR-^ positive T cells from dLNs of mice with prostate
tumors receiving carrier treatment expressed normal levels of TCR-^ molecules with
85%. Surprisingly, T cells from the spleens of mice receiving flt3-L or combination of
flt3~L and CD40L therapy displayed a reduced percentage of TCR-<^ expressing T cells.
The average percentage o f T cells expressing zeta chain was reduced from -85% for
normal spleens to -40% in flt3-L treated spleens.

Statistical analysis indicated a

significant decrease in the percentage of T cells expressing the TCR-^ chain in splenic T
cells from tumor-bearing mice receiving flt3-L compared with mice that did not receive
flt3-L (P<0.001).
In order to determine whether the percentage of TCR-^ positive T cells from
prostate tumors treated with immunotherapies decreased, phenotyping studies were
performed using the same orthotopic tumors as previous experiments. Fig. 6 B shows
that the percentage of TCR-^ positive T cells was significantly decreased in T cells
isolated from prostate tumors of carrier and CD40L treated mice. The mean percentage
of gated T cells expressing TCR-^ chain was -80% in tumor-bearing spleens and only
-55% and -50% for T cells isolated from carrier and CD40L treated tumors respectively.
Statistical analysis was performed in order to determine whether the differences of TCRC, positive T cells between tumor-infiltrating T cells and tumor-bearing spleen cells was
significant. Statistical analysis indicated a significant decrease in the percentage of TCR^ positive T cells within tumors. The P values were <0.05 and <0.001 for carrier and
CD40L treated tumors, respectively.
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Fig. 6 . Prostate tumor microenvironment mediated alteration of T cell expression of the
TCR-^ molecule. Panels A-C represent pooled data from 2-5 experiments. A, Percentage
of T cells expressing the TCR-i^ molecule from the indicated peripheral lymphoid organs. Single
cells suspensions were made according to Fig. 3 legend with the following modifications. T cells
were immunostained using FITC-conjugated anti-TCR-£ antibody and PE-conjugated anti-CD5
or biotinylated anti-CD3s antibody to identify T cells. Cells were permeabilized with digitonin
before anti-TCR-^ staining. B, Percentage of tumor-infiltrating T cells expressing the TCR-^
chain compared with T cells isolated from peripheral lymphoid organs. The P values of the
comparisons between the orthotopic splenic T cells and tumor-infiltrating T cells are indicated
above each column. C, Percentage of tumor infiltrating T cells expressing TCR-i^ molecules after
20 hour incubation in tissue culture media containing 100 units/ml of IL-2. The indicated P
values show the statistical probability of differences between the indicated groups and the
comparison group. D, Flow Cytometry Histograms shows typical flow cytometry histograms
from selected tubes of a single representative experiment. The numbers in each quadrant
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Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

78

Finally, experiments were performed to determine if tumor-infiltrating T cells
could re-express the TCR-^ molecule. In order to determine the extent to which in vitro
culture o f isolated tumor-infiltrating T cells allowed for the re-expression of TCR-<^
molecules, I cultured freshly isolated tumor-infiltrating T cells for 20 hours in tissue
culture media supplemented with 100 units/ml IL-2. Panel C demonstrates that cultured
T cells re-express the signal-transducing molecule TCR-^. Statistical analysis indicated a
significant decrease in the percentage of TCR-^ positive T cells in freshly isolated tumorinfiltrating T cells (P<0.05 and 0.001) for carrier treated and CD40L treated tumors
respectively compared with tumor bearing carrier treated spleens (Fig. 6 B). There was
no significant difference in the percentage of TCR-^ positive T cells compared with
tumor-bearing spleens after culture in IL-2.

After culture the expression of TCR-^

molecule returned to normal levels (Fig. 6 C).
Therefore, these studies indicate that expression of the components of the CD3
complex on T cells exposed to the TRAMP TME is significantly decreased compared
with T cells isolated from tumor-bearing mice but not exposed to the TME. Each of the
molecules examined in these studies were signal-transducing molecules whose function
had been directly linked to the proper function of T cells (29, 21). Significantly, the loss
of crucial signaling molecules was not permanent, however, because culture with IL-2
allowed the T cells to express the components of the CD3 complex. These results imply
that some component of the TRAMP TME mediated these alterations.
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C5.

Summation of phenotyping studies analyzing components of the CD3/TCR

complex
Preliminary studies indicated that TRAMP tumors contain high percentages of
infiltrating myeloid-lineage cells and that flt3-L immunotherapy dramatically increases
the number of infiltrating myeloid cells (Fig. 1).

Additionally, tumor-bearing mice

receiving flt3-L therapy survived longer then tumor-bearing control mice (Fig. 2).
Additionally, these experiments show that T cells exposed to the TRAMP TME express
decreased levels of components of the CD3/TCR complex (Figs. 3, 5 and

6

).

The

percentage of CD3s, TCR-P and TCR-^-positive T cells isolated from late stage TRAMP
tumors was significantly decreased compared to T cells from tumor-bearing spleens. Of
particular interest, however, is the observation that this loss of CD3/TCR components is
not permanent. After 20 hours of incubation of tumor-infiltrating T cells in tissue culture
containing 100 units/ml human IL-2 a clear re-expression of CD3/TCR components was
noted. Because the signal transducing molecules associated with the CD3/TCR complex
are known to be required for proper function of T cells, the biologic significance of these
results is that tumor-infiltrating T cells have likely lost their ability to recognize and
respond to their specific antigens within tumors. Once removed from factor(s) associated
with the TME however tumor-infiltrating T cells re-express the signal transducing
molecules allowing for the potential to recognize and respond to their antigens properly.
One surprising result from phenotyping studies to determine the percentage of
TCR-8 /y positive T cells was the observation that gamma/delta T cells comprised a
significantly greater percentage of T cells in all lymphoid organs of late stage tumorbearing mice (Fig. 4).

Spleens and dLNs contained about three times as many
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gamma/delta T cells and there was about ten times as many gamma/delta T cells isolated
from TRAMP tumors compared to normal C57B1/6 mice. Unlike the alpha/beta T cells,
the gamma/delta T cells did not lose the expression of their TCR indicating that the TCRy/S complex was more stable in the TRAMP TME. The biologic implication is that
gamma/delta T cells have the potential to recognize tumor-associated antigens within the
TME while alpha/beta T cells have lost their antigen recognition complex. It should be
noted however, that gamma/delta T cells have lost their expression of the signal
transducing molecule CD3s indicating that even these cells may not function normally
within the TRAMP TME.

D.

EXPRESSION OF T CELL SPECIFIC MOLECULES ON TUMOR-

INFILTRATING T CELLS THAT ARE NOT PART OF THE CD3/TCR
COMPLEX

D 1. Examination of Thy-1 expression on tumor-infiltrating T cells
Since our data indicated that expression of components of the CD3 complex are
decreased in T cells isolated from TRAMP tumors, we decided to examine the expression
of Thy-1 on tumor-infiltrating T cells.

The expression of the Thy-1 molecule was

determined using flow cytometry with fluorochrome conjugated antibodies against the
Thy-1 protein. The goal of these studies was to identify a T cell restricted molecule not
altered by the TRAMP TME in order to identify a more representative population of
tumor-infiltrating T cells.
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Fig. 7. Prostate tumor microenvironment mediated alteration of T cell expression of the
Thy-1 molecule. Panels A-C represent pooled data from 2-5 experiments. A, Percentage
of T cells expressing the Thy-1 molecule from the indicated peripheral lymphoid organs.
Single cells suspensions and the cells were stained according to Fig. 3 legend. T cells
were stained using FITC-conjugated anti-Thy-1, PE-conjugated anti-CD5 and Cychrome-conjugated CD3e. T cells were identified by the expression of the CD5
molecule. *Identifies the T cell source to which treated T cells were statistically
compared, n.s. indicates no statistically significant difference between the indicated
column and the control column. B, Percentage of tumor-infiltrating T cells expressing
the Thy-1 chain compared with T cells isolated from peripheral lymphoid organs. C,
Percentage of tumor infiltrating T cells expressing Thy-1 molecules after 20-hour
incubation in tissue culture media containing 100 units/ml of IL-2. D, Flow Cytometry
Histograms shows typical flow cytometry histograms from selected tubes of a single
representative experiment. The numbers in each quadrant represent the percentage of
Thy-1 gated lymphoid cells that were identified in each quadrant.
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The Thy-1 protein, also known as CD90, is a 25-30 kDa GPI-linked membrane
bound glycoprotein. Thy-1 is involved in T cell adhesion and development and is also a
signal-transducing molecule involved in T cell activation. Thy-1 is expressed on most T
cells and can also be expressed on NK cells and early hematologic progenitor cells (105).
Fig. 7A summarizes the results from three orthotopic TRAMP tumor phenotyping
studies examining the percentage of T cells expressing Thy-1 molecule in spleens and
dLNs o f tumor-bearing mice receiving carrier treatment. The results indicate that there
was a decrease in the percentage of T cells expressing Thy-1 in spleens of tumor-bearing
mice but not in the dLNs compared with normal C57B1/6 spleens. The percentage of
Thy-1 positive T cells was -85% in normal spleens but only -65% in spleens from
tumor-bearing mice. The percentage of Thy-1 positive T cells from dLNs was similar to
the normal spleen as -85% of gated T cells expressed the Thy-1 protein. Statistical
analysis indicated that the percentage of Thy-1 positive T cells from normal spleens was
significantly higher compared to tumor-bearing splenic T cells (P<0.05. There was no
statistical difference between normal spleen and dLNs however.
Next comparisons were made between Thy-1 expression on tumor-bearing splenic
T cells and tumor-infiltrating T cells. Panel B demonstrates that the percentage of T cells
expressing the Thy-1 protein from TRAMP tumors was very similar to the percentage of
Thy-1 positive T cells in tumor bearing spleens. In both cases approximately 65-70% of
T cells expressed the Thy-1 protein. Multi-variant statistical analysis comparing tumorbearing splenic T cells with tumor-infiltrating T cells demonstrated no statistically
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significant differences. Thy-1 expression on tumor-infiltrating T cells was not altered by
flt3-L therapy.
Finally, in order to determine whether culture of tumor-infiltrating T cells with
IL-2 is able to reverse the loss of Thy-1 expression in tumor-bearing mice, isolated
tumor-infiltrating T cells were cultured for 20 hours in IL-2 and then analyzed by flow
cytometry. The results are shown in Panel C demonstrate that there is a trend toward re
expression of Thy-1 molecules on cultured T cells that approached the levels seen on
normal splenic T cells.

However, statistical analysis did not indicate a significant

difference between cultured and freshly isolated tumor-infiltrating T cells. In summary,
these results indicated a slight systemic decrease of Thy-1 expression in tumor-bearing
mice, but no significant difference on T cells regardless of the organs/tissues examined in
tumor-bearing mice.

D 2. Expression of CDS on tumor-infiltrating T cells
CD5, a 67kDa type I transmembrane glycoprotein of the scavenger receptor
cysteine rich superfamily, is expressed on most T cells and a very small sub-population
of B lymphocytes (105). CD5 is a surface accessory/co-stimulatory molecule of T cells
and is involved in the regulation o f T cell activation and antigen presenting cell/T cell
interactions (105). The expression of CDS was next examined in the order to determine
if CD5 expression was lost in the tumor-bearing host.
Using the same three phenotyping studies, Fig.

8

shows pooled data and

demonstrates that -85% o f T cells isolated from the spleens of orthotopic tumor-bearing
mice expressed CD5. The same percentage of T cells from dLNs of tumor-bearing mice
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Fig. 8 . Prostate tumor microenvironment mediated alteration of T cell expression of the
CD5 molecule. Panel A represents pooled data from 2-5 experiments. A, Percentage of T
cells expressing the CD5 molecule from the indicated peripheral lymphoid organs and
fresh and cultured tumor-infiltrating T cells. Single cells suspensions were made
according to Fig. 3 legend. T cells were immunostained using FITC-conjugated antiThyl antibody, PE-conjugated anti-CD5 antibody and biotinylated anti-CD3e antibody to
identify T cells. The expression of the CDS molecule was determined using isotype
matched negative controls from normal C57B1/6 spleens, ^identifies the T cell source to
which treated T cells were statistically compared, n.s. indicates no statistically
significant difference between the indicated column and the control column. B, Flow
Cytometry Histograms shows typical flow cytometry histograms from selected tubes of a
single representative experiment. The numbers in each quadrant represent the percentage
o f Thyl gated lymphoid cells that were identified in each quadrant.
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expressed CDS. The average percentage of T cells isolated from prostate tumors that
expressed CD5 was decreased and only ~60% of T cells from TRAMP tumors expressed
CD5. The error bars in this pooled data were quite large and in some studies there was
no decrease in CD5 expression.

Statistical analysis failed to indicate a significant

decrease in CD5 expression in tumor-infiltrating T cells.

When the isolated tumor-

infiltrating T cells were cultured for 18 hours with IL-2 the expression of CDS increased
from ~60% to ~75% which is closer to the levels noted in tumor-bearing spleens and
dLNs. These results indicate that there is a small, but not statistically significant decrease
in the percentage of CD5 positive T cells in tumor-infiltrating T cells.

D 3. Expression of CTLA-4 on tumor-infiltrating T cells
The molecule designated CTLA-4 (cytolytic T lymphocyte-associated antigen 4)
is also known as CD 152 or Ly-56. This protein is a marker of activation of T cells. The
molecule is a glycosylated transmembrane protein of the Ig superfamily and two
glycosylated forms have been detected, 33-34 and 36-37 kDa in size (105).

CTLA-4 is

only expressed on activated T cells and its function is the negative regulation of the
immune response by inhibiting cytokine production and proliferation of activated T cells.
Previous studies that used antibodies that blocked the inhibitory signals by the CTLA-4
molecule demonstrated increased survival in tumor bearing mice (30). Because of the
reported properties o f blocking CTLA-4/Ig, the next experiments were designed to
determine whether CTLA-4 expression was modulated by the TRAMP-C1P3 TME. In
these studies the percentage of T cells expressing CTLA-4 was compared between
normal C57B1/6 spleens, spleens recently vaccinated with WT1 protein, ectopic and
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Percentage o f tumor-infiltrating T cells expressing the CTLA-4 molecule compared with
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cells expressing Thyl molecules after 20 hour incubation of isolated cells with 100
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orthotopic tumor-bearing spleens, dLNs from orthotopic tumor-bearing mice and fresh
and cultured tumor-infiltrating T cells from ectopic and orthotopic TRAMP tumors.
The results of these studies are shown in Fig. 9 indicating that in all the spleen groups
examined there was not a significant increase in the percentage of CTLA-4 positive T
cells. Normal spleens expressed -1% CTLA-4 positive cells while the percentage of
CTLA-4 positive T cells from vaccinated and tumor-bearing spleens ranged from ~ l- 6 %
with no statistically significant increase in positive cells noted using statistical analysis.
Additionally, Panel A indicates that the percentage of CTLA-4 positive T cells from
dLNs was not above the levels detected in tumor-bearing spleens.
In order to identify the percentage of activated T cells from within TRAMP
tumors phenotyping studies incorporating anti-CTLA-4 antibodies were performed on
both ectopic and orthotopic tumors.

Fig. 9B shows that the percentage of CTLA-4

positive T cells from ectopic tumors was -7% and not significantly different then tumorbearing spleens. However, there was a statistically significant increase in the percentage
of CTLA-4 positive T cells from freshly isolated T cells from orthotopic tumors. The
percentage of CTLA-4 positive T cells increased from -6-7% to -17% (P<0.001). The
expression of the activation marker CTLA-4 returned to normal levels when the isolated
tumor-infiltrating T cells were cultured for 20 hours with IL-2 as shown in 5C,

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

88

D 4. Summation of phenotyping studies of T cell signal transducing molecules not
associated with the CD3/TCR complex.
The results o f the phenotypic analysis of expression of signal transducing
molecules in T cells from tumor-bearing mice were less consistent then those for
molecules associated with the CD3/TCR complex. For example, there was a significant
decrease in the percentage of T cells that expressed the Thy-1 marker in tumor-bearing
spleens and tumor-infiltrating T cells compared with normal splenic T cells (Fig. 7A&B).
Conversely, there was no decrease in the percentage of T cells that expressed CD5 from
tumor-bearing spleens and tumor-infiltrating T cells (Fig.

8

A). Additionally, in vitro

culture with IL-2 did not increase the percentage of tumor-infiltrating T cells that
expressed CD5. The CTLA-4 molecule is a marker of activation for T cells and its
expression was significantly increased in freshly isolated tumor-infiltrating T cells
compared with normal spleens (P<0.001) (Fig. 9B). The percentage of tumor-infiltrating
T cells that expressed CTLA-4 after removal and culture with IL-2 decreased, returning
to levels similar to the percent CTLA-4 positive cells from normal spleens (Fig. 9C).
The biologic significance of these studies is that signal transducing molecules on
T cells exposed to TRAMP TME not associated with the CD3/TCR complex is generally
more stable, with the possible exception of the Thy-1 molecule.

This molecule was

significantly decreased in tumor-bearing spleens and tumor infiltrating T cells but not in
the dLNs. Therefore, for investigators analyzing T cells within tumors, gating on cells
that express T cell specific molecules not associated with the CD3/TCR complex is more
likely to identify greater numbers of T cells and will likely yield better results because of
the more representative population of T cells analyzed.
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E.

IDENTIFICATION OF WT-1 TETRAMER-BINDING TUMOR-SPECIFIC

CELLS WITHIN TRAMP TUMORS
We next wanted to identify tumor-infiltrating T cells that are able to bind
tetramers that mimic the MHC-I/WT1 (130-138) peptide complex in order to identify
tumor-infiltrating, tumor-specific T cells.

WT1 is a common tumor antigen that is

expressed on many tumors including TRAMP-C1P3 cells. The peptide 130-138 is the
immunodominant epitope for this molecule in C57B1/6 mice so any T cells that are able
to bind the tetramer are also able to recognize WT1 expression of tumor-cells and are
therefore tumor-specific.
As shown in Fig. 10A, the number of cells within the light scatter lymphoid gate
expressing TCR complexes capable of binding WT1(130-138) tetramers from tumorbearing mice was always a very small percentage of the lymphoid events. Tetramer
positive lymphoid cells consistently represented less then 1 % of lymphoid events in all
freshly isolated samples examined by flow cytometry in these studies. Four different
tubes were stained with tetramers for each sample and the percentage of tetramer binding
lymphoid cells is given as the average expression of the four tubes.
In order to identify the percentage o f tetramer binding T cells in tumor-bearing
mice, I compared the percentage of CD5 positive cells that bound the tetramers from
tumor-bearing and normal mice.

Additionally, I compared CD5 cells from normal

BALB/c spleens, ectopic and orthotopic tumor-bearing spleens, dLNs from orthotopic
tumor-bearing mice and freshly isolated and cultured tumor-infiltrating T cells from
ectopic and orthotopic TRAMP tumors. In these studies the tetramers were created with
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Fig. 10. Tumor antigen specific tetramer binding of T cells from mice with TRAMP
tumors. Panel A represents pooled data from three experiments. A, Percentage of T cells
that bound the tumor antigen-specific tetramer WT 1(130-138) from the indicated
peripheral lymphoid organs and fresh and cultured tumor-infiltrating T cells. Single cells
suspensions were made according to Fig. 3 legend. T cells were immunostained using
FITC-conjugated anti-Thyl antibody, PE-conjugated anti-CD5 antibody, biotinylated
anti-CD3e antibody and the Cy 5-conjugated tumor
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(Fig. 10 legend continued) antigen specific tetramer WT1(130-138). The expression of
Thyl and/or CD5 was used to identify T cells for these studies and the stained cell
suspension was double gated using forward vs. side scatter to identify lymphoid cells and
expression o f Thyl or CD5 molecules to identify T cells. The percentage of T cells that
bound the WT1 tetramer was determined using isotype matched negative controls from
normal C57B1/6 spleens. * Identifies one T cell source to which treated T cells were
statistically compared. ** Identifies a second T cell source to which treated T cells were
statistically compared. B, Typical Flow Cytometry Histograms shows typical flow
cytometry histograms from selected tubes of a single representative experiment. The
numbers in each quadrant represent the percentage of Thyl gated lymphoid cells that
were identified in each quadrant.

the APC (Allophycocyanin) fluorochrome allowing us to perform four-color flow
cytometry on these samples without interfering with the staining of the other T cell
markers used in previous studies. Tetramers were incubated with the T cells for 2 hours
prior to labeling with the remaining antibodies. In these studies all the antibodies used
were directly conjugated to individual fluorochromes in order to reduce non-specific
binding of the tetramers which incorporate Ultra-avidin capable of binding biotinconjugated antibodies.
Fig. 10A shows the pooled results of phenotyping experiments incorporating
tetramers in order to identify T cells with TCRs capable of recognizing tumor antigens.
These experiments demonstrate that the background staining in the non-MHC matched,
negative control spleen from a normal BALB/c spleen was very low at 0.013% of gated
CD5 positive T cells. The percentage of T cells that bound tetramers in the spleens of
tumor-bearing mice was also very low. Only 0.03% and 0.02% of splenic T cells from
ectopic and orthotopic tumor-bearing mice bound the tetramers. Tetramer-positive CDS
positive cells from dLNs were also very rare with only 0.05% of T cells positive for
tetramer binding.

Statistical analysis indicated no difference in the tetramer binding

capacity between any of these groups.
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In order to determine the percentage of tetramer positive T cells from freshly
isolated T cells from ectopic and orthotopic TRAMP tumors, phenotyping studies were
performed. Surprisingly, the percentage of freshly isolated tetramer binding cells within
TRAMP tumors was also very low with only 0.11% and 0.31% of lymphoid cells binding
tetramers from ectopic tumors and orthotopic tumors respectively.

However, when

ectopic tumor-infiltrating T cells were cultured for 20 hours with IL-2, the percentage of
tetramer positive T cells increased form 0.11% to 2.8% (P<0.01). The percentage of
tumor-infiltrating tetramer positive T cells from orthotopic TRAMP tumors increased
from an average of 0.31% to 4.9% o f T cells with culture (P<0.001). Fig. 10B shows
representative histograms from these studies and Panel B1 demonstrates the CD5 gate
used for Fig. B2-9.

E 1. Expression of CD3 e on tumor-infiltrating tetramer-binding T cells
To characterize the integrity of TCR/CD3 signaling complex on WT1-specific T
cells, we used tetramers to gate on WT1-specific lymphoid cells and determined co
expression of signaling and regulatory molecules from cells isolated from prostate
tumors. Fig. 11A & B compares the expression of the T cell signal-transducing molecule
CD3s on the rare tetramer positive lymphoid cells with the more common Thy-1 positive
T cells in tumor-bearing mice.

In order to perform this analysis, four-color flow

cytometric analysis was performed on lymphoid cells from tumor-bearing mice. Normal
BALB/c splenic T cells were used as a negative control for tetramer staining and splenic
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Fig. 11. CD3e expression of tetramer positive T cells compared with all T cells from
TRAMP tumor-bearing mice. Panels A & B represent pooled data from three different
experiments. A, Expression of CD3s molecules on T cells isolated from TRAMP tumorbearing C57B1/6 mice. Single cells suspensions were made according to Fig. 3 legend. T
cells were immunostained using FITC-conjugated anti-Thyl antibody, PE-conjugated
anti-CD5 antibody, Cy chrome conjugated anti-CD3s antibody and the Cy 5-conjugated
tumor antigen specific tetramer WTl(130-138)/H-2Db. The expression of Thyl and/or
CDS was used to identify T cells. * Identifies one T cell source to which treated T cells
were statistically compared. B, Expression of CD3s molecules on tetramer positive cells
isolated from TRAMP tumor-bearing C57B1/6 mice. The binding of the tumor antigen
specific tetramer was used to identify tumor-specific T cells for these studies.
* Identifies one T cell source to which treated T cells were statistically compared.
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T cells from ectopic and orthotopic tumor-bearing mice were compared with fresh and
cultured tumor-infiltrating lymphoid cells.
Fig. 11 demonstrates that ~85% of Thy-1 positive cells from spleens of tumorbearing mice expressed CD3s. The percentage of CD3s positive cells decreased slightly
in T cells isolated from orthotopic tumors but this decrease was not statistically
significant. Surprisingly, expression of CD3e on cultured Thy-1 cells was significantly
decreased in this study. Statistical analysis gave P values <0.001 for the difference in
cultured tumor-infiltrating cells compared with orthotopic tumor-bearing spleen.

This

was an unexpected result and actually contradicts the previous studies shown in Fig. 5
Panel C. There appeared to be a technical problem with the anti-CD3s antibody in this
study. The best explanation is that the addition of tetramer staining somehow hindered
the binding of the anti CD3s antibody in these studies.
When CD3e expression on tetramer-binding cells was examined a different
pattern was seen. The percentage o f the rare tetramer positive cells in spleens from
tumor-bearing mice expressing the CD3s molecule was always less then 1%. Since we
showed that CD3s is not lost in T cells from tumor-bearing spleens this result implies that
the tetramer positive cells may not actually have been T cells but instead were rare non-T
cells and cellular debris that non-specifically bound the tetramers. In simple terms the
flow cytometer is not designed to discriminate extremely rare cell subpopulations from
random background binding of cellular fragments and sub-cellular compartments.
Enzymatically digested tumor TRAMP tumors contained a relatively high percentage of
fragments and debris despite our efforts to clean the samples with ficoll-hypaque
isolation of mononuclear cells, see Materials and Methods section. Fig. 10 shows that
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less then 0.1% o f T cells were tetramer positive in the spleens and dLNs of tumor bearing
mice. The fact that the rare tetramer positive cells in the spleens of tumor-bearing mice
did not express other T cell associated molecules like CD3e indicates that these were not
tumor-specific T cells but rather non-specific binding of the tetramers to non-T cells or
debris. As shown in 11 A, T cells from the periphery of tumor-bearing mice do not show
decreased expression of the CD3s molecule. With the above caveat, the percentage of
CD3s positive tetramer-binding cells increased to -60% of tetramer positive cells in
dLNs from orthotopic tumor-bearing mice. This result indicated that unlike the tetramer
positive cells from the spleens of tumor-bearing mice many of the rare (< 0 . 1 %) tetramer
positive cells isolated from dLNs actually reflect tumor-specific T cells.
I next examined CD3e expression of tetramer positive cells from ectopic and
orthotopic TRAMP tumors. Tetramer binding of cells isolated from TRAMP tumors
constituted a very small percentage of lymphoid cells as demonstrated in Fig. 10. In this
study there were no tetramer positive cells detected in the ectopic tumors so the
percentage of CD3e positive tetramer binding cells could not be determined. However,
the percentage o f CD3e positive cells within the very rare (<0.2%) tetramer-binding
population from the fresh orthotopic tumors was -80%. Like the expression of CD3e on
the Thy-1 gated cells, the expression of CD3s decreased with in vitro culture with IL-2 in
the tetramer positive cells. The decrease was not as dramatic however, with <50% of
tetramer positive cells in the cultured samples expressing CD3e and the unexpected result
probably reflects technical problems with antibody binding perhaps steric hindrance
between CD3s and tetramers. Fig. 11C shows representative histograms that were pooled
to generate the summary figures in Panels A & B.

Panels C l-4 show typical flow
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histograms of Thy-1 gated cells and Panels C5-8 show typical flow histograms of
tetramer gated cells from the indicated organs.

E 2. TCR-p expression in tumor-infiltrating tetramer positive cells
We next used a similar strategy to compare the percentage of TCR-P positive
cells from CD3e and Thy-1 gated cells with tetramer positive cells. Fig. 12 shows the
results o f a single four-color flow cytometry study comparing the percentage of TCR-p
positive cells isolated from a normal BALB/c spleen, ectopic and orthotopic tumorbearing spleens, orthotopic dLNs and fresh and cultured T cells isolated from ectopic and
orthotopic TRAMP tumors. Fig. 12A shows the percentage of T cells that between 6075% of gated T cells isolated from normal BALB/c and tumor-bearing spleens expressed
TCR-P chains in this study. The percentage of TCR-p positive T cells increased to -90%
in T cells isolated from dLNs of orthotopic tumor-bearing mice. Statistical analysis
indicated that there was a significant increase in TCR-P expression in T cells from dLNs
(P<0.01). The difference in the percentage of TCR-P positive T cells was not significant
in the other groups analyzed in this study. TCR-p expression on T cells from cultured
tumor-infiltrating T cells demonstrated very wide error bars indicating variability of
TCR-P expression depending on the choice of molecules used to identify T cells and no
statistical differences were noted.
Fig. 12B shows the percentage of TCR-p positive cells of the rare tetramer
binding cells in these samples.

No expression o f TCR-p was detected on the rare

tetramer positive cells in spleens from normal or tumor-bearing mice indicating that the
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Fig. 12. TCR-p expression of tetramer positive T cells compared with all T cells from
TRAMP tumor-bearing mice. Panels A & B represent pooled data from three different
experiments. A, Expression of TCR-P molecules on T cells isolated from TRAMP tumorbearing C57B1/6 mice. Single cells suspensions were made according to Fig. 3 legend. T
cells were immunostained using FITC-conjugated anti-Thyl antibody, PE-conjugated
anti-TCR-p antibody, biotinylated anti-CD3s antibody and the Cy 5-conjugated tumor
antigen specific tetramer WTl(130-138)/H-2Db. The expression of Thyl or CD5 was
used to identify T cells for these studies. * Identifies one T cell source to which treated T
cells were statistically compared. B, Expression of TCR-P molecules on tetramer positive
cells isolated from TRAMP tumor-bearing C57B1/6 mice. C, Flow cytometry histograms
from a single study. The numbers in each quadrant represents the percentage of gated
cells within each quadrant.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

98

tetramers most likely bound to non-T cells and debris in these samples. However, -20%
of tetramer positive cells isolated from dLNs expressed TCR-P molecules. This is in
contrast with the 90% o f TCR-P positive cells in the CD3s or Thy-1 gate shown in Panel
A. These results indicate that either the tetramers are still binding to non-T cells 80% of
the time or that the tetramer positive T cells are not a/p Tcells. In order to resolve this
question, TCR-8 /y expression was analyzed in the same samples (see Fig. 13).
Fig. 12B shows that no tetramer positive and TCR-P positive cells could be
identified in freshly isolated tumor-infiltrating cells. The percentage o f TCR-P positive
tetramer positive cells increased from undetectable to 50% and 60% for cultured ectopic
and orthotopic tumor-infiltrating cells, respectively. Like the previous experiments, these
results shown in Figs. 3, 5 & 6 , the results shown in Fig. 12B support the observation that
removal of tumor-infiltrating cells from the TRAMP-TME followed by in vitro culture
with IL-2 allows for the re-expression of the CD3/TCR complex. This study specifically
demonstrates that tetramer positive cells are also able to re-express components of the
TCR-P chain with culture in IL-2.
Surprisingly, as with the results shown in fig. 11, there was a decrease in the
percentage o f T cells that expressed the TCR-P chain with culture in IL-2. This result
contradicts the results seen in fig. 3. The best explanation of this observation is that the
tetramer staining of cultured tumor-infiltrating T cells somehow hindered the binding of
the anti-TCR-P antibody.
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E 3. Expression of TCR-S/y chains in tetramer binding tumor-infiltrating T cells
Because the gamma/delta T cells represented a significant minority of T cells
from dLNs and cultured tumor-infiltrating cells, the percentage of WT1-specific T cells
expressing the TCR-y/ 8 complex in TRAMP tumor-bearing mice was determined. In
order to do this four color flow cytometric analysis was performed on cells isolated from
the spleens o f normal and tumor-bearing mice. Cells from dLNs and fresh and cultured
tumor-infiltrating cells were also examined. Finally, the percentage of tetramer positive
cells that were TCR-y/ 8 positive was determined in each sample.

The results are

summarized in fig. 13.
As expected the percentage of T cells of the delta/gamma lineage was relatively
low in the spleens and dLNs of tumor-bearing mice. Fig. 13A shows that less then 10%
of T cells expressed TCR-y/ 8 molecules in tumor-bearing spleens and dLNs. Freshly
isolated T cells from ectopic TRAMP tumors expressed the same percentage of
delta/gamma T cells as tumor-bearing spleens. In T cells isolated from orthotopic tumors
however, there was a slight but statistically significant increase of delta/gamma T cells
increasing to -30%. Removal of tumor-infiltrating lymphoid cells from the TRAMP
TME and culture with IL-2 did not increase the percentage of TCR-8 /y positive cells
which is similar to the results shown in fig. 4.
Surprisingly, the percentage of TCR-8 /y positive tetramer binding cells was much
higher in T cells isolated from dLNs and ectopic and orthotopic tumors. T cells isolated
from tumor-bearing spleens contained less then 10% TCR-yS positive cells. However,
tetramer positive T cells from dLNs of mice bearing orthotopic TRAMP tumors
contained very high percentages of cells that also bound the TCRS/y antibody. In fact, as
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Fig. 13. TCR-5/y expression of tetramer positive T cells compared with all T cells from
TRAMP tumor-bearing mice. Panels A & B represent pooled data from three different
experiments. A, Expression of TCR-8 /y complex on T cells isolated from TRAMP
tumor-bearing C57B1/6 mice. Single cells suspensions were made according to fig. 3
legend. T cells were immunostained using FITC-conjugated anti-Thyl antibody, PEconjugated anti-TCR-8 /y antibody, Cy chrome-conjugated anti-CD3s antibody and the
Cy 5-conjugated tumor antigen specific tetramer WT 1(130-138)/H-2Db. The expression
of Thyl was used to identify T cells for these studies and the stained cell suspension was
double gated using forward vs. side scatter to identify lymphoid cells. B, Expression of
TCR-8 /y complex on tetramer positive cells isolated from TRAMP tumor-bearing
C57B1/6 mice. The binding of the tumor antigen specific tetramer was used to identify
tumor-specific T cells for these studies. C, Representative flow cytometry histograms
from a single study summarized above. The numbers in each quadrant represents the
percentage o f gated cells within each quadrant.
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shown if fig. 13B, -100% of tetramer-positive cells from dLNs and ectopic tumors were
TCR-y8 positive. The percentage tetramer positive cells that were gamma/delta positive
isolated from orthotopic tumors was also high with about 80% of tetramer positive cells
expressing the TCR-5y complex.

When tumor-infiltrating mononuclear cells were

cultured with IL-2 for 22 hours the percentage of gamma/delta T cells
decreased from -90% to -30%.

This decrease may not represent an actual loss of

gamma/delta chains in cultured cells but rather may actually represent the re-expression
of the beta chains on a(3 T cells now included in the analysis because they are able to
bind tetramers. This explanation is plausible since fig. 3C demonstrated that TCR-p
expression increased with overnight culture in IL-2. Fig. 13C shows representative flow
cytometric histograms used to construct the pooled data graph shown in Panels A and B.
These surprising results must be tempered by recognition of the fact that tetramer
positive cells in certain populations in these studies were very rare events. Very often the
number of gated tetramer positive cells was less then

10

cells so any percentages obtained

from this complex gating strategy may only give an estimate of the true percentages. As
many events as possible were included in these studies, typically 500,000 cells were
analyzed. Higher numbers of acquired events and/or repeats of these studies are needed
to confirm these observations.

E 4. CTLA-4 expression on tetramer positive tumor-infiltrating T cells
The expression o f the activation marker CTLA-4 is an early and transient event
in T cell activation. CTLA-4 functions to dampen the immune response by transmitting
inhibitory signals within T cells.

In order to determine the expression of CTLA-4
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proteins, fluorochrome-conjugated antibodies against the mouse CTLA-4 molecule were
used. Four color flow cytometric analysis was performed in this study and the results are
represented in fig. 14. The first objective was to determine the extent to which T cells
isolated from spleens or dLNs of tumor-bearing mice were activated and expressed
CTLA-4 molecules. Fig. 14A shows the percentage of CTLA-4 positive T cells (defined
as Thyl positive) isolated from the spleens, dLNs and tumors of normal and late-stage
ectopic and orthotopic TRAMP tumor-bearing mice.
The results of the phenotyping studies for the expression of CTLA-4 molecules on
T cells from the peripheral lymphoid organs of tumor-bearing mice are summarized in
Panel A. The percentage of T cells from the spleens of tumor-bearing mice expressing
CTLA-4 was ~4% for both ectopic and orthotopic tumor-bearing mice. The percentage
o f T cells isolated from dLNs of orthotopic TRAMP tumor-bearing mice did not
demonstrate a significant increase of CTLA-4 expression since only ~5% of these T
cells were positive for expression of this antigen.

Multi-variant comparison of the

average percentage of CTLA-4 positive T cells from Panel A indicated no statistically
significant increase in CTLA-4 expression in T cells from secondary lymphoid organs
o f tumor-bearing mice. Therefore, these studies indicate that T cells from the secondary
lymphoid organs of tumor-bearing mice in do not express increased levels of CTLA-4
molecules. Fig. 14A shows that the percentage of T cells from normal and orthotopic
tumor-bearing mice that expressed CTLA-4 was only ~3% while the percentage of T
cells isolated from orthotopic tumors that expressed CTLA-4 increased to 15%.
Statistical analysis indicated a significant increase (P<0.001) in the percentage of T
cells that were positive for CTLA-4.
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Fig. 14. CTLA-4 expression of tetramer positive T cells compared with all T cells from
TRAMP tumor-bearing mice. Panels A & B represent pooled data from two different
experiments. A, Expression of CTLA-4 complex on T cells isolated from TRAMP tumorbearing C57B1/6 mice. Single cells suspensions were made according to fig. 3 legend. T
cells were immunostained using FITC-conjugated anti-Thyl antibody, PE-conjugated
anti-CTLA-4 antibody, Cy chrome-conjugated anti-CD3e antibody and the Cy 5conjugated tumor antigen specific tetramer WT 1(130-13 8)/H-2Db. The expression of
Thyl was used to identify T cells for these studies and the stained cell suspension was
double gated using forward vs. side scatter to identify lymphoid cells and expression of
Thyl molecules to identify T cells. B, Expression of CTLA-4 complex on tetramer
positive cells isolated from TRAMP tumor-bearing C57B1/6 mice. The binding of the
tumor antigen specific tetramer was used to identify tumor-specific T cells for these
studies and the stained cell suspension was double gated using forward vs. side scatter to
identify lymphoid cells and the binding of tetramers was used to identify tumor-specific
T cells. C, Flow cytometry histograms from a single study show the raw data for one
study. The numbers in each quadrant represents the percentage of gated cells within each
quadrant.
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In order to determine the extent to which tetramer positive T cells isolated from
TRAMP tumors expressed increased levels of CTLA-4 tetramer positive cells were
gated and analyzed by flow cytometry. This study was only performed once so no
statistical analysis could be performed.
The results of this study are summarized in Panel B and demonstrate that there
were no tetramer positive cells in ectopic tumors so expression of CTLA-4 could not be
determined. However, the percentage of tetramer positive T cells that expressed CTLA-4
from orthotopic tumors was dramatically increased. Fig. 14B shows that in this study the
percentage of tetramer positive cells that were also CTLA-4 positive increased from
-20% in orthotopic tumor-bearing spleens to -80% in both dLNs and freshly isolated
lymphoid cells from tumors.
Finally, in order to determine the extent to which removal of the T cells from the
TRAMP TME and culture with IL-2 altered the expression of CTLA-4, tumor infiltrating
cells were cultured for 20 hours in IL2 and phenotyped in the same fashion as described
above. The results of this study are summarized in Fig. 14. It is apparent that fresh TILs
from orthotopic tumors contained a very high percentage of CTLA-4 positive cells
(-100%) in the tetramer positive fraction but only -20% of all T cells isolated from
tumors expressed CTLA-4 molecules. Overnight culture resulted in a decrease in the
number of WT1-specific and CTLA4-positive T cells; decreasing from almost 100% in
freshly isolated tumor-infiltrating tetramer positive T cells to - 30% of the WT1-specific
T cells still expressing CTLA-4 after -2 0 hours of culture.
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E 5. Summation of the analysis of tumor-specific (WTl(130-138)/H-2Db specific)
cells
The results of the analysis of the tumor-specific T cells indicated that tetramerbinding cells were rare in all freshly isolated lymphoid organs of tumor-bearing mice.
However, with culture in IL-2 the percentage of tetramer positive cells significantly
increased. Because T cells must contain their TCR complexes in order to bind tetramers
these results are in agreement with the previous studies showing recovery of TCR-a/p
complexes with culture (Fig. 3C).

The biologic significance is that T cells within

TRAMP tumors are unable to recognize tumor antigens, even with proper presentation
(complexed with MHC-I molecules) and removal of these cells from the TME allows for
tumor antigen recognition. The implication is that some factor(s) within the TRAMP
TME mediates the loss of these T cell molecules and therefore the ability of tumorinfiltrating T cells to recognize tumor antigens.
Phenotyping studies comparing T cells and tetramer positive cells in tumorbearing mice showed that about ~60% of the rare tetramer positive cells in the dLNs were
T cells and -80% of the rare tetramer positive cells freshly isolated from orthotopic
tumors were T cells; also expressing the CD3s molecule.

Surprisingly, phenotyping

studies showed that a disproportionate number of tetramer binding cells were y/8 T cells,
since only -20% of tetramer positive cells in dLNs were a/p T cells and -90% were y/8
T cells. None of the tetramer binding cells freshly isolated from orthotopic tumors were
a/p T cells but -95% and -80% of fresh tumor-infiltrating cells were y/8 T cells. This
result indicates that y/8 T cells are a significant population of tumor-infiltrating T cells
which is consistent with previous studies (Fig. 4). With culture however, the percentage
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o f tetramer positive cells that expressed the a/p TCR complex increased which is also
consistent with the observation that removal of T cells from the TRAMP TME allows for
the re-expression o f the a/p TCR (Fig. 3C).
Finally, tetramer studies that compared the expression of the activation marker
CTLA-4 on T cells and tetramer-binding cells from tumor-bearing mice indicated that
tetramer-binding cells were more activated in dLNs and within tumors than T cells
overall.

With 20 hour culture in IL-2 the expression of the CTLA-4 molecule on

tetramer-binding cells decreased which is consistent with previous studies (Fig. 9C)

E 6 . Summation of the phenotypic studies of tumor-infiltrating T cells
Therefore, flow cytometric analysis indicated that expression of signal
transducing components of the CD3 complex was reduced in tumor-infiltrating T cells.
Expression o f T cell specific molecules not part of the CD3 complex such as CDS and
Thy-1 was also decreased but not as dramatically and the decrease was generally not
statistically significant. Specifically, the percentage of T cells expressing the molecules
CD3s, TCR-P and TCR-£| was decreased but the expression returned to normal levels
with removal of tumor-infiltrating T cells and culture with IL-2.

Surprisingly, the

percentage of tumor-infiltrating y/S-T cells was significantly increased compared to
spleens of tumor-bearing mice. The percentage of T cells from tumor-bearing spleens
that expressed TCR-8 /y receptors was -10% which increased to -30% in T cells isolated
from prostate tumors. There was no increase in the percentage of gamma/delta T cells in
cultured tumor-infiltrating T cells indicating that TCR-8 /y expression is not decreased in
the TRAMP TME like the TCR of the alpha/beta T cells. Finally, the percentage of T
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cells that expressed the transient activation marker CTLA-4 was only increased in freshly
isolated T cells from orthotopic tumors and not from cultured tumor-infiltrating T cells.
With culture the activation marker expression decreased reflecting the transient nature of
CTLA-4 expression and also that removal from tumor-associated antigens decreased
activation o f infiltrating tumor-specific T cells.
Analysis of the expression of signaling molecules on tumor-specific T cells as
identified by WT1 (130-138)/H-2Db tetramers indicated that freshly isolated tumorinfiltrating T cells failed to bind tetramers in sufficient numbers for analysis.

The

percentage of T cells that bound tetramers in freshly isolated tumor-infiltrating T cells
was consistently less then 0.5% but the percentage increased to 2.5% and 5% of T cells in
cultured tumor-infiltrating T cells from ectopic and orthotopic tumors, respectively. The
very rare tetramer positive cells in freshly isolated T cells did not bind antibodies against
any T cell specific proteins, indicating that tetramers were probably binding non-T cells
or cellular debris which is an artifact of tumor digestion to single cell suspension.
However, with culture a greater percentage of tetramer binding cells expressed the TCRP molecule. The same phenomenon was noted with tumor-infiltrating T cells generally,
indicating that tetramer positive T cell expression of TCR-p molecules is decreased with
exposure to TRAMP TME but re-expression occurs with in vitro culture with IL-2.

F.

TRAMP TUMORS AND FLT3-LIGAND TREATED SPLEENS SHARE

COMMON CHARACTERISTICS OF HEAVY MYELOID CELL INFILTRATE
Because of the decrease in the percentage of T cells expressing TCR-^ from
TRAMP tumors and flt3-L treated spleens, I next wanted to determine if both
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Fig. 15. Determination of the cell types that constitute the host immune cells of TRAMP
tumors. A, Phenotyping of orthotopic TRAMP-inflltrating immune cells. Panel A
represents pooled data from 3 studies. Single cell suspensions from orthotopic TRAMPC1P3 tumors were stained using lineage specific antibodies. The stained cells were
analyzed in a flow cytometer and the percentage positive cells for each antibody was
determined by comparing fluorescence o f stained cells with the fluorescence from isotype
matched negative antibodies. B, Percentage of cells from the indicated organs/tumors
that expressed the myeloid lineage specific molecule C D llc. The biotinylated antiC D llc antibody was used to stain cells and the percentage of positive cells within the
indicated organs/tumors. *Indicates the cell population that the other groups were
compared to. The P values above the indicated columns indicate the statistical
significance of differences in the percentage of C D llc positive cells compared with the
control population (normal C57B1/6 spleen), n.s. indicates no significant difference in
between the control groups and the indicated groups.
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microenvironments contain common cell types. Phenotyping studies were performed to
determine the percentage of myeloid lineage cells in both populations. We showed in
Fig. 1 that TRAMP tumors contained a high percentage of myeloid cells with -30% of
cells expressing the myeloid lineage restricted molecule C D llc. Phenotyping studies of
orthotopic TRAMP tumor infiltrates were performed and shown in Fig. 15 A, which
demonstrate that the predominant infiltrating cells within these tumors express myeloid
lineage markers including C D llc (-25%), GR1 (-24%) and F4/80/MAC+ (~ 23%). T
cells were less common cells representing less then 5% of the more restrictive lymphoid
gate in these studies as shown in Fig. 15A.
It is well established that flt3-L therapy induces the generation of large numbers
o f myeloid precursor cells that concentrate in all lymphoid organs (104). Flt3-L treatment
resulted in mice with extreme splenomegaly. In our studies the cell yields from flt3-L
treated spleens was 5-10 times higher then from normal spleens.

For example, after

mechanical shearing with spatulas and RBC lysis, the total number of cells recovered
o

from normal C57B1/6 spleens ranged from 0.6 to 1 x 10 cells. The total number of cells
recovered from flt3-L treated mice ranged from 3-8 x 108 cells (data not shown).
Additionally, the mechanical separation procedure used for these studies resulted in an
under-estimation of myeloid cells in spleens since myeloid cells are often intimately
associated with the stroma of spleens.

A large fraction of myeloid cells remain

associated with the stroma and are lost in the discarded debris and therefore not counted
in these studies.
Macrophage and dendritic cell recoveries increased with collagenase digestion of
spleens and TRAMP tumors. Since the cells used in these phenotyping studies were the
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result of mechanical shearing, the true percentage of myeloid cells in flt3-L spleens was
most likely higher. Fig. 15B shows that the percentage of C D llc positive cells in flt3-L
treated spleens increased from about 3% in normal spleens to 5-7% in tumor-bearing
spleens without flt3-L treatment. This increase was not statistically significant. The
percentage of myeloid precursor cells as identified by C D llc expression increased to
-35% in tumor-bearing flt3-L treated spleens. Studies, presented in Fig. 15B, show that
-30% of the cells recovered at the Ficoll interface of carrier treated orthotopic TRAMP
tumors expressed the myeloid restricted marker CD1 lc. Therefore, like TRAMP tumors,
flt3-L treated spleens resulted in a microenvironment rich in myeloid-lineage cells.
Since T cells isolated from both or these organs displayed altered expression of
the signal-transducing TCR-^ molecules as demonstrated in Fig. 6, I hypothesized that
these myeloid cells mediate the loss of CD3/TCR complex components.

Therefore,

studies were initiated to examine the characteristics of tumor-infiltrating myeloid cells.

F 1. Many GR1 positive cells separate at the ficoll/liquid interface indicating low
buoyant density of TRAMP-infiltrating granulocytes
It was unclear however whether TRAMP-infiltrating myeloid cells expressed
normal myeloid characteristics or if they too were modified by the TME. We decided to
first examine which fraction of the Ficoll-Hypaque separation gradient contained the
myeloid cells. Typically, granulocytes (GRs) are dense cells, containing many granules
and they separate out in the pellet fraction of the ficoll gradient. Surprisingly, almost
50% of tumor-infiltrating GRs remained at the ficoll/liquid interface with the
mononuclear cells indicating that some factor(s) within the TRAMP TME caused the
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granulocytyes to become less buoyant with a density closer to lymphoid cells (data not
shown).

F 2.

TRAMP-infiltrating C D llc cells (DCs) lack MHC class II expression

indicating an immature phenotype of these cells.
To determine whether TRAMP-infiltrating DCs expressed MHC class II
antigens (I-Ab) and the DC co-stimulatory molecule B7.2, three color flow cytometric
analysis was performed as shown in Fig. 16. DCs were identified by first expanding the
FSC vs. SSC lymphoid gate to include larger and more granular cells (see panels A and
D) then gating C D llc positive population of these cells for analysis. Normal mouse
splenic DCs are shown in Panel I which shows that -46% of these cells express both I-Ab
and B7.2 molecules.
In contrast, only -28% of DCs isolated from TRAMP-C1P3 tumors from carrier
treated mice and only -11% o f DCs from flt3-L treated mice expressed both antigens.
Both I-Ab and B7.2 antigens are expressed on mature DCs and both are involved with
proper function o f DCs as antigen presenting cells. B7.2 binds to the stimulatory CD28
antigen on T cells and is required to activate antigen specific T cells (Gabrilovich et. a l,
2001 ).

Fig. 16 also shows that the percentage of DCs that expressed the CD8a molecule
increased from day 7 to day 14 of treatment. This increase was apparent regardless of
whether the mice received flt3-L therapy or were left untreated, receiving carrier
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Fig. 16. Characterization of dendritic cell subsets infiltrating TRAMP-C1 tumors during
Flt3-L immunotherapy. Mice were treated with either carrier (panels A, D, G) of Flt3-L
(panels B, E, H) when TRAMP tumors became palpable. After 7 or 14 days of therapy,
tumors were digested, TILs isolated and subjected to three-color flow cytometry. Panels
A and B illustrate a representative single color analysis using anti-CD llc to stain DCs
present in TILs isolated from mice treated with either carrier or Flt3-L for 14 days.
Dendritic cells were gated and the distribution of CD8, and I-Ab on the C D llc+ DCs
were determined by flow cytometry. Panels C, F and I illustrate the distribution of B7.2
and I-Ab on splenic DCs (panel c) and intra-tumor DCs isolated after 21 days (panel F)
and 28 days (panel I) o f treatment with carrier.
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treatment only. CD8a positive DCs are immunosuppressive and have been linked to
global immunosuppression of mice with tumors (Gabrilovich et. a l, 2001).
Besides the host immune cells that infiltrate TRAMP tumors, chemokines
secreted by these cells contribute to the TME and can regulate infiltrating T cells. To
determine the chemokines to which infiltrating T cells were exposed, RNAse protection
assays for chemokine mRNA were performed (personal communication with laboratory
personnel, Nazita Yousefieh).

These assays indicated that the chemokines within

TRAMP tumors include RANTES, M IP-la, MIP-1(3, MIP-2, IP-10 and MCP-1 (data not
shown). These chemokines are also typically seen in inflammatory sites.
We hypothesized that the TRAMP TME, being composed of host immune cells
and secreted factors like cytokines and chemokines from these cells mediated the
alterations o f infiltrating T cells seen. To determine the contribution of several of the
major cell types found in great abundance in TRAMP tumors, in vitro co-culture assays
were developed utilizing ratios of these cell types similar to those found within in vivo
tumors.

G.

AN I N

VITRO CO-CULTURE ASSAY SYSTEM TO INVESTIGATE

INTERACTIONS OF THE MAIN TUMOR-INFILTRATING CELLS UPON T
CELLS
The results outlined above indicate that tumor-infiltrating T cells demonstrate
decreased expression of signal transducing molecules and that TRAMP tumors were also
rich in myeloid cells and inflammatory cytokines and chemokines. I hypothesized that the
inflammatory microenvironment within TRAMP tumors mediated the decrease in
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signaling molecules of infiltrating T cells. In order to determine the extent to which
individual myeloid lineage cell types contributed to the phenotypic changes of T cells, an
in vitro co-culture system that mimics the TRAMP TME that can be experimentally
manipulated was developed.
The cells used in these studies include nylon wool enriched T cells from normal
C57B1/6 spleens, myeloid subtypes fromflt3 -Ltreated spleens enriched by lineage specific
antibody binding and separation with Miltenyi magnetic bead columns, and in vitro
grown TRAMP-C1P3 cells. The nylon wool adherence step resulted in a purity o f >80%
normal T cells not previously exposed to TRAMP TME (data not shown).

These cells

were used as indicator cells in this analysis since they have not been exposed to the
TRAMP TME in vivo. The magnetic bead separation resulted in ~80% pure populations
o f myeloid lineage specific cells. The three cell types were co-incubated in varying ratios
for 48 hours in TRAMP tissue culture media to support TRAMP cell survival. Fortyeight hours was selected for the length o f time for culture since this provided enough time
for the cells to interact without causing extensive cell death from in vitro culture.

G 1. Expression of TCR-^ molecules in T cells co-cultured with GR1 positive cells
and TRAMP cancer cells
The same co-culture assays were used to examine the expression of TCR-^ on T
cells exposed to the in vitro co-culture with GR1 positive and TRAMP-C1P3 cells. Fig.
17 summarizes the results of three co-culture assays and demonstrates that the percentage
of TCR-<^ positive T cells is not significantly different when T cells are cultured with
GR1 positive cells alone at increasing concentrations of GRs as shown in columns 2-5.
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Fig. 17. Expression of TCR-<^ molecules on T cells co-cultured with GR1+ cells and
TRAMP tumor cells. The percentage of T cells that expressed TCR-C, molecules was
determined in normal C57B1/6 splenic cells in varying in vitro conditions designed to
replicate the in vivo TRAMP TME. Column designations; Fresh T cells, analyzed the
percentage o f T cells expressing TCR-£| in freshly isolated, normal C57B1/6 mouse spleen
cells. (1:0:0) analyzed the percentage of T cells that expressed TCR-^ in T cells
(5xl06/well) cultured in TRAMP media for 48 hours without TRAMP-Cl-p3 or GR1+
cells. (1:0.5X:0) analyzed the percentage of T cells expressing TCR-£, molecules from
assay wells with T cells (5xl06/well) and 0.5X (2.5x106/well) GR1+ cells and no
TRAMP-Cl-p3 cells.
(1:2X:0) analyzed the expression of TCR-^ on T cells
(5x106/well) cultured with 2X (10xl06/well) GR1+ cells and no TRAMP-Cl-p3 cells.
(1:5X:0) analyzed T cells (5x106/well) cultured for 48 hours with 5X cells (25xl06/well)
GR1+ cells and no TRAMP-Cl-p3 cells. (1:0:0.5X) analyzed the expression of TCR-^
on T cells (5xl06/well) cultured for 48 hours with no GR1+ cells and 0.5X TRAMP-C1p3 cells. (1:0:0.25X) analyzed TCR-^ expression on T cells cultured with 0.25X
TRAMP-Cl-p3 cells and no GR1+ cells. (1:0:0.125X) analyzed TCR-(^ expression on T
cells cultured with 0.125X TRAMP-Cl-p3 cells and no GR1+ cells. (1:0.5X:0.5X)
analyzed TCR-^ expression on T cells (5x105/well)cultured for 48 hours with 0.5X GR1+
cells and 0.5X TRAMP-Cl-p3 cells. (1:2X:0.5X) analyzed TCR-^ expression on T cells
(5xl06/well) cultured with 2X GR1+ cells and 0.5X TRAMP-Cl-p3 cells. (1:5X:0.5X)
analyzed TCR-£ expression on T cells (5xl06/well) cultured for 48 hours with 5X
(25xl06/well) GR1+ cells and 0.5X (2.5xl06/well) TRAMP-Cl-p3 cells. (l:2Xtum:0.5X)
analyzed the TCR-<^ expression of T cells (5xl06/well) cultured for 48 hours with 2X
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Fig. 17 (continued) TRAMP-infiltrating GR1+ cells (10xl06/well) and 0.5X TRAMP-C1p3 cells. The assay conditions were established using TRAMP tissue culture media with
agitation and re-suspension of the cell mixtures after 24 hours of culture. T cells were
identified by flow cytometry using double gating of FSC vs. SSC for lymphoid cells and
expression o f Thyl or CD5 to identify T cells. *Identifies the control condition used for
statistical comparison with indicated groups. **Identifies a second control group for
subsequent comparisons with indicated groups, n.s. indicates no statistically significant
differences between the indicated groups. The P values indicate the probability of
differences between the indicated groups using the student’s T test.

Approximately 80% o f T cells in each these cultures expressed molecules and there was
no statistically significant differences noted.

So when co-cultured with increasing

numbers o f GR1 positive flt3-L treated spleen cells the percentage of TCR-^ positive T
cells is unchanged. When co-cultured with TRAMP-C1P3 cells alone at ratios between
0.125:1 and 0.5:1 there was no decrease in the percentage of T cells expressing TCR-<^
molecules as shown in columns 6-8.

The percentages of T cells expressing TCR-£,

ranged from 90-95% and there was no statistically significant decrease in the percentage
o f T cells expressing the TCR-^ molecule. This was not statistically different then the
percentage o f T cells expressing TCR-C, in the wells with T cells cultured alone in column
2. When T cells were co-cultured with the highest number of TRAMP-C1P3 cells and
increasing numbers of GR1 positive cells, the percentage of TCR-^ positive T cells
decreased in a dose response fashion as shown in columns 9-11. Multi-variant analysis
indicated that the difference was only statistically significant with the highest
concentration of GR1 positive cells were co-cultured with T cells and TRAMP-C1P3
cells as shown in column 11(P<0.01).
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There was a significant decrease in TCR-(^ expression when T cells cultured alone
were compared with the wells containing all three cell types and the highest
concentration of GR1 positive cells, compare column 2 with column 11. T cells cocultured with the highest concentration of GR1 positive cells with and without TRAMPC1P3 cells did not show a statistically significant decrease in the percentage of TCR-C,
positive T cells, compare column 5 with column 11. These apparently contradictory
results indicate that there is a slight decrease in the percentage of TCR-^ positive T cells
upon co-culture with GR1 positive cells alone and a greater and statistically significant
decrease upon co-culture with GR1 positive cells and TRAMP-C1P3 cells.
In order to determine whether GR1 positive cells isolated from the ficoll interface
of orthotopic TRAMP tumor digests were able to induce the same loss of TCR-C,
molecules GR1 positive cells from the from the ficoll interface of tumor digests were
evaluated in these co-culture assays. When tumor-infiltrating GR1 positive cells were
substituted for flt3-L treated splenic GR1 cells there was no loss of TCR-(^ positive T
cells, compare Fig. 17 columns 11 and 12. This result indicates that granulocytes within
TRAMP tumors were no longer able to decrease TCR-^ expression when co-cultured
with T cells and TRAMP cells.
In summary, when normal T cells are co-cultured with high numbers o f GR1
positive cells from flt3-L treated spleens there is a slight but not statistically significant
decrease in TCR-C, positive T cells.

The loss of TCR-£ was greater and became

statistically significant in a dose response fashion when TRAMP cells were co-cultured
with T cells and GR1 positive cells.
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The percentage of T cells expressing TCR-i^ was -80% with T cells cultured
alone and was reduced to -60% when the highest number of GR1 positive cells and
TRAMP-C1P3 cells were added. Therefore, GR1 positive cells alone can slightly reduce
TCR-^ expression but this reduction is augmented when TRAMP-C1P3 cells are
included indicating that a triad of cells are required to significantly reduce TCR-C,
expression in these co-culture assays.

G 2.

Expression of CD3s molecules on T cells co-cultured with GR1 positive

myeloid cells and TRAMP-C1P3 tumor cells
We analyzed the extent to which GR1 positive myeloid cells ffomflt3-Ltreated
spleens were able to mediate decreased expression of the signal transducing molecule
CD3s and the contribution of TRAMP-C1P3 cells to these changes. The same co-culture
assays were used to determine the percentage of T cells that expressed CD3s. Fig. 18
shows the pooled data from three studies showing the percentages of cultured T cells that
expressed CD3e when co-cultured with varying numbers of GR1 positive cells and or in
vitro grown TRAMP-C1P3 cells.
When T cells were cultured alone in these assays the percentage of T cells that
expressed CD3s was -90% as shown in column 2. When increasing numbers of GR1
positive cells were added there was a slight but not statistically significant decrease in the
percentage of T cells that expressed CD3e, see columns 3-5. Co-culture of normal T cells
with TRAMP-C 1P3 cells did not statistically reduce the percentage of T cells expressing
CD3e in column 6.
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Fig. 18. Expression of CD3e molecule on T cells co-cultured with GR1 positive cells and
TRAMP tumor cells. The percentage of T cells that expressed the CD3e molecule was
determined in normal C57B1/6 splenic cells in varying in vitro conditions designed to
replicate the in vivo TRAMP TME, as described in Fig. 17 legend. T cells were identified
by flow cytometry using double gating o f FSC vs. SSC for lymphoid cells and expression
o f Thy 1 or CD5 to identify T cells.
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However, when normal T cells were co-cultured with TRAMP-C 1P3 cells and
increasing numbers of GR1 positive myeloid cells, the percentage of T cells expressing
CD3e decreased in a dose-dependent manner in columns 7-9.

Only the highest

concentration of GR1 positive cells and tumor cells resulted in statistically significant
reduction o f CD3s expression. Statistical analysis yielded P value of <0.05 for wells with
five times the number of GR1 cells with TRAMP-C 1P3 cells and T cells. When tumorinfiltrating GR1 positive cells isolated from the ficoll interface of digested TRAMP
tumors were used in the assay there was no statistically significant decrease in CD3s
expression in column 10.
Therefore, the expression of CD3e on the T cells in this assay is only slightly but
statistically significant decreased when normal T cells were co-cultured with the highest
concentrations of GR1 positive cells and tumor cells, compare column 2 with column 9
(P>0.01). There was no decrease in CD3s expression when normal T cells were cocultured with in vitro grown TRAMP-C1P3 cells alone, see columns 3-5. When all three
cell-types were co-cultured there was a statistically significant decrease in the percentage
o f T cells that expressed CD3e, indicating that a triad of cells was required to reduce the
expression of CD3s molecules in the co-culture assays.

There was no statistical

difference between wells with T cells co-cultured with five times the number of GR1
positive cells and wells with T cells co-cultured with five times GR1+ and TRAMP-C 1P3
cells, compare column 5 with column 9.
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G 3.

Expression of TCR-p molecules on T cells co-cultured with GR1 positive

myeloid cells and TRAMP-C 1P3 tumor cells
Fig. 19 shows the percentage of T cells that expressed TCR-p molecules in co
culture assays from the same co-culture experiments using the same ratios of cell types.
In these studies the percentage of T cells that expressed TCR-P was -90% in wells with T
cells alone in column 2. There was no statistically significant decrease in this percentage
in any of the co-culture conditions tested.

Statistical analysis indicated no statistical

differences in the percentage of T cells that expressed TCR-P in any of the co-culture
conditions studied. These results indicate that unlike TCR-^ and CD3e, the expression of
TCR-p is not altered by GR1 positive cells from the spleens offlt3-Ltreated mice
implying that some other cell type within in vivo TRAMP tumors mediated the observed
loss of TCR-P on tumor-infiltrating T cells.

G 4.

Expression of Thy-1 molecules on T cells co-cultured with GR1 positive

myeloid cells and TRAMP-C 1P3 tumor cells
In order to examine expression of T cell specific molecules not components of the
CD3 complex in these co-culture assays phenotyping studies were performed as
described above. Results o f these in vivo phenotyping studies in Fig. 7 demonstrated that
the percentage of T cells from the spleens of TRAMP tumor-bearing mice that expressed
Thy-1 was decreased on tumor-infiltrating T cells and was also decreased on T cells from
the spleens of tumor-bearing mice.

These results indicated systemic loss of Thy-1

expression in mice with TRAMP tumors. I therefore wanted to evaluate the extent to
which GR1 positive cells from flt3-L treated spleens decreased the percentage o f T cells
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Fig. 19. Expression of TCR-P molecules on T cells co-cultured with GR1 positive cells
and TRAMP tumor cells. The percentage of T cells that expressed TCR-P molecules was
determined in normal C57B1/6 splenic cells in varying in vitro conditions designed to
replicate the in vivo TRAMP TME. Column designations according to Fig. 17 legend.
The assay conditions were established using TRAMP tissue culture media with agitation
and re-suspension of the cell mixtures after 24 hours of culture. T cells were identified
by flow cytometry using double gating of FSC vs. SSC for lymphoid cells and expression
of Thy 1 or CD5 to identify T cells.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

123

that expressed Thy-1 in co-culture assays. Using the same co-culture assays, Fig. 20
column 2 shows that >90% of T cells cultured alone expressed Thy-1 and that co-culture
with GR1 positive cells alone or in vitro grown TRAMP-C1P3 cells alone did not
decrease Thy-1 expression, see columns 2-8.
There was a statistically significant decrease in the percentage of T cells that
expressed Thy-1 when normal T cells were co-cultured with high concentrations of GR1
positive cells and TRAMP-C 1P3 cells in columns 9-11 (P<0.01 and 0.001).

The

percentage of T cells that expressed Thy-1 decreased to -80% and -70% for T cells from
wells with TRAMP cells and two times and five time the number of GR1 positive cells
respectively.

The decreased Thy-1 expression was dose-dependent and only the two

highest concentrations of GR1 positive cells reached statistical significance in these
studies. Multi-variant analysis gave P values of <0.01 and <0.001 for the wells with T
cells, TRAMP-C 1P3 cells and two times and five times the number of GR1 positive cells
respectively.
Fig. 20 column 12 shows that when GR1 positive cells isolated from the ficoll
interface of TRAMP tumor suspensions were used in these co-culture assays there was no
decrease in the percentage of T cells expressing Thy-1. In these assays -90% of T cells
co-cultured with TRAMP cells and twice the number of TRAMP tumor infiltrating GR1
positive cells expressed Thy-1 (see column 12). This is identical with the percentage of T
cells that expressed Thy-1 in wells with T cells cultured alone and T cells cultured with
TRAMP cells. These results indicated that tumor-infiltrating GR1 positive cells from the
ficoll interface were unable to mediate the observed decrease in Thy-1 expression seen in
T cells from TRAMP tumor-bearing mice. Because the Thy-1 molecule is anchored to
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Fig. 20. Expression of Thy-1 molecules on T cells co-cultured with GR1 positive cells
and TRAMP tumor cells. The percentage of T cells that expressed Thy-1 molecules was
determined in normal C57B1/6 splenic cells in varying in vitro conditions designed to
replicate the in vivo TRAMP TME as defined in Fig. 17 legend column designations. T
cells were identified by flow cytometry using double gating of FSC vs. SSC for lymphoid
cells and expression of Thy-1 or CD5 to identify T cells. *Identifies the control condition
used for statistical comparison with indicated groups and the indicated P values indicate
the probability of statistical differences using the student’s T test.
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the cell wall by a GPI-linked segment which is susceptible to cleavage by compounds
secreted by GR1 positive cells. Examples of such compounds include proteases and
phospholipases. Additional studies are required to determine the mechanism for the GR1
cell-associated loss of Thy-1 molecules on T cells.

G 5. Expression of CDS on T cells co-cultured with GR1 positive cells and TRAMPC1P3 cells
The percentage of T cells from these co-culture assays that expressed the CD5
molecule was next evaluated in these co-culture assays with GR1 positive cells. The
pooled results of these studies are shown in Fig. 21 and demonstrate that the percentage
of T cells that expressed CD5 was not significantly altered following co-culture with
GR1 positive myeloid cells from the spleens of flt3-L treated mice. The percentage of
CD5 positive T cells when cultured alone was -95% in column 2. CD5 expression
remained constant regardless of co-culture with increasing numbers of GR1 positive
cells. Co-culture o f normal T cells with TRAMP cells did not alter CD5 expression.
When T cells were co-cultured with TRAMP and GR1 positive cells there was a slight
but non-significant decrease in the percentage of cells expressing CD5.
When tumor-infiltrating GR1 positive cells from the ficoll interface were
evaluated, there was no decrease in the percentage of T cells expressing CDS.

The

percentage of CD5 positive T cells with tumor-infiltrating GR1 cells and TRAMP cells
was -95%, equivalent to that detected with T cells alone and T cells and TRAMP cells
only. Because the slight decrease in the percentage of T cells that expressed CD5 was
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Co-culture conditions

Fig. 21. Expression of CD5 molecules on T cells co-cultured with GR1 positive cells and
TRAMP tumor cells. The percentage of T cells that expressed CD5 molecules was
determined in normal C57B1/6 splenic cells in various in vitro conditions designed to
replicate the in vivo TRAMP TME according to the column designations in Fig. 17
legend. T cells were identified by flow cytometry using double gating o f ESC vs. SSC
for lymphoid cells and expression of Thyl or CD5 to identify T cells. *No statistically
significant differences were detected between the groups using the student’s T test.
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not statistically significant, these results suggest that GR1 positive cells from flt3-L
treated spleens are unable to decrease CDS expression in these co-culture assays. This
result was expected since T cells isolated from TRAMP tumors did not demonstrate
decreased expression of the CD5 molecule, see fig. 8.

G 6. Phenotypic determination of the CD4 to CD8 ratios of T cells co-cultured with

GR1 positive cells and TRAMP-C 1P3 cancer cells
In order to determine the extent to which co-culture of normal T cells with
TRAMP-C 1P3 cells and GR1 positive cells from flt3-L treated spleens altered the
expression o f CD4 or CD8 on T cells, co-culture assays were performed. The summary
o f the results of these experiments is shown in Fig. 22.

This figure shows that The

percentage of T cells that expressed CD4 over the percentage of T cells that expressed
CD8 (the CD4/CD8 ratio) from fresh splenic T cells was -1.5, see column 1.
Surprisingly, the results indicated that the CD4/CD8 ratio of T cells cultured alone
increased to -4.6.

This result implied that T cells cultured alone resulted in loss

predominately of CD8 positive cells, thereby skewing the ratio in favor of CD4 cells.
When T cells were cultured with increasing numbers of GR1 positive cells, the
CD4/CD8 ratio decreases at the highest concentration of GR1 positive cells, compare
column 1 with 3, 4 and 5. The CD4/CD8 ratio was about 0.5 (indicating twice as many
CD8 cells as CD4 cells) with the highest concentration of GR1 cells and was -1.5 in the
freshly isolated splenic T cells. When T cells were cultured with TRAMP cells alone
there was no change in the CD4/CD8 ratio compared with fresh T cells in any
concentration of tumor cells, compare column 1 with 6, 7 and 8. When normal T cells
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were cultured with a constant number of tumor cells and increasing concentrations of
GR1 positive cells, the decrease in CD4/CD8 ratios was even greater then co-culture with
GR1 positive cells alone, compare column 1 with 9, 10 and 11. When T cells were cocultured with TRAMP tumor-infiltrating GR1 positive cells from the ficoll interface and
in vitro grown TRAMP-C 1P3 cells, the CD4/CD8 ratio was the same as T cells cultured
alone and T cells cultured with TRAMP cells only.
These results indicate 48-hour culture of normal T cells in TRAMP media without
other cells resulted in decreased numbers of CD8 positive T cells.

Co-culture with

increasing numbers of GR1 positive cells resulted in a decrease in the number of CD4
positive T cells and preservation of the number of CD8 positive T cells. This loss of CD4
positive T cells was even more dramatic in the wells with both GR1 positive cells and
TRAMP tumors cells indicating that the combination of all three cell types results in a
greater decrease in CD4 positive T cells in culture. When tumor-infiltrating GR1 positive
cells were used there was no decrease in CD4 positive T cells.

No data has been

generated to specifically determine whether increasing CD4/CD8 ratios correspond to
loss of CD4 cells and decreasing CD4/CD8 ratios correlates to loss of CD4 cells. The
incubation times for this assay of 20 hours was too short for appreciable cell division to
occur. Cell counts of the recovered cells from the wells indicated that the loss of T cells
during culture was minimal using CD5 expression to identify T cells, data not shown.
Multi-variant analysis one the values and only the CD4/CD8 ratio of the well with
T cells alone showed a statistically significant difference from the freshly isolated T cells.
Because these values are ratios of independent factors minor changes may signify
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Fig. 22. CD4 over CD8 ratios of T cells co-cultured with GR1+ cells and TRAMP tumor
cells. The ratio of CD4/CD8 T cells of C57B1/6 splenic cells in varying in vitro
conditions designed to replicate the in vivo TRAMP TME was determined using
procedures and column designations as defined in Fig. 17 legend. T cells were identified
by flow cytometry using double gating of FSC vs. SSC for lymphoid cells and expression
of CDS was used to identify T cells. CD4 and CD8 expression was determined using
monoclonal antibody staining for these antigens from the same staining tube. *Indicates
the control group to which other groups were compared. The indicated P value identifies
the probability of differences between the indicated groups and n.s. indicates not
statistical differences using the student’s t test.
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important changes in the cell populations even without statistical significance.

For

example, co-culture of fresh T cells with GR1 positive cells and TRAMP-C1P3 cells
appears to decrease the CD4/CD8 ratio to a greater extent than co-culture with either cell
type alone. This indicates that the CD4 molecule may be more susceptible to loss than
the CD8 molecules in these co-culture studies.

G 7. Summation of the influence of GR1 cells on TCR/CD3 expression evaluated by
co-culture assays
In order to recreate the TRAMP TME and evaluate the extent to which the tumorinfiltrating GR1 positive cells alter the expression of T cell signal transducing molecules
an in vitro co-culture assay system was developed. The results described above support
the hypothesis that GR1 positive cells within TRAMP tumors mediate the loss of TCR-£,,
CD3e and Thy-1 expression on tumor-infiltrating T cells in vivo. When all three celltypes were included in the culture assay the percentage of splenic T cells expressing these
markers was decreased.
The results of these co-culture assays do not support the hypothesis that tumorinfiltrating GR1 positive cells mediate the loss of TCR-P molecules since there was no
statistically significant decrease of TCR-P expression. Therefore, some other TRAMP
tumor-infiltrating cell type may mediate the loss of TCR-p in tumor-infiltrating T cells.
An additional explanation is that the in vitro co-culture assay is deficient in some
component o f the in vivo TRAMP TME masking the ability of GR1 positive cells to
decrease the expression of TCR-P molecules on T cells.
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H.

ROLE OF MACROPHAGES IN THE TUMOR-INDUCED LOSS OF

CD3/TCR SIGNALING MOLECULES ASSESSED IN VITRO CO-CULTURE
ASSAYS
Since macrophages represent the second most common TRAMP tumorinfiltrating myeloid cell type, I next evaluated the extent to which macrophages isolated
fromflt3-Ltreated spleens were able to mediate loss of signaling molecules in co-culture
assays.

To perform these experiments, flt3-L treated spleen cells were enriched for

macrophages using the macrophage specific biotin conjugated antibody F4/80 and anti
biotin magnetic beads and magnetic column purification according to the procedures
described in the Materials and Methods section. The resulting population of >80% F4/80
positive was used in co-culture assays similar to the assays performed using GR1 positive
cells.

H 1. Evaluation of the extent to which macrophages from flt3-L treated spleens are
able to mediate loss of TCR-^ in co-culture assays
A series of two co-culture assays were performed using F4/80 positive cells from
flt3 -L treated spleens in place of GR1 positive cells used in the previous set of studies.
The results o f the studies were pooled and are summarized in Fig. 23. In contrast to the
findings with GR1 positive cells, there was no statistically significant reduction in the
percentage of T cells expressing TCR-£ in any of the co-culture conditions studied using
F4/80 positive cells. Statistical analysis showed that comparison of T cells cultured alone
with T cells cultured with macrophages and in vitro grown TRAMP-C1P3 cells gave no
statistically significant differences in any of the assay conditions. Ninety percent of T
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Fig. 23. Expression o f TCR-£, molecules on T cells co-cultured with splenic macrophages
(F4/80+) cells and TRAMP tumor cells. The percentage of T cells that expressed TCR-C,'
molecules was determined in normal C57B1/6 splenic cells in varying in vitro conditions
designed to replicate the in vivo TRAMP TME. Column designations; Fresh T cells,
analyzed the percentage of T cells expressing TCR-C in freshly isolated, normal C57B1/6
mouse spleen cells. (1 :0 :0) analyzed the percentage of T cells that expressed TCR-C in T
cells (5xl06/well) cultured in TRAMP media for 48 hours without TRAMP-C l-p3 or
F4/80+ cells.
(1:0.5M:0) analyzed the percentage of T cells expressing TCR-C
molecules from assay wells with T cells (5xl06/well) and 0.5X (2.5x106/well) F4/80+
cells and no TRAMP-C 1-p3 cells. (1:2XM:0) analyzed the expression of TCR-C on T
cells (5xl06/well) cultured with 2X (10xl06/well) F4/80+ cells and no TRAMP-Cl-p3
cells. (1:5XM:0) analyzed T cells (5xl06/well) cultured for 48 hours with 5X F4/80+cells
(25xl06/well) and no TRAMP-Cl-p3 cells. (l:0:0.5Tr) analyzed the expression of TCRC on T cells (5xl06/well) cultured for 48 hours with no F4/80+ cells and 0.5X TRAMPCl-p3 cells. (1 :0.5M:0.5) analyzed TCR-C expression on T cells (5x 106/well)cultured for
48 hours with 0.5X F4/80+ cells and 0.5X TRAMP-Cl-p3 cells. (1:2XM:0.5) analyzed
TCR-C expression on T cells (5xl06/well) cultured with 2X F4/80+ cells and 0.5X
TRAMP-C 1-p3 cells. (1:5XM:0.5) analyzed TCR-C expression on T cells (5xl06/well)
cultured for 48 hours with 5X (25xl06/well) F4/80+ cells and 0.5X (2.5xl06/well)
TRAMP-C l-p3 cells. T cells were identified by flow cytometry using double gating of
FSC vs. SSC for lymphoid cells and expression of Thyl or CD5 antibodies were used to
identify T cells. *No statistically significant differences were detected between the
groups using the student’s T test.
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cells cultured alone expressed TCR-C and when cultured with increasing numbers of
F4/80+ cells, there was only a slight decrease in TCR-C, expression that was not
statistically significant, compare column 2 with 3, 4 and 5. The trend showed a dose
response and increasing macrophages correlated with decreased TCR-C, expression that
never reached statistical significance in these assays. Thus no loss of TCR-C, expression
could be attributed to co-culture with macrophages.
There was no decrease in the percentage of TCR-C, positive T cells when
TRAMP-C 1P3 cells were co-cultured with T cells, compare column 2 with 6. When T
cells were co-cultured with tumor cells and increasing numbers of macrophages from
flt3-L treated spleens there was no decrease in the percentage of TCR-C positive T cells
noted, compare column 2 with 7, 8 and 9.
These results are in contrast with the results of co-culture assays with GR1
positive cells from flt3-L treated spleens which showed that the triad of T cells, GR1
positive spleen cells and TRAMP-C1P3 tumor cells resulted in the loss of TCR-C,
expression in T cells. Therefore, these results of the macrophage co-culture studies do
not support the hypothesis that tumor-infiltrating macrophages contribute to the observed
loss of TCR-C in tumor-infiltrating T cells.

H 2. Expression of CD3e on T cells co-cultured with macrophages and TRAMP
tumor cells in co-culture assays
The same series of in vitro co-culture studies were performed to determine
whether F4/80 positive cells used in this in vitro co-culture assay are able to mediate the
loss of CD3e noted on tumor-infiltrating T cells. The results of the pooled data from
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these studies are shown in Fig. 24. This fig. shows no statistically significant differences
in the percentage of T cells that expressed CD3e. Greater then 90% of T cells cultured
alone expressed CD3s and increasing numbers of splenic macrophages did not decrease
expression o f CD3s, compare column 2 with 3, 4 and 5. When T cells were co-cultured
with increasing numbers of macrophages and in vitro grown TRAMP-C 1P3 cells, there
was also no statistically significant decrease in the percentage of CD3s positive T cells
and no dose response was noted, compare column 2 with 6, 7 and 8. Additionally, co
culture of T cells with TRAMP-C 1P3 cells did not decrease the percentage of CD3s
positive T cells, compare column 2 with column 9.
These results indicate that F4/80 positive macrophages isolated from flt3-L
treated spleens were unable to mediate decreased expression of CD3e on co-cultured T
cells. Furthermore, there was no decrease in the percentage of CD3e positive T cells
when the triad o f T cells, splenic macrophages and in vitro grown TRAMP-C 1P3 cells
were co-cultured.

These results do not support the hypothesis that TRAMP tumor-

infiltrating macrophages mediate the observed loss of CD3s on tumor-infiltrating T cells
in vivo.

An alternative explanation is that the co-culture system lacks some crucial

component present in the TME established in vivo that is required for macrophagemediated loss of CD3e expression. These results are in contrast to the co-culture assays
using GR1 positive cells from flt3-L treated spleens that indicated that GR1 positive cells
mediated the loss of CD3e expression in co-culture assays (Fig. 18).
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Fig. 24. Expression of CD3e molecules on T cells co-cultured with splenic macrophages
(F4/80+cells) and TRAMP tumor cells. The percentage of T cells that expressed CD3e
molecules was determined in normal C57B1/6 splenic cells in varying in vitro conditions
designed to replicate the in vivo TRAMP TME according to the procedures and column
designations described in Fig. 23 legend. T cells were identified by flow cytometry using
double gating ofFSC vs. SSC for lymphoid cells and expression of Thy 1 or CDS proteins
were used to identify T cells. *No statistically significant differences were detected
between the groups using the student’s T test.
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H 3. Expression of TCR-p on T cells co-cultured with macrophages and TRAMPC1P3 cells
To determine whether macrophages induced loss of TCR-P in vitro, flt3-L
expanded splenic macrophages were co-cultured with T cells either alone or in the
presence o f TRAMP-C1P3 cells in the same two experiments described above.

The

results of this analysis are presented in Fig. 25 and show that flt3-L treated F4/80 positive
cells are unable to mediate the loss of TCR-P molecule in these co-culture assays.
Statistical analysis indicated no statistically significant differences between the
percentage of TCR-P positive T cells in any of the assay wells in these studies.
These studies demonstrated that 90% of T cells expressed TCR-P when T cells
were cultured alone, see column 2. When increasing numbers of macrophages were
added to the assay wells, the percentage of TCR-P positive T cells did not decrease,
compare column 2 with 3, 4 and 5. Co-culture of T cells with TRAMP cells also failed to
decrease the percentage of TCR-P positive T cells, compare columns 2 and 6.

Finally,

when T cells were co-cultured with both TRAMP-C 1P3 cells and increasing numbers of
macrophages there was no statistically significant decrease in the percentage of T cells
expressing TCR-p, compare column 2 with 7, 8 and 9.
These results indicate that F4/80 positive macrophages isolated from flt3-L
treated spleens were not able to mediate loss of TCR-P expression in these co-culture
assays.

Therefore, these studies do not support the hypothesis that tumor-infiltrating

macrophages mediate the observed loss of TCR-P in tumor-infiltrating T cells in vivo.
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Fig. 25.
Expression of TCR-(3 molecules on T cells co-cultured with splenic
macrophages (F4/80+cells) and TRAMP tumor cells. The percentage of T cells that
expressed TCR-fi molecules was determined in normal C57B1/6 splenic cells in varying
in vitro conditions designed to replicate the in vivo TRAMP TME using conditions and
column designations in Fig. 24 legend. T cells were identified by flow cytometry using
double gating ofFSC vs. SSC for lymphoid cells and expression of Thy 1 or CDS proteins
were used to identify T cells. *No statistically significant differences were detected
between the indicated groups using the student’s T test.
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An alternative explanation is that the in vitro co-culture system lacks a crucial
component o f the in vivo TRAMP TME that is critical for macrophage-mediated loss of
TCR-(3 expression.

H 4. Expression of Thy-1 on T cells co-cultured with macrophages and TRAMPC1P3 cells
Fig. 26 shows the pooled data from a series of in vitro co-culture assays that
examined the expression of Thy-1 on normal T cells co-cultured with F4/80 positive
macrophages and TRAMP-C1P3 cells.

Ninety-five percent of T cells cultured alone

express Thy-1. When increasing numbers of isolated splenic macrophages were included
in the assay well, there was no decrease in the percentage of T cells expressing Thy-1.
When normal T cells were co-cultured with in vitro grown TRAMP-C1P3 cells and
increasing numbers of macrophages, there was a slight but statistically significant
decrease in the percentage of T cells expressing Thy-1. The percentage of Thy-1 positive
T cells decreased from 95% to ~80% with the both TRAMP-C1P3 and the highest
number of F4/80 positive cells. Interestingly, there was a significant decrease it the
percentage of Thy-1 positive T cells in these co-culture assays with the highest number of
macrophages were cultured with T cells, regardless of whether TRAMP-C1P3 cells were
included.
These results support the hypothesis that tumor-infiltrating macrophages mediate
the loss of Thy-1 molecules noted in tumor-infiltrating T cells in vivo. Therefore, in vitro
co-culture assays indicated that both GR1 positive cells and F4/80 positive cells were
able to mediate slight but statistically significant reduction in the percentage of T cells
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Fig. 26. Expression of Thy-1 molecules on T cells co-cultured with splenic macrophages
(F4/80+) cells and TRAMP tumor cells. The percentage of T cells that expressed Thy-1
molecules was determined in normal C57B1/6 splenic cells in varying in vitro conditions
designed to replicate the in vivo TRAMP TME using conditions and column designations
listed in Fig. 24. T cells were identified by flow cytometry using double gating of FSC
vs. SSC for lymphoid cells and expression of CDS antibodies were used to identify T
cells. *Indicates the T cells used for comparisons and the P values shown above
individual columns indicates the probability of statistically significant differences using
multivariant statistical analysis, n.s. indicates no statistically significant difference.
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that expressed Thy-1 in co-culture assays.

One distinct difference between GR1

positive and F4/80 positive cells was that in order for GR1 cells to mediate a significant
loss o f the Thy-1 molecule TRAMP cells had be included in the assays while
macrophages were able to decrease Thy-1 expression alone (compare figs. 20 and 26).

H 5. Expression of CDS on T cells in co-culture assays with F4/80 positive splenic
macrophages and TRAMP-C1P3 cells
In order to determine the extent to which F4/80 positive macrophages were able
to mediate decreased expression of CD5 on T cells, in co-culture assays were performed
as described above. Although the phenotyping studies shown in Fig.

8

demonstrated that

CD5 expression was not significantly decreased on TRAMP tumor-infiltrating T cells it
was decided to determine the extent to which the percentage of T cells that expressed
CD5 in co-culture assays is decreased with co-culture with macrophages and TRAMPC1P3 cells. The pooled data from the same two series of co-culture studies are shown in
Fig. 27.
The results o f these studies indicate that there was a slight but statistically
significant decrease in the percentage of T cells that expressed the CD5 molecule only
when T cells were co-cultured with the highest concentration of F4/80 positive cells and
TRAMP-C1P3 cells. Approximately 100% of T cells expressed CDS in wells with T
cells alone (column 2). When increasing numbers of F4/80 positive macrophages were
co-cultured with the T cells there was no decrease in the percentage of T cells expressing
CD5 (columns 3 through 5). Co-incubation of T cells with TRAMP-C1P3 cells alone also
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Co-culture Conditions

Fig. 27. Expression of CD5 molecules on T cells co-cultured with splenic macrophages
(F4/80'i) cells and TRAMP tumor cells. The percentage of T cells that expressed CDS
molecules was determined in normal C57B1/6 splenic cells in varying in vitro conditions
designed to replicate the in vivo TRAMP TME using conditions and column designations
listed in Fig. 24. Flow cytometry using double gating ofFSC vs. SSC for lymphoid cells
identified T cells and Thy-1 expression was used to identify T cells. *Indicates the T
cells used for comparisons and the P values shown above individual columns indicate the
probability o f statistically significant differences using multivariant statistical analysis.
n.s. indicates no statistically significant difference.
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did not significantly decrease the percentage of T cells expressing CDS, compare column
2 with 9. Finally, when T cells were cultured with both TRAMP-C1P3 cells and
increasing numbers o f F4/80 positive macrophages there was a slight but statistically
significant decrease in the percentage of T cells that expressed CD5, compare column 2
with 8 (PO.Ol).
The results of these co-culture assays indicate that co-culture of T cells with high
numbers o f macrophages and TRAMP-C1P3 tumor cells reduces the percentage of CD5
positive T cells slightly but significantly.

This result appears at odds with the

phenotyping studies of tumor-infiltrating T cells shown in Fig. 8 showing that there was a
not a statistically significant decrease of CD5 positive T cells within TRAMP tumors.
Both studies show a slight decrease in the percentage of CD5 positive T cells; the
difference is that in the co-culture study the difference reached statistical significance
while in the phenotyping study no statistical significance was reached. An alternative
explanation is that the co-culture system contains a crucial component or factor that is
missing or mitigated within the in vivo TRAMP TME.

I.

EXAMINATION OF SECRETED FACTORS IN CO-CULTURE IN VITRO
ASSAYS

I I. Expression of TCR-£ in T cells co-cultured with GR1 positive cells and TRAMP
cell conditioned media
The results described above indicated that GR1 positive cells from the spleens of
flt3-L treated mice were able to decrease the expression of TCR-^, CD3s, Thy-1 and the
CD4/CD8 ratios of T cells when co-cultured with TRAMP-C1P3 cells. The extent to
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which direct interaction between TRAMP-C1P3 cells and GR1 positive cells was
required for the loss of T cell associated molecules was next evaluated using a
modification of the co-culture system. I wanted to determine if TRAMP conditioned
media (CM) could replace the TRAMP cells in these co-culture assays. TRAMP-C1P3
conditioned media (CM) was tissue culture media in which TRAMP-C1P3 cells were
grown to confluency in 3-4 days. For these studies, fresh normal T cells were co-cultured
with GR1 cells alone. In some wells 3-4 day old TRAMP-C1P3 conditioned media was
added at 100%, 50% and 10% of the assay volume. The cells were then incubated for 48
hours after which the T cells were phenotyped for expression of signaling molecules.
In Fig. 28A, normal T cells were co-cultured alone in fresh TRAMP media and
100% TRAMP-C1P3 conditioned media in columns 2 and 3.

No difference in the

percentage of T cells that expressed the TCR-^ molecule was noted between these two
samples. In this study, the percentage of T cells expressing the TCR-Cj molecule was
90% in freshly isolated T cells and did not change with culture in either normal TRAMP
media or conditioned media.

There was no decrease in the percentage of T cells

expressing TCR-^ when T cells were co-cultured with five times the number of GR1
positive cells in normal media compare column 2 with column 4.
When T cells and GR1 positive cells were cultured with increasing concentrations
of TRAMP cell conditioned media there was a trend that the percentage of T cells
expressing TCR-^ decreased in a dose response with the concentration of conditioned
media, compare columns 5, 6 and 7. However, while the average percentage of T cells
expressing TCR-^ decreased with increasing concentration o f conditioned media, the
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Fig. 28. Ability of TRAMP-C1P3 conditioned media to replace TRAMP cells in co
culture assays. A, The percentage of cultured T cells that expressed TCR-^ molecules
was determined in assay wells with naive T cells and five times the number of GR1
positive cells and various concentrations of TRAMP conditioned media (CM). Media
means fresh TRAMP media, the ratios of T cells:GR1 positive cells:TRAMP-ClP3 cells
is shown in parenthesis. B, The ratios of CD4 over CD8 T cells were determined in the
same assay wells as described in panel A. Both these assays were only performed once
so no statistical analysis could be performed.
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difference was slight and variable and never attained statistical significance.
Approximately 90% of T cells co-cultured with GR1 cells and 10% CM expressed TCRC, molecules in column 8. When the same cell ratios were cultured in 50% CM, the
percentage of TCR-^ positive T cells decreased to -80% in column 7 and to -70% with
100% CM.

These results do not support the hypothesis that a secreted factor from

TRAMP-C1P3 cells allows GR1 positive cells to decrease the expression of TCR-<£
molecules in T cells and implies that direct contact between TRAMP-C1P3 cells and
GR1 positive cells is required to alter TCR-d^ molecules in T cells.

I 2. Alteration of CD4/CD8 ratios of T cells co-cultured with GR1 positive cells and
TRAMP-C1P3 conditioned media
I next wanted to determine the extent to which TRAMP-C1P3 CM was able to
replace TRAMP-C1P3 cells in the observed decrease in the CD4/CD8 ratios of cultured
T cells. The results o f this study are shown in Fig. 28B and demonstrate that freshly
isolated T cells had a CD4/CD8 ratio of about 1.0 in column 1. As with the other
CD4/CD8 studies, culture of T cells alone actually increased the ratio to about 7. This
phenomenon was consistent and observed in all assays indicating that CD8 cells may be
lost when T cells are cultured alone while CD4 cells remained to a greater extent in
column 2.

When T cells were cultured alone with 100% CM the CD8 cells were

preserved and the ratio remained near normal at about 1.0, see column 3.
When T cells were co-cultured with five times the number of GR1 positive cells
in normal media the CD4/CD8 ratio was unaltered in column 4. However, when T cells
and GR1 positive cell were cultured with increasing CM, the CD4/CD8 ratio decreased in
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a dose response indicating that CM is able to function like TRAMP cells in this co
culture system, compare column 4 with columns 5, 6 and 7.

This assay was only

performed once so no statistics could be performed.

I 3. Expression of CD3e on T cells co-cultured with GR1 positive cells and TRAMPC1P3 conditioned media
TRAMP-C1P3 CM was not able to replace the requirement for TRAMP-C1P3
cells for the loss of CD3s expression in this co-culture assay. In Fig. 29A, the percentage
of T cells that expressed CD3e when T cells were co-cultured with GR1 positive cells and
CM were compared. When T cells were cultured alone in normal TRAMP media about
85% expressed CD3s, see column 1. The percentage of CD3e positive T cells increased
when T cells were co-cultured alone in conditioned media to -100% in column 2. When
T cells were co-cultured with five times the number of GR1 positive cells in normal
media the percentage of CD3s positive T cells decreased to -75% in column 3. This
study was only performed once so no replicates were available for statistical analysis.
However, when T cells were cultured with GR1 positive cells and increasing
concentration of CM there was no decrease in the percentage of T cells expressing CD3e,
compare column 3 with columns 4, 5 and 6.

These results indicated that CD3s

expression on T cells was not decreased with co-culture of GR1 positive cells and
TRAMP-C1P3 CM. The results of these CM studies indicated that with respect to CD3e,
a TRAMP-C1P3 secreted factor is not sufficient to mediate the decreased expression of
by GR1 positive cells and direct interaction between tumors and GR1 positive cells were
required.
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Fig. 29. Ability of TRAMP-C1P3 conditioned media to replace TRAMP cells in co
culture assays with regards to CD3s and Thy-1 expression. A, The percentage of
cultured T cells that expressed CD3s molecules was determined in assay wells with naive
T cells and five times the number of GR1 positive cells and various concentrations of
TRAMP conditioned media (CM). “Media” indicates TRAMP media, the ratios of T
cells to GR1 positive cells or TRAMP-C1P3 cells are shown in parenthesis. B, shows the
percentage o f cultured T cells that expressed Thy-1 molecules was determined in the
same assay wells as described in panel A. Both these assays were only performed once
so no statistical analysis could be performed.
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I 4.

Expression of Thy-1 on T cells co-cultured with GR1 positive cells and

TRAMP-C1P3 conditioned media
We next wanted to examine the ability of TRAMP-C1P3 CM to replace TRAMPC1P3 cells in the loss of the percentage of Thy-1 positive T cells in co-culture assays.
Fig. 22 demonstrated that co-culture of normal T cells with TRAMP-C1P3 cells and GR1
positive spleen cells resulted in the significant decrease in the percentage of Thy-1
positive T cells. This decrease was dose dependent with greater numbers of GR1 cells
causing greater decreases in the percentage of Thy-1 positive T cells. Fig. 29B shows
that TRAMP-C1P3 CM is not able to replace TRAMP-C1P3 cells in co-culture assays
with respect to Thy-1 expression. The percentage o f T cells expressing Thy-1 was 95%
when T cells were cultured alone in normal media, see column 2. There was no decrease
in the percentage of Thy-1 positive T cells when T cells were cultured alone in 100% CM
in column 3 indicating that CM itself could not decrease Thy-1 expression. When T cells
were cultured with five times the number of GR1 positive cells in normal media the
percentage of Thy-1 positive T cells was still 95% in column 4. Columns 5, 6 and 7
represent T cells co-cultured with GR1 cells and increasing concentrations of CM. There
was no statistically significant reduction of the percentage of Thy-1 positive T cells in
these wells. These results indicated that, with regard to the loss of Thy-1 on T cells,
TRAMP-C1P3 CM was not sufficient to replace TRAMP-C1P3 cells in co-culture
assays.
Therefore the results of the CM studies do not support the hypothesis that a
secreted factor from TRAMP-C1P3 cells induce GR1 positive spleen cells to mediate the
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loss TCR-<^, CD3s or Thy-1 noted in co-culture assays. Rather, the data imply that direct
interaction between GR1 positive, TRAMP-C1P3 and T cells is required for the loss of
signal transducing molecules seen on tumor-infiltrating T cells.

I 5. Co-culture assays using co-culture assay supernatant from 48 hour cultures of
T cells, TRAMP-C1P3 and GR1 positive cells
In order to determine the extent to which supernatant from co-culture assay wells
were able to mediate the loss of TCR-^ molecules when T cells were cultured in this
media alone co-culture assays were performed using fresh splenic T cells and assay
media only. To address this question, I first set up co-culture conditions that were known
to suppress TCR-^ expression. The conditions of maximum loss of TCR-^ molecules
were co-culture with T cells, TRAMP-C1P3 cells and five times the number of GR1
positive cells. Studies confirmed that the co-culture conditions resulted in the expected
loss o f TCR-^ expression. After 48 hours of co-culture supernatant from a negative
control well, T cells cultured alone, and a positive well, T cells with GR1 and TRAMP
cells (1:0:0) were removed, centrifuged to remove cells and debris and fresh T cells were
cultured alone in the supernatant for an additional 48 hours. Fig. 30 shows the result of
this assay and demonstrates that -90% of T cells cultured alone for 48 hours were
positive for TCR-^ expression in column 1. When T cells were cultured with TRAMP
cells alone or GR1 positive cells alone there was no decrease in the percentage of TCR-^
positive T cells, compare column 1 with columns 2 and 3. As shown previously in Fig.
17, co-culture of T cells with TRAMP cells and GR1 cells resulted in a significant
decreased the percentage of T cells expressing the TCR-^ molecule, see Fig. 30 col. 4.
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Fig. 30. Ability of Assay conditioned media to replace both GR1 positive cells and
TRAMP-C1P3 cells in co-culture assays with regard to TCR-^ expression. Naive T cells
were co-cultured either alone (1:0:0), with TRAMP-C1P3 cells only (1:0:0.5X), with five
times the number of GR1 positive cells only (1:5X:0) or with both cell types at the
indicated concentrations (1:5X:0.5X), see columns 1-4. Then for columns 5 and 6 fresh,
naive T cells were co-cultured alone in the supernatant from assay column 1 (see column
5) and column 4 (see column 6). *Indicates the comparison T cells for statistical analysis
and the P values above the indicated columns indicate the probability o f statistically
different percentage o f TCR-^ positive T cells using multivariant statistical analysis.
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When fresh T cells were added to cell-free supernatants from columns 1 and 4 and
cultured for an additional 48 hours, there was a significant decrease in the percentage of
T cells expressing TCR-^ in the conditioned supernatant from the well with all three cell
types. However, there was no loss of TCR-i^ in the conditioned supernatant from T cells
cultured alone. These results indicate that a soluble factor, elicited by the co-culture of T
cells, GR1 positive spleen cells and TRAMP-C1P3 cells was sufficient to mediate a
significant decrease in the percentage of TCR-^ positive T cells. As discussed earlier,
granulocytes secrete many factors that may alter signal-transducing molecules in T cells.
One factor secreted by GR1 positive cells is hydrogen peroxide and other oxidative
radicals. I then decided to examine the extent to which H 2 O2 from GR1 positive cells
mediated the loss of TCR-^ and CD3e in co-cultured T cells. To do this I used the
enzyme catalase that specifically inactivates H 2 O2 by converting it to H 2 O.

J. EXAMINATION OF THE ABILITY OF CATALASE TO PREVENT THE
LOSS OF SIGNAL MOLECULE EXPRESSION IN T CELLS CO-CULTURED
WITH GR1 AND TRAMP-C1P3 CELLS

J 1. Protection of Thy-1 expression on T cells co-cultured with GR1 and TRAMP
cells by catalase
Catalase inactivates hydrogen peroxide, converting the radical oxygen molecule
from a toxic molecule to the non-toxic molecules water and oxygen.
reaction is shown below:
H 2 O2 + H 2 O2

2

H2 O and O2
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In order to determine the extent to which hydrogen peroxide mediates the loss of
signaling molecules of T cells I decided to include various concentrations of catalase in
co-culture assays. The percentage T cells expressing Thy-1 and TCR-t, and CD3e in T
cells co-cultured with GR1 and TRAMP cells with increasing concentrations of catalase
were examined in these assays. Fig. 20 showed that co-culture of T cells with GR1 cells
and TRAMP-C1P3 cells resulted in significant reduction in the percentage of T cells
expressing Thy-1 molecules. I used these optimal co-culture conditions and evaluate the
effect o f three different doses of catalase on the expression of Thy-1.
The results of this study are shown in Fig. 31 demonstrating that the addition of
catalase to assay wells with T cells and GR1 positive cells only had no effect on the
percentage of T cells expressing the Thy-1 molecule. When T cells were co-cultured
with GR1 and TRAMP cells there was a slight but statistically significant reduction in the
percentage T cells expressing the Thy-1 molecule, compare column 2 with 8 (P<0.01).
Approximately 90% of T cells expressed Thy-1 when T cells were cultured alone and
-80% of T cells expressed Thy-1 when T cells were cultured with GR1 positive and
TRAMP-C1P3 cells. When increasing concentrations of catalase were included in the
assay wells, the percentage of T cells expressing Thy-1 increased to normal levels at the
highest dose o f 1000 units per ml. Statistical analysis gave P values of <0.01 when T
cells alone were compared with T cells cultured with GR1 and TRAMP cells and no
catalase.
One surprising result of these catalase studies was the observation that the lowest
dose of catalase actually reduced the expression of the very molecules that the higher
doses o f catalase protected. For example, there was the indication that the percentage of
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Fig. 31. Ability o f Catalase to preserve the expression of Thy-1 molecules on T cells cocultured with GR1 positive spleen cells and TRAMP-C1P3 cells. Co-culture assays were
performed in order to determine the percentage of Thy-1 positive T cells according to the
conditions described below; (Fresh T cells) nai've T cells, not cultured, (1:0:0) T cells
cultured alone, (1:0:0.5) T cells and TRAMP-C1P3 cells co-cultured, (1:5X:0) no cat
indicates T cells co-cultured with five times the number of GR1 positive cells only with
no catalase added, columns 5, 6 and 7 list the doses of catalase added to well with T cells
and GR1 positive cells only. (1:5X:0.5) no cat indicates T cells co-cultured with five
time the number of GR1 positive cells and 0.5 times the number of TRAMP-C1P3 cells
and no catalase, columns 9, 10 and 11 indicate the doses of catalase added to co-culture
wells of T cells co-cultured with GR1 positive cells and TRAMP-C1P3 cells. *Indicates
the T cell population used for statistical comparisons and the indicated P values above
columns indicates the probability of statistically significant differences in the percentage
ofT cells that expressed Thy-1. n.s. indicates no statistically significant difference.
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T cells expressing Thy-1 actually decreased when 10 units per ml of catalase was
included in the assay wells. This observation was noted for the expression both Thy-1
and TCR-^.

One potential explanation o f this observation is that the lowest dose of

catalase was unable to completely inactivate any H 2 O2 produced by the GR1 positive
cells in these co-culture assays. It is possible that an intermediate chemical oxidative
radical is formed in the conversion from H2 O2 to H 2 O and O2 by catalase that is actually
more damaging to T cells than hydrogen peroxide. While the chemical reaction mediated
by catalase is extremely rapid, it is possible that some inhibitors of catalase may be
present in the components of the TRAMP media (i.e. FBS, Nu-Serum, Insulin or DHT) or
may be secreted by GR1 positive cells, that slows the reaction allowing a greater amount
of intermediate species (106). A second explanation for the observed loss of signaling
molecules at the lowest dose of catalase is that a contaminant in the catalase decreased
expression of the molecules at the lowest dose but whose inhibitory effect was
countermanded by the protective effect of catalase upon T cells at higher doses.
When 100 units/ml of catalase was added to the assay wells there was still a slight
decrease in the percentage of Thy-1 positive T cells compared to T cells cultured alone
which was just significant (PO.05). The difference in the percentage of Thy-1 positive T
cells with 1000 units per ml was not significant compared to T cells cultured alone
indicating that 1000 units/ml of catalase is able to protect the expression of Thy-1 on T
cells when co-cultured with GR1 positive and TRAMP-C1P3 cells. These results support
the hypothesis that hydrogen peroxide secreted by GR1 positive cells in co-culture assays
mediated the loss of Thy-1 molecules on T cells in these co-culture assays. Furthermore,
these results support the hypothesis that hydrogen peroxide secreted by activated GR1
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positive cells mediated the decreased Thy-1 expression of splenic T cells in tumorbearing mice. Figs. 32 and 33 represent four in vitro co-culture studies and the data was
pooled and shown.

J 2. Protection of TCR-^ expression in T cells co-cultured with GR1 positive and
TRAMP cells by catalase
In order to determine the extent to which the addition of catalase to co-culture
wells of T cells with GR1 positive and TRAMP cells was able to prevent the decrease in
the percentage of TCR-^ positive T cells modification of co-culture assay was performed.
In Fig. 32, I used the same assay conditions that were previously shown to mediate a
significant decrease in the percentage of T cells that expressed TCR-^ by first coculturing T cells with five times the number of GR1 positive cells without TRAMP cells.
As with the previous studies shown in Fig. 17, GR1 cells alone were able to significantly
reduce the percentage of TCR-^ positive T cells in these co-culture assays.

The

percentage of T cells expressing TCR-^ molecules in T cells cultured alone was 95%
with no decrease when TRAMP-C1P3 cells were added, compare columns 2 and 3.
When five times the number of GR1 positive cells was added without catalase there was
a significant decrease in the percentage of T cells that expressed TCR-^ molecules;
decreasing from >90% to -60%, compare columns 2 and 4. Columns 5-7 represent assay
wells with T cells co-cultured with GR1 cells and increasing concentrations of the
catalase enzyme.

The results show that increasing catalase concentration resulted in

increasing TCR-^ expression and protection of the TCR-C, chain from loss mediated by
co-culture with GR1 positive cells at the highest dose.
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Fig. 32. Ability of Catalase to preserve the expression of TCR-^ molecules on T cells cocultured with GR1 positive spleen cells and TRAMP-C1P3 cells. Co-culture assays were
performed to determine the percentage of TCR-^ positive T cells according to the
conditions described below; (Fresh T cells) naive T cells, not cultured, (1:0:0) T cells
cultured alone, (1:0:0.5) T cells and TRAMP-C1P3 cells co-cultured, (1:5X:0) no cat
indicates T cells co-cultured with five times the number of GR1 positive cells only with
no catalase added, columns 5, 6 and 7 list the doses of catalase added to well with T cells
and GR1 positive cells only. (1:5X:0.5) no cat indicates T cells co-cultured with five
time the number of GR1 positive cells and 0.5 times the number of TRAMP-C1P3 cells
and no catalase, columns 9, 10 and 11 indicate the doses of catalase added to co-culture
wells of T cells co-cultured with GR1 positive cells and TRAMP-C1P3 cells. *Indicates
the T cell population used for statistical comparisons and the indicated P values above
columns indicate the probability of statistically significant differences in the percentage
of T cells that expressed TCR-^ between these groups, n.s. indicates no statistically
significant difference.
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When T cells were co-cultured with GR1 positive cells and TRAMP cells without
catalase there was a greater decease in the percentage of T cells that expressed TCR-^
molecules decreasing from >90% to ~40%, compare columns 2, 4 and 8.

This

observation was noted in previous in vitro co-culture studies, see Fig. 17. Increasing
concentrations of catalase resulted in an increase in the percentage of T cells expressing
TCR-£,. As noted with the Thy-1 studies above, the assay well with 10 units/ml of
catalase showed a decreased percentage of T cells that expressed TCR-^.

Statistical

analysis showed that the re-expression in TCR-^ did not demonstrate statistical
significance when all three cell-types were co-incubated. This result indicates either that
TRAMP-C1P3 cells contribute other factor(s) that was not inactivated by catalase or the
level of H2 O2 produced was greater than the ability of the enzyme to neutralize it.

J 3. Expression of CD3e in co-culture assays with catalase
Because the percentage of T cells that expressed CD3s was statistically decreased
with co-culture of T cells with GR1 positive cells and TRAMP-C1P3 cells in Fig. 18, I
next wanted to determine the extent to which catalase was able to protect epsilon chain
expression in this in vitro system.

Fig. 33 demonstrates no protection of CD3e

expression. Statistical analysis was performed and demonstrated no differences in the
percentage of T cells that expressed CD3e in any of the assay wells with catalase.
These results do not support the hypothesis that hydrogen peroxide from GR1
positive cells mediated the observed loss of CD3e expression when T cells were cocultured with GR1 positive cells and TRAMP-C1P3 cells. Some other factor(s) secreted
by GR1 positive cells may be responsible the loss of CD3e including proteases or other
reactive oxygen species.
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Fig. 33. Ability of Catalase to preserve the expression of CD3s molecules on T cells cocultured with GR1 positive spleen cells and TRAMP-C1P3 cells. Co-culture assays were
performed to determine the percentage of CD3e positive T cells according to the
conditions described below; (Fresh T cells) naive T cells, not cultured, (1:0:0) T cells
cultured alone, (1:0:0.5) T cells and TRAMP-C1P3 cells co-cultured, (1;5X:0) no cat
indicates T cells co-cultured with five times the number of GR1 positive cells only with
no catalase added, columns 5, 6 and 7 list the doses of catalase added to well with T cells
and GR1 positive cells only. (1:5X:0.5) no cat indicates T cells co-cultured with five
time the number of GR1 positive cells and 0.5 times the number of TRAMP-C1P3 cells
and no catalase, columns 9, 10 and 11 indicate the doses of catalase added to co-culture
wells of T cells co-cultured with GR1 positive cells and TRAMP-C1P3 cells. * and **
Indicate the T cell populations used for statistical comparisons and the P values above
columns indicate the probability o f statistically significant differences in the percentage
of T cells that expressed CD3e between these groups, n.s. indicates no statistically
significant difference.
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CHAPTER V
CONCLUSIONS

There is controversy regarding which signaling molecules are diminished and
the extent to which this loss is found in T cells within tumors and also within secondary
lymphoid organs of cancer patients.

Animal tumor models using chemical induced

tumors demonstrated that decreased T cell signaling molecules were detected in T cells
from spleens of mice bearing tumors for greater then 30 days. This time point correlates
with advanced disease in human patients (57).

The most commonly studied T cell

signaling molecule has been the zeta chain of the CD3 complex. In cancer patients, some
investigators report decreased zeta chain expression in blood T cells and others report no
loss o f TCR-Cj chain (54 , 18).
The animal tumor model used for our in vivo studies was the orthotopic TRAMP
prostate model in syngeneic immunocompetent C57B1/6 mice.

This model mimics

prostate cancer in men because the cancer is growing within the prostate, it allows for
normal interaction between the cancer cells and the host immune system and the tumor
has the potential to metastasize to typical metastatic sites (manuscript in preparation).
Additionally, this model allowed for extensive evaluation of the TRAMP TME and to
determine the extent to which factors within the TME mediated changes to tumorinfiltrating T cells. By comparing T cells isolated from prostate tumors, dLNs and the
spleens of prostate cancer bearing mice the contribution of the TME to alterations to
infiltrating T cells was determined.
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A. ALTERATIONS OF T CELLS BY THE TRAMP TME

A l. Components of the CDS complex are lost in T cells exposed to prostate tumor
TME (Orthotopic TRAMP Model), but recover after removal from in vivo tumors.
The CDS complex is considered the primary antigen detection and cellular
signal-transducing complex o f T cells. Many investigators have evaluated components of
this complex in T cells in order to determine the presence and function of signal
transducing molecules. The majority of previous immunology studies have evaluated T
cells from the blood of cancer patients because of the ease of sample collection. These
investigators assumed that any changes in T cells from blood reflect changes in T cells
from other secondary lymphoid organs and by extension the tumor itself. One weakness
o f these studies has been that they disregard the effect of established TME upon tumorinfiltrating T cells. This is a weakness of many of the tumor vaccination studies where
tumor-specific immune cells can be detected in the peripheral blood of vaccinated
patients even with progressing disease. Because of the very real technical difficulties of
isolating tumor-infiltrating T cells very few studies have been attempted to directly
evaluate TME-mediated changes to T cells.
We therefore decided to use the orthotopic TRAMP transplantable murine
prostate model to characterize the signal transducing molecules of tumor-infiltrating T
cells. In Figs. 3-6 the percentage of T cells that expressed the main signal transducing
molecules o f the CD3/TCR complex was determined for T cells from secondary
lymphoid organs o f tumor bearing mice. In these studies, secondary lymphoid organs
included both spleens and dLNs. These studies directly compared the percentage of T
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cells that expressed signal-transducing molecules of the CD3/TCR complex from fresh or
cultured TILs.
The main signal transducing molecules of the CD3 complex examined in these
studies were the CD3s molecule, the TCR-^ chain and the TCR-p chain or TCR-8/y
chains. The results indicated that exposure of T cells to the TRAMP TME resulted in
decreased percentage of T cells that expressed components of the CD3 complex. This
loss o f expression was not permanent since removal of the cells and in vitro culture in
media with IL-2 for 18-20 hours resulted in the re-expression o f the signaling molecules.
One previous report demonstrated that the percentage of T cells that expressed
the zeta chain was decreased in T cells isolated from prostate tumors but no publications
have indicated loss of the other components of the CD3 complex in T cells isolated from
prostate tumors (31). Other studies have demonstrated a decrease in the percentage of
TCR-^ positive T cells within solid tumors in patients but only a few have noted a
decrease in the percentage of CD3e positive T cells (22). No studies have detected a loss
of TCR-p molecules in tumor-infiltrating T cells. In fact, the CD3 complex is considered
the major T cell specific complex and the majority of investigators use antibodies against
components o f this complex to identify T cells.
This demonstration of a decrease in components of the CD3 complex has
implications for researchers who want to study tumor-infiltrating T cells using flow
cytometry since gating on T cells expressing a marker that is lost within tumors results in
a bias in the results. Using antibodies against components of the CD3 complex would
result in an underestimation of tumor-infiltrating T cells with a bias toward cells with
more normal expression of other components of the CD3 complex. The results of figs. 3-
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6 indicated that the CD3 complex can be used to identify T cells in the spleens and dLNs
of tumor-bearing mice because these T cells are relatively normal in their expression of
CD3 complex components.

However, T cells isolated from TRAMP-C1P3 prostate

tumors expressed significantly decreased levels of components of the CD3 complex.
Very few tumor-infiltrating T cells expressed normal levels of the three molecules
studied and the majority was defective in at least one CD3 signal-transducing molecule.
The CD3 complex is organized with multiple signal transducing molecules and
various downstream effector targets after antigen detection by the TCR-a/p complex.
Loss of any of these components decreases the detection of antigen and the normal
function o f the T cells.

Each of the three main components of the CD3 complex

evaluated are crucial for proper T cell function with the zeta molecule considered the
major downstream signal transducing molecule and the TCR-a/p complex required for
antigen binding and detection. The observed loss of the TCR-a/p complex on tumor
infiltrating T cells has important implications for tumor immunology because T cells
lacking this complex become unable to detect tumor-specific antigens within tumors.
This obviously affects the function of killer T lymphocytes within tumors rendering them
essentially blind to their target antigens within tumors.
Figs 3 through 6 demonstrate that T cells from orthotopic prostate cancer-bearing
mice that were not exposed to the TME did not demonstrate a decrease in the expression
of components o f the CD3 complex. Some investigators have indicated that in animal
models using chemically induced tumors that the tumors must be present for greater then
30 days before systemic loss of TCR-^ molecules could be detected (57).
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In our cancer model, I detected no significant loss of the components of the CD3
complex in secondary lymphoid organs in tumor-bearing mice. However, the majority of
mice died o f urinary complications 28-35 days after implantation and prostate tumors
could only be palpated for about two weeks before the mice succumbed to urologic
complication o f their disease.

Only T cells exposed to the in vivo TRAMP TME

expressed decreased levels of components of the CD3 complex. This result implies that
some factor within TRAMP tumors mediated the loss of CD3 complex and that this
factor was not shared with the spleens or dLNs of tumor-bearing mice.
There is controversy in the scientific literature concerning the extent to which T
cells that have lost expression o f the zeta chain are undergoing apoptosis and the extent to
which they are able to recover if removed from the TME. Some investigators indicated
that the zeta chain is a target of caspase 3 and that T cells without zeta molecules are
actively undergoing apoptosis (21). Other investigators believe that the loss of signaling
molecules leads to apoptosis with time and that cells without zeta chain are still able to
recover with removal from the TME (22). In fact, clinical immunotherapy models that
use tumor-infiltrating T cells expanded in vitro with IL-2 and re-administered to patients
are based on the assumption that tumor-infiltrating T cells are able to recover both their
signaling molecules and anti-tumor functions (107).

A2. Orthotopic TRAMP TME-mediated alterations of signaling molecules not
directly associated with the CD3 complex.
Because our studies indicated that a TRAMP TME-associated factor within
prostate tumors mediated a transient loss of components of the CDS complex in T cells, I
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next decided to investigate the extent to which other T cell signaling molecules were
altered in T cells isolated from TRAMP prostate tumors. Our objective was two fold: 1)
to determine if the TRAMP TME preferentially decreases the expression of only the CDS
complex components, and 2) determine whether the expression of other non-CD3
associated T cell signal transducing molecules are decreased in T cells exposed to the
TRAMP TME. In order to address this question, I examined the expression of three
additional T cell specific signal transducing molecules that are not intimately associated
with the CD3 complex and that have been used by other investigators to identify T cells
in previous studies. The expression of the CD5 antigen was examined because it is only
found on T cells and a rare subset of B cells. The expression of the Thy-1 antigen that is
expressed only on T cells, NK cells and rare subpopulations of myeloid cells was also
examined in these studies. The third T cell specific signal-transducing molecule not part
of the CD3 complex was the activation-induced molecule CTLA-4. The results from
figs. 7-9 examined the expression of CD5, Thy-1 and the activation marker CTLA-4 on T
cells from tumor-bearing mice.
Fig. 7 demonstrated that unlike the components of the CD3 complex signaling
molecules the percentage of T cells that expressed Thy-1 was significantly decreased in
the spleens o f tumor-bearing mice compared with normal mouse splenocytes.

The

percentage o f T cells expressing Thy-1 within prostate tumors was also reduced but was
not different than the percentage Thy-1 positive T cells in spleens of tumor-bearing mice.
Surprisingly, the percentage of T cells that expressed Thy-1 in dLNs of prostate tumorbearing mice was the same as normal mouse spleens. There was a significant difference
in the percentage o f Thy-1 positive T cells in tumor-bearing spleens compared to dLNs.
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These results indicated that the loss of Thy-1 was not TRAMP TME specific but
was the result of a systemic immunosuppression mediated by TRAMP prostate cancer.
T cells isolated from dLNs of tumor-bearing mice expressed normal levels of Thy-1
molecules. The expression of Thy-1 increased with removal from tumor-bearing mice
and culture with IL-2. While there was a trend toward the increase in the percentage of
T cells expressing Thy-1 with in vitro culture with IL-2 the differences did not achieve
statistical significance as occurred with the components of the CDS complex.

The

decrease in the percentage of T cells that expressed the Thy-1 molecule was not very
great, and the differences in expression levels just barely reached statistical
significance.
The implications of these results are that prostate cancer is able to mediate a slight
decrease in the expression of Thy-1 on T cells in the spleens and within prostate tumors
but the dLN T cells are somehow protected from this loss of Thy-1. The biological
significance of this slight decrease in Thy-1 expression remains to be further elucidated.
Thy-1 molecules are members of the Ig superfamily of surface molecules, structurally
related to Fc, MHC-I and -II, TCR and immunoglobulin molecules.

There is no

transmembrane spanning region of this molecule and its function has been proposed to
play a role in cell recognition (108). The question remains whether this phenomenon
represents systemic immunosuppression mediated by TRAMP tumors and further the
mechanism of escape o f the loss of Thy-1 within the dLNs remains unknown.
In fig. 8, the extent to which CD5 expression is altered by the TRAMP TME was
evaluated. The results indicated that there was no significant difference in the percentage
o f T cells expressing CD5 in any of the samples studied.

There was a slight but
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statistically non-significant decrease in CD5 expression in freshly isolated tumorinfiltrating T cells and this decrease recovered with culture in IL-2.
Fig. 9 represents studies that were performed to determine the extent to which the
TRAMP TME mediated alterations of CTLA-4 expression. In these studies, there were
no statistically significant differences in the percentage of T cells that expressed CTLA-4
from normal, vaccinated and tumor-bearing spleens or from dLNs of prostate tumorbearing mice.

Further, when ectopic and orthotopic tumor-infiltrating T cells were

examined, no increase in the percentage of CTLA-4 positive T cells were detected in
ectopic tumors. However, these studies did show a statistically significant increase in the
percentage of freshly isolated T cells that expressed CTLA-4 from orthotopic tumors.
With culture the percentage of T cells that expressed CTLA-4 from orthotopic tumors
decreased to levels seen in vaccinated spleens and was closer to the levels seen in tumorbearing spleens. These results indicated that the T cells from orthotopic tumors were
more likely to express the activation marker CTLA-4 then splenic T cells from tumorbearing mice indicating that the TRAMP TME activated the infiltrating T cells.
The fact that ectopic tumor-infiltrating T cells did not express increased levels of
CTLA-4 likely reflects the fact that CTLA-4 is only transiently expressed on activated T
cells. The ectopic tumors used in these studies were older tumors typically greater than
60 days post implantation. Since the CTLA-4 antigen is an early activation antigen its
expression may be up regulated and then down regulated before the analysis was
performed. The cultured T cell results also support this observation since culture of the
cells outside of the TME allowed for the percentage of T cells that expressed CTLA-4 to
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return to more normal levels, indicating that removal of activated T cells from the
TRAMP TME reduced the activation of infiltrating T cells.

A3. T cells re-express antigens after in vitro culture of tumor-infiltrating T cells
with IL-2
In order to determine whether T cells isolated from orthotopic TRAMP tumors are
able to recover the expression of signaling molecules, I cultured tumor-infiltrating
mononuclear cells for 20 hours in tissue culture media supplemented with IL-2. These
studies indicated that the majority of T cells were able to re-express signal-transducing
molecules and were not actively undergoing apoptosis. Cell counts performed before and
after culture indicated only a slight loss of cells, generally less then 10%, so the recovery
was real and not simply the selection of a subpopulation of viable cells. A preliminary
study was performed that indicated that the IL-2 functioned as a survival factor for the
cultured T cells and was not required for the recovery of lost signaling molecules (data
not shown). Cultured T cells without IL-2 still recovered their lost molecules but the
recovered cell numbers were greatly reduced without IL-2.
The results of studies analyzing the components of the CDS complex indicate that
TRAMP-infiltrating T cells were able to recover from the deleterious effects of the
TRAMP TME, expressing almost normal levels of CD3 associated molecules. TCRs,
CD3s and the zeta molecules each recovered in cultured T cells. These results indicated
that alterations to the CD3 complex of tumor infiltrating T cells are not permanent and
they also support the hypothesis that some factor (either cellular function or secreted
factor) within the TRAMP TME mediated the loss of components of the CD3 complex.
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This hypothesis is also supported by the observation that only T cells within
prostate tumors express decreased levels of CD3 components, and that T cells isolated
from spleens or dLNs of tumor-bearing mice expressed normal levels of CD3/TCR
components.

B. GAMMA/DELTA T CELLS WERE MORE COMMON IN TUMORS AND
LESS ALTERED WITH REGARDS TO CD3s THAN ALPHA/BETA T CELLS
Surprisingly, the percentage of T cells expressing delta/gamma restricted TCRs
was greater within prostate tumors than either tumor-bearing spleens or dLNs. Fig. 4
showed that approximately 10% of T cells in tumor-bearing spleens and dLNs were
gamma/delta T cells but -30% of T cells freshly isolated from tumors expressed the
TCR-5/y molecules. Unlike the a/p complex the gamma/delta complex did not appear to
be lost in tumor-infiltrating T cells because 20 hour culture with IL-2 did not increase the
percentage of gamma/delta T cells.

The fact that in our prostate cancer model a

significantly greater percentage of T cells express TCR-5/y and that the TRAMP TME
does not appear to decrease TCR-8/y expression indicated that these cells were somehow
protected from the TME-associated factors that alter the alpha/beta T cells within
TRAMP tumors.
The observation that gamma/delta T cells represent a significantly more common
fraction of tumor-infiltrating T cells than anticipated supports the novel notion that these
atypical T cells play a role in either cancer defense or perhaps lead to immune tolerance
and/or cancer progression. Additionally, the observation that the TRAMP TME appears
not to decrease the expression of the TCR-8/y complex as potently as the TCR-a/(3
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complex indicates different biological consequences of TME exposure between these two
T cell subtypes. Because gamma/delta T cells may represent a link between the innate
and acquired immune systems, these tumor-infiltrating cells deserve additional study in
the context o f the TRAMP TME. Therefore, the strong immunoregulatory functions of
gamma/delta T cells could represent a potential new weapon against cancer and may be
targets of future therapies designed to exploit the anti-cancer properties of these cells
within tumors.

C. TUMOR-SPECIFIC (TETRAMER POSITIVE) T CELLS WERE RARE IN
TRAMP TUMORS, BUT THE FEW CELLS PRESENT WERE LESS ALTERED
BY THE TME
There have been no published reports on tumor-infiltrating tetramer positive T
cells within solid tumors from either cancer patients or animal models. There have been
very few published studies of tumor-infiltrating tetramer positive cells, one of which used
transplanted transgenic T cells in mice with tumors to mimic the natural process in
tumor-bearing mice (109).

Additionally, there has been one recent publication that

looked at tumor infiltrating tetramer positive T cells in murine tumors, but this study used
a strong artificial tumor antigen (110). This model is different from ours since the tumor
cells were transfected with a lymphocytic choriomeningitis virus antigen while our model
used a naturally occurring weakly antigenic tumor antigen. Even with these differences,
the investigators found strikingly similar results to ours including the observation that
tetramer positive cells could be detected in tumors only after a 24 hour in vitro rest
period.
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The vast majority of tumor-specific tetramer studies in humans and animals have
reported only on the tetramer positive cells from peripheral blood, dLNs or spleens. My
studies indicate that these cells may be much more normal with regard to the expression
of signal transducing molecules than general tumor-infiltrating T cells. The presence of
circulating T cells expressing TCR complexes capable of recognizing immunodominant
MHC/tumor antigen peptide complexes has been evaluated in several tumor vaccination
studies. However, T cells capable of recognizing and killing tumors must enter tumors
and function within the TME in order to generate an effective anti-cancer response.
My results demonstrated that the TRAMP TME mediated the decreased
expression of many crucial T cell signaling molecules. Of most interest for studies using
tumor-specific tetramers were the studies examining the expression of the TCR-P
molecule in tumor-infiltrating T cells. The beta chain of the TCR complex is required for
antigen recognition and the documented loss on T cells isolated from prostate tumors
correlated with the observation that tetramers did not bind to freshly isolated tumorinfiltrating T cells. Therefore, investigators who searched for tetramer positive T cells
freshly isolated from tumors may grossly underestimated the number of potentially
tumor-specific T cells.
As noted above, the percentage of tetramer binding cells was often very low,
particularly in the freshly isolated tumor-infiltrating population. In peripheral lymphoid
cells from tumor-bearing animals, the rare tetramer positive cells were negative for the
expression of T cell specific proteins indicating that tetramers bound non-specifically to
non-T cells and cellular debris. Conversely, a higher percentage of the tetramer positive
cells identified in cultured tumor-infiltrating cells expressed the T cell specific proteins
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TCRs (Figs. 12B & 13B) and CD3e (Fig. 11B). This result indicated that the tetramers
were binding rare cellular debris or non-T lymphocytes in fresh T cells from tumorbearing mice but were binding to T cells in dLNs and cultured tumor-infiltrating
lymphoid cells.
The most useful information of the previously described phenotyping studies
comes from the in vitro culture of tumor-infiltrating T cells with IL-2. These studies
demonstrated that signal-transducing molecules are re-expressed after removal from the
cell(s) and factor(s) associated with the TRAMP TME. The practical implications of
these studies are that investigators looking for tetramer positive T cells within solid
tumors may be forced to culture the isolated T cells overnight before staining with
tetramers, My studies, documented in fig. 10, indicated no tetramer positive T cells in
freshly isolated tumor infiltrating T cells and 3-5% tetramer positive T cells after culture.
The biologic implications of these studies are that tumor-specific tumor-infiltrating T
cells likely have greatly reduced functions because each of these signal transducing
molecules are required for optimal anti-tumor function (110).
The possibility exists that TRAMP tumors are unique to a subset of solid
cancers and not representative of all cancers.

Certainly the very high percentage of

infiltrating myeloid cells is unusual for many types of tumors. Some solid tumors contain
large numbers o f inflammatory cells including some breast cancers, colon cancers and
Hodgkin’s lymphomas among others (70). For tumors with a similar TME as TRAMP
tumors (i.e. highly inflammatory) these tetramer studies indicated that using tetramers
specific for tumor-specific peptide/MHC complexes would have only limited usefulness
in fresh samples.

The implication is that some factor associated with the TME
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diminished the expression of T cell signaling molecules and also prevented binding of
tumor-specific tetramers to freshly isolated T cells.
The fact that T cell signal transducing molecule expression returned to normal
when tumor-infiltrating T cells were cultured overnight with IL-2 indicated that these T
cells were not actively undergoing apoptosis as some investigators propose (57). The
results of these in vitro culture studies indicated that tetramer binding by tumorinfiltrating T cells could only be detected after culture. Unfortunately, because the cells
required in vitro culture for tetramer binding, the co-expression of other molecules on
freshly isolated tumor-infiltrating tumor-specific T cells could not be determined. I then
decided to compare the expression of beta and gamma/delta TCR molecules, CD3s
chains and CTLA-4 molecules on all identified tumor-infiltrating T cells versus tetramerpositive T cells within TRAMP tumors. My objective was to determine the extent to
which tetramer binding T cells expressed different levels of signaling molecules than
other T cells within tumors. Furthermore, I wanted to determine the extent to which
tetramer positive cells were more likely to be activated and to express either alpha/beta or
gamma/delta TCRs.
In fig. 1 1 ,1 compared the expression of CD3s molecules on Thy-1 positive T cells
in tumor bearing mice with CD3e expression on tetramer-binding T cells.

Panel B

demonstrated that less than 5% of tetramer binding cells from the spleens of BALB/c
mice, or tumor-bearing C57B1/6 mice expressed CD3e. These results indicated that the
very rare tetramer-binding cells in these spleens were not T cells. The percentage of
tetramer positive cells that also expressed CD3e within the dLNs o f tumor-bearing mice
increased to -60%. This result indicated that tetramers were binding to tumor-specific T
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cells within the lymph nodes and that the factors within the TRAMP TME were not
present within dLNs. Freshly isolated tumor-infiltrating tetramer positive T cells did not
express CD3s molecules but cultured tetramer positive T cells did, indicating that
tetramer positive cells were capable of expressing CD3s after removal from TRAMP
TME.
The results of these double-gating experiments indicated that -50% of cultured
tetramer positive cells expressed the CD3e molecule indicating that many tetramer
positive cells were actually T cells. Additionally, after culture -50% of tetramer positive
cells expressed the TCR-P molecule which corresponds with the recovery of CD3
complex associated molecules noted in previous phenotyping studies. Finally, -40% of
cultured tumor-infiltrating tetramer positive T cells expressed the TCR-y/8 complex.
This result was extremely surprising since gamma/delta T cells are rare T cells in normal
organs. The fact that TRAMP tumors contained an unexpectedly large percentage of
gamma/delta T cells implies that these unusual T cells may play a far greater role in the
immune response against tumors then previously appreciated. There have been only rare
evidence that 5/y T cells are able to bind tetramers and these studies have used viral
antigens (111).
Perhaps the most surprising results of these tetramer binding phenotyping studies
was that freshly isolated tumor-infiltrating T cells that bound tetramers were almost
exclusively gamma/delta T cells. However, with culture the percentage of gamma/delta
T cells decreased to -40% indicating that there were hidden a/p T cells localized within
TRAMP tumors that only became visible after culture. The implication of these
phenotyping studies is that gamma/delta T cells respond differently than alpha/beta T
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cells within the TME. This result indicates that gamma/delta chains are not lost within
prostate tumors but rather that with culture the alpha/beta T cells recovered their
expression to a greater extent than the tumor-infiltrating gamma/delta cells.

With

removal of alpha/beta T cells from the tumor, these cells re-express many of the
conventional T cell markers including the TCR complexes that are required for tetramer
binding.

Conversely, gamma/delta T cells appear not to lose the expression of their

TCRs within the TME so that freshly isolated tetramer positive cells appear to be
exclusively gamma/delta cells.
These results indicated that gamma/delta T cells comprise a significant percentage
of tumor-infiltrating T cells. This implies that gamma/delta T cells either selectively
migrate into prostate tumors or, once there, have a survival advantage over alpha/beta T
cells resulting in increased percentage of gamma/delta T cells in late stage prostate
tumors. Finally, tumor-infiltrating gamma/delta T cells appear to be less altered by the
TRAMP TME then the tumor-infiltrating alpha/beta T cells. Little is know about the
function o f y/8 T cells in normal immunology and even less is known about the role of
these cells within solid tumors so there are many unanswered questions from these
tetramer staining and flow cytometric phenotyping studies. The significance of the
presence of tumor infiltrating y/5 T cells is that future therapies against cancer may
exploit these cells linking both the innate and acquired arms of the immune system.
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D.

TRAMP CELLS AND GR1 POSITIVE CELLS MEDIATE LOSS OF CD3

COMLEX MOLECULES IN A SYMBIOTIC FASHION IN CO-CULTURE
STUDIES
In vitro co-culture studies showed that GR1 positive flt3-L treated spleen cells
mediated the loss of CD3 complex components of normal C57B1/6 splenic T cells in a
dose response fashion when TRAMP tumors cells were included in the assay wells. If
either cell type alone was co-cultured with naive T cells, there was significantly less loss
o f CD3 components.

These studies indicated that the GR1 positive cells within the

TRAMP tumors may be at least partially responsible for the alterations of signaling
molecules in tumor-infiltrating T cells.
These results are important because they indicate for the first time that one of
the more common cell-types infiltrating TRAMP tumors mediated the loss of signaling
molecules in tumor-infiltrating T cells.

GR1 positive cells constitute about 30% of

tumor-infiltrating cells and are able to alter signaling molecules to a degree similar to
levels noted for in vivo TRAMP infiltrating cells. Other myeloid lineage cells also are
common in these tumors but in these co-culture assays GR1 positive cells were able to
alter T cell signaling molecules.
The results of the supernatant and conditioned media studies indicated that T cells
must be intimately associated with GR1 positive cells and TRAMP cells in order to
express decreased levels of signaling molecules. These studies implied that either direct
cell/cell interactions were required, of if a secreted factor from the GR1 positive cells
mediated the effect the factor was a short acting factor, whose function was rapidly
dissipated in TRAMP tissue culture media. These studies indicated that some factor
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secreted by GR1 positive, flt3-L treated, spleen cells, “activated” by exposure to TRAMP
tumor cells, mediated the observed alterations of signaling molecule expression seen in
co-cultured T cells and intra-tumor T cells. GR1 positive cells isolated from TRAMP
tumors 1) increasingly separated at the Ficoll interface indicating a decreased density
because of degranulation (activation) within the TME and 2) when used in co-culture
assays were not able to mediate the expected loss of T cell signaling molecules.
GR1 positive cells comprise a heterogeneous group of myeloid-lineage cells
including neutrophils, cells of monocyte/macrophage lineage and the recently identified
immunosuppressive cell called plasmacytoid dendritic cell (91). Plasmacytoid dendritic
cells also express C D llc and B220 antigens. Phenotyping studies demonstrated that as
many as 10% o f splenic GR1+ cells, isolated for these co-culture studies, co-expressed
the three markers (data not shown). Each of these cell types are know to secrete many
factors capable o f altering signaling molecule expression in T cells including proteases,
nitric oxide (NO) and H 2 O2 . Additionally, the granules of neutrophils contain H 2 O2 ,
proteases and other anti-microbial molecules. I then decided to evaluate the extent to
which H 2 O2 expression by GR1 positive cells alters T cells in co-culture assays.

E.

H202 PRODUCED BY GR1 POSITIVE SPLEEN CELLS CO-CULTURED

WITH TRAMP CELLS IS RESPONSIBLE FOR THE LOSS OF TCR
MOLECULES BUT NOT OTHER CD3/TCR COMPONENTS EVALUATED
The catalase co-culture studies performed identified the peroxide molecule as the
molecule responsible for the loss of the zeta chain in tumor-infiltrating T cells. Catalase
was added to in vitro co-culture assays because previous investigators have demonstrated
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that H 2 O2 from neutrophils from cancer patients with rheumatoid arthritis reduced the
percentage o f TCR-^ positive T cells (61). These studies indicated that the molecule was
secreted by GR1 positive cells exposed to TRAMP tumor cells and not by TRAMP or
GR1 positive cells alone. Catalase is an enzyme capable of inactivating H 2 O2 molecules
and increasing doses of the enzyme protected T cells in co-culture assays in a dose
response fashion. H2 O2 molecules have been shown to decrease the zeta chain expression
o f T cells exposed to chronic inflammation in diseases like rheumatoid arthritis,
inflammatory bowel disease and chronic viremia from HCV or HIV (Reviewed in 112).
This result is one of the first to link immune suppression mechanisms from chronic
inflammation with immune suppression in prostate cancer.
However, catalase was not able to protect other components of the CD3 complex
including the epsilon chains in these co-culture studies. The implications are that some
other factor secreted by GR1 positive cells exposed to TRAMP tumor cells mediated the
loss of the other CD3-associated signaling molecules in tumor-infiltrating T cells. Other
potential candidates include proteases that could theoretically cleave the surface
molecules of the CD3 complex or other oxidative radicals generated by GR1 positive
flt3-L treated spleen cells after exposure to tumor cells.
Co-culture studies using F4/80+ cells (macrophages) indicated that these cells
played no role in the loss of signal transducing molecules in TRAMP tumors. No loss of
CD3 components were detected when F4/80+ cells were co-cultured with T cells and
TRAMP cells, indicating that either macrophages played no role in the loss of CD3associated signal molecules or that the co-culture system lacks a crucial component(s)
necessary to activate macrophages to alter T cells. Potential candidates for crucial tumor
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components not considered in these studies include: other immune host cells,
microvessels and tumor stromal cells.

Co-culture studies with F4/80 positive

macrophages did indicate that they were able to mediate a slight, but statistically
significant reduction of CD5 and Thy-1 molecules.

This observation supports the

hypothesis that different tumor-infiltrating cells alter the expression of individual T cell
associated molecules.
In simplest terms, however, these co-culture studies indicated that co-culture of
TRAMP cells, GR1 positive cells and T cells were sufficient to induce loss of T cell
signaling molecules and that H 2 O2 from GR1+ cells mediated the loss of zeta but not
epsilon of alpha chains.

One factor not evaluated by these co-culture studies is the

beneficial anti-tumor properties of tumor-infiltrating GR1 positive cells.

Additional

studies need to be performed to determine if H202 can be detected in the co-culture wells
that demonstrated decreased percentage of TCR-^ positive T cells.
Additionally, both neutrophils and granulocytes has been demonstrated to secrete
enzymes such as phospholipases, that have been shown to cleave the GPI anchor segment
of T cell associated molecules including the Thy-1 molecule (113, 114). For example,
researchers at Eastern Virginia Medical School have demonstrated that human
neutrophils secrete phospholipase A2 when stimulated by the ionophore A23187 (113).
Additionally, macrophages stimulated with specific allergens secrete phospholipase A2
(114).

Phospholipases secreted by these cells may be the effector molecules from

neutrophils and macrophages that mediated the loss of Thy-1 in the in vitro co-culture
assays.

Future studies are required to address this question as well as studies to

determine if soluble Thy-1 molecules can be detected in these co-culture assays.
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Therefore, neutrophils and macrophages can directly kill tumor cells but they can
also secrete angiogenic factors and are able to break down the tumor stroma, which is
beneficial for tumor progression. Myeloid cells within tumors, therefore, represent a
double-edged sword for tumor progression, containing both tumor inhibiting and tumor
promoting qualities.

F. LINKAGE OF CANCER-MEDIATED AND INFLAMMATION-MEDIATED
IMMUNE DYSFUNCTION
Linkage o f the immune system with cancer has been a common theme in cancer
research for decades. Previously the concept has been that the immune system functions
to protect the host, and that cancer develops because the disease somehow overcomes the
immune system. Recent studies suggest more complex interactions between the immune
system and cancer development. For example, many examples of cancer developing in
the context of chronic inflammatory conditions have been noted, including pancreatic and
hepatic cancer with pancreatitis and hepatitis (88). A second example of cancer linked to
inflammation is gastric lymphoma with H. pylori infection and colon cancer with Crohn’s
disease (88).

Additionally, simple anti-inflammatory drugs like aspirin or COX-2

inhibitors have been shown to decrease colon cancer incidence by up to 50% in high-risk
individuals, implying that inflammation is linked to cancer development.
European theories of cancer consider cancer a disease of an organ and imply that
cancer cells actively modify the TME in order to support their growth and survival. The
cancer cells have been described as “masters” and infiltrating macrophages their slaves
allowing tumor progression supported by cells expected to kill the cancer cells (reviewed
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in 72).

These studies demonstrate that the immune system and cancer are more

intimately involved with each other then previously appreciated. The results of these
studies demonstrate unknown interactions between the immune system and cancer and
this new information may lead to improved therapies for solid tumors in humans.
If side effects of chronic inflammation are a major source of local immune
suppression in other solid tumors this could lead to novel immunotherapies for solid
tumors. For example, if GR1-mediated secretion of peroxide also alters the expression of
signal transducing molecules in T cells within human tumors then these studies have
identified a new immune-evasion strategy used by some solid tumors to inhibit the T cellmediated anti-tumor response. These new therapies may incorporate anti-inflammatory
drugs that either decrease the number of tumor-infiltrating GR1 positive cells or are able
to decrease the amount of H 2 O2 produced within tumors.
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TUMOR ENZYMATIC DIGESTION
Reagents fo r Enzymatic Digestion o f TRAMP tumors
Materials:
Tools/solutions:
Sterile IX PBS
3 petri dishes
2 sterile disposable scalpels with handles
Sterile Dissecting tools (forceps, scissors)
Sterile Digestion flask (5 0 mis)
Sterile stirrer bar
Stirring plate.
Digestion buffer preparation (lOOmls):
lOmM Hepes

(0.2383g/100mls)

142 mM NaCL

(0.8298g/100mls)

0.67 mM KC1

(Q.0Q5g/100mls)

0.67 mM CaC12 (0.01g/100 mis)
To prepare 20 mis o f enzyme digestion buffer:
20mg Collagenase Type I (Sigma) per ml of final digestion buffer volume.
Typically 20 mis of buffer are prepared at a time. Then, add 0.20 mg of DNAse I
(Sigma) into the 20 ml volume. Finally, add 50Units of hyluronidase (Sigma) to this
solution for complete digestion buffer. Store any unused digestion buffer at AC.
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CELL SEPARATION AND GROWTH MEDIA
1. Ficoll-Hypaque gradient separation o f mononuclear cells
Materials:
4-10 Sterile 17 x 100mm polystyrene tubes (Fisher)
2.5 mis of Isolymph solution- one step gradient for isolation of lymphocytes
(Gallard-Schlesinger Industries) per tube used. Less then 4 x 107 cells per gradient were
used.
Procedure:
The ficoll-hypaque solution is added to the bottom of the centrifuge tubes, then the
cell suspension is carefully over layered on top of the ficoll layer making certain that the
layers are not mixed and a clean separation of the layers remains. To do this, the cells are
slowly added to the side o f the tube, while the tube is inclined. Typically this process
takes 1-2 minutes per tube to ensure the best separation of mononuclear cells.
Then the cells are centrifuged at 1400 rpm in the IEC Centra-8 Centrifuge for 45
minutes with the brake off. After centrifugation the mononuclear cells will be at the
interface between the cell buffer and the ficoll gradient, typically seen as a buffer layer.
This layer of cells is carefully removed using a pipette, being careful not to take any
ficoll with the cells.
2. Contents o f TRAMP media:
DMEM tissue culture media with
5% fetal bovine serum
5% NuSerum (Collaborative Biomedical Products, Bedford, MA)
L-glutamine (2mM), 5pg/ml insulin, O.OlnM dihydrotestosterone (DHT)
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ANTIBODIES
Optimal Concentrations ofAntibodies fo r flow cytometric staining:
Antibody
PE-anti-IFN-y

Optimal concentration/106
0.03 pg

Source
Pharmingen/Becton Dickerson

PE-anti-IL-2

0.25pg

Pharmingen/BD

Biot-anti-CD44

0.06pg

Pharmingen/BD

Biot-anti-CD25

0.05pg

Pharmingen/BD

Streptavidin-FIT C 0.25pg

Pharmingen/BD

Biot-CD4

0.06pg

Pharmingen/BD

Biot-B220

0.06pg

Pharmingen/BD

Biot-CD3e

0.06pg

Pharmingen/BD

Biot-DX5

0.06pg

Pharmingen/BD

Biot-anti-GRl

0.06pg

Pharmingen/BD

Biot-anti-CDl lc

0.06pg

Pharmingen/BD

Biot-anti-CDl IB 0.06pg

Pharmingen/BD

Biot-CD8

0.06pg

Pharmingen/BD

FITC-anti-CD4

0.06pg

Pharmingen/BD

Streptavidin-Cyc 0.06pg

Pharmingen/BD

PE-anti-I-A

0.25pg

Pharmingen/BD

Streptavidin-PE

0.25pg

Pharmingen/BD

PE-anti-CD69

0.06pg

Pharmingen/BD

PE-anti-TCR-b

0.06pg

Pharmingen/BD
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ANTIBODIES
PE-anti-CD8

0.1 pig

Pharmingen/BD

FITC-anti-Thyl.2 0.063 |4g

Pharmingen/BD

PE-anti-B7.2

0.06(ag

Pharmingen/BD

FITC-anti-I-A

0.25pig

Pharmingen/BD

PE-anti-CD4

0.06p.g

Pharmingen/BD

FITC-anti-CD8

0.06(ag

Pharmingen/BD

FITC-anti-TCR-^ lOpl undiluted antibody

Immunotech/Coulter
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RED BLOOD CELL LYSIS
Red Blood Cell (RBC) Lysing Reagent (hypotonic buffer)
Recipe:
Reagent 1.
1 liter of 1.5% NH4CL (w/v)
Add 15 grams NH4CL to 1 liter of sterile distilled H 2 O
Stir to dissolve.

Reagent 2 (0.034M P 0 4 Buffer, pH 7.45)
Add 12.5 mis sterile Na2HP04 (0.5M)
Add 3.9 mis sterile NaH2P 0 4 (0.5M)

Then bring this solution up to a total volume of 240 mis using sterile H20.
Adjust pH to 7.2 using concentrated HC1.
Filter sterilize this solution.

To produce and use the final RBC Lysing Buffer:
Mix 1 part Reagent 1 with 1 part Reagent 2. Store at 4C between use.
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